<?xml version="1.0" encoding="utf-8"?>
<XML>
<JOURNAL>
<YEAR>1396</YEAR>
<VOL>27</VOL>
<NO>154</NO>
<MOSALSAL>0</MOSALSAL>
<PAGE_NO>257</PAGE_NO>


<ARTICLES>

	<ARTICLE> 
		<TitleF>تمایز سلول‌های بنیادی مزانشیمی ژله‌وارتون انسان به سلول‌های شبه تخمک با استفاده از مایع فولیکولی</TitleF>
		<TitleE>Differentiation of Human Wharton's jelly Mesenchymal Stem Cells into Oocyte-like Cells by Follicular Fluid</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: مایع فولیکولی منبعی غنی از ترکیبات ویژه برای تکوین تخمک است. ازطرفی سلول&#8204;های بنیادی ژله وارتـــون با سلول&#8204;های زایای بدوی منشاء تمایزی یکسان دارند. از این رو ممکن است بتوانند در حضور فاکتور&#8204;های القایی مناسب به سلول&#8204;های شبه&#8204;تخمک تمایز یابند. هدف این مطالعه جداسازی سلول&#8204;های بنیادی ژله وارتـــون و تمایز آن به سلول&#8204;های شبه&#8204;تخمک با استفاده از مایع فولیکولی بوده است.
مواد و روش&#8204;ها: در این مطالعه تجربی قطعات ژله&#8204;وارتون، در محیط &#945;-MEM حاوی10درصد FBS کشت داده شدند. سلول&#8204;های مزانشیمی جدا شده از بافت، در پاساژ سوم به سلول&#8204;های استخوان و چربی تمایز داده شدند، سپس بیان مارکر&#8204;های مربوط به سلول&#8204;های مزانشیمی تحت آنالیز فلوسایتومتری سنجیده شد. جهت تمایز سلول&#8204;های بنیادی ژله وارتـــون به سلول&#8204;های شبه&#8204;تخمک از محیط &#945;-MEM حاوی10درصد مایع فولیکولی انسان، به مدت 21 روز استفاده شد و درنهایت سلول&#8204;ها با آنالیز ایمونوسیتوشیمی ارزیابی شدند.
یافته&#8204;ها: سلول&#8204;های بنیادی ژله وارتـــون توانستند به سلول&#8204;های استخوان و چربی تمایز پیدا کنند. آنالیز فلوسایتومتری نشان داد، سلول&#8204;های بنیادی ژله وارتـــون مارکر سلول&#8204;&#8204;های خونی (CD34-45) را بیـــان نمی&#8204;کنند و مــــارکر&#8204;های سلول&#8204;های مزانشیمی CD73)، CD90 و CD105) را بیـــان می&#8204;کنـند. سلول&#8204;های بنیادی ژله وارتـــون تحت تیمار با مایع فولیکولی، به سلول&#8204;های شبه&#8204;تخمک تمایز یافتند و آنالیز ایمونوسیتوشیمی نشان داد این سلول&#8204;ها بیان مثبتی از مارکر&#8204;های تخمک ZP3) و SYCP3) و سلول زایا (VASA) را دارند.
استنتاج: مطالعه حاضر نشان داد، سلول&#8204;های بنیادی ژله وارتـــون می&#8204;توانند به سلول&#8204;های شبه&#8204;تخمک (از نظر ظاهری) تحت تأثیر مایع فولیکولی تمایز یابند، هم&#8204;چنین مارکر&#8204;های ZP3، VASA و SYCP3 را به طور مثبت بیان کردند. با توجه به توانایی&#8204;های سلول&#8204;های بنیادی ژله وارتـــون ، به نظر می&#8204;رسد این سلول&#8204;ها می&#8204;توانند مناسب جهت استفاده در پروژه&#8204;های سلول&#8204;درمانی با رویکرد بهبود درمان ناباروری باشند.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Follicular fluid (FF) is a rich source of compounds for the development of oocyte. Wharton&#39;s jelly mesenchymal stem cells (WJ-MSCs) have a same differentiation origin with primordial germ cells, therefore, WJ-MSCs could differentiate into oocyte-like cells (OLCs) in the presence of appropriate factors. The purpose of present study was to isolate WJ-MSCs and then investigate their differentiation capacity to OLCs by FF.
Materials and methods: The fragments of Wharton&#39;s jelly were cultured in &#945;-MEM supplemented with 10% FBS. WJ-MSC at the 3rd passage were studied for differentiation ability to adipocytes and osteocytes. Furthermore, WJ-MSCs related markers were assessed by flow cytometry. In the same passage, WJ-MSCs were induced to differentiate into oocyte-like cells by adding 10% human FF in &#945;-MEM for 21 days.
Results: WJ-MSCs could differentiate into adipocytes and osteocytes. Flow cytometry analysis indicated that WJ-MSCs do not express hematopoietic marker (CD34-CD45) and express MSCs markers (CD73, CD90 and CD105). WJ-MSCs which were under influence of FF differentiated into OLCs and immunocytochemistry analysis showed these cells have positive expression of ZP3, SYCP3 (oocyte&#8217;s markers) and VASA (germ cell&#8217;s marker).
Conclusion: The present study demonstrated that WJ-MSCs could differentiate into OLCs (morphologically) under the influence of FF and also expressed ZP3, VASA, and SYCP3 markers positively. According to the capabilities of WJ-MSCs, these cells seem to be suitable for use in cell therapy projects to improve infertility treatments.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>1</FPAGE>
			<TPAGE>11</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/9
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/7/18
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/8
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/8/17
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>مونا</Name>
				<MidName></MidName>
				<Family>ذوالفقار</Family>
				<NameE>Mona</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zolfaghar</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد زیست‌شناسی سلولی و مولکولی، دانشکده علوم و فناوری‌های نوین، واحد علوم دارویی دانشگاه آزاد اسلامی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>روح الله</Name>
				<MidName></MidName>
				<Family>فتحی</Family>
				<NameE>Rouhollah</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Fathi</FamilyE>
				<Organizations>
				<Organization>استادیار، گـروه جنـین شناسی، مرکز تحقیقـات پزشـکی تولیـد مثـل، پژوهشگاه رویان، پژوهشکده زیست شناسی و علوم پزشکی تولید مثل جهاددانشگاهی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>rfathi79@royaninstitute.org</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>طاهره</Name>
				<MidName></MidName>
				<Family>ناجی</Family>
				<NameE>Tahereh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Naji</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه آموزشی علوم سلولی مولکولی، دانشکده علوم و فناوری‌های نوین، واحد علوم دارویی دانشگاه آزاد اسلامی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>stem cell</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Wharton’s jelly</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>follicular fluid</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>oocyte-like cells</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سلول بنیادی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>ژله‌وارتون</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>مایع فولیکولی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سلول‌های شبه تخمک</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>##1.	Adamson GD, de Mouzon J, Lancaster P, Nygren KG, Sullivan E, Zegers-Hochschild F. World collaborative report on in vitro fertilization, 2000. Fertil Steril. 2006;85(6):1586-1622.##2.	Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356.##3.	Hubner K, Fuhrmann G, Christenson LK, Kehler J, Reinbold R, De La Fuente R, et al. Derivation of oocytes from mouse embryonic stem cells. Science .2003;300(5623):1251-1256.##4.	Nikoozad Z, Ghorbanian MT, Rezaei A. Comparison of the liver function and hepatic specific genes expression in cultured mesenchymal stem cells and hepatocytes. Iran J Basic Med Sci. 2014;17(1):27-33.##5.	Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5-14.##6.	Greco SJ, Liu K, Rameshwar P. Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells. Stem cells (Dayton, Ohio). 2007;25(12):3143-3154.##7.	Ding DC, Shyu WC, Chiang MF, Lin SZ, Chang YC, Wang HJ, et al. Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis. 2007;27(3):339-353.##8.	Fong CY, Gauthaman K, Cheyyatraivendran S, Lin HD, Biswas A, Bongso A. Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo. J Cell Biochem. 2012;113(2):658-668.##9.	Campard D, Lysy PA, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology. 2008;134(3):833-848##10.	Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol. 2009;175(1):303-313.##11.	Fahiminiya S, Gerard N. [Follicular fluid in mammals]. Gynecol Obstet Fertil. 2010;38(6):402-404.##12.	Qiu P, Bai Y, Pan S, Li W, Liu W, Hua J. Gender depended potentiality of differentiation of human umbilical cord mesenchymal stem cells into oocyte-Like cells in vitro. Cell Biochem Funct. 2013;31(5):365-373.##13.	Basuino L, Silveira CF, Jr. Human follicular fluid and effects on reproduction. JBRA Assist Reprod. 2016;20(1):38-40.##14.	Dulak J, Szade K, Szade A, Nowak W, Jozkowicz A. Adult stem cells: hopes and hypes of regenerative medicine. Acta Biochim Pol. 2015;62(3):329-337.##15.	Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.##16.	Ding DC, Shyu WC, Lin SZ, Li H. Current concepts in adult stem cell therapy for stroke. Curr Med Chem. 2006;13(29):3565-3574.##17.	Wang Y, Han ZB, Ma J, Zuo C, Geng J, Gong W, et al. A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys. Stem Cells Dev. 2012;21(9):1401-1408.##18.	Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24(3):339-347.##19.	Panula S, Medrano JV, Kee K, Bergstrom R, Nguyen HN, Byers B, et al. Human germ cell differentiation from fetal- and adult-derived induced pluripotent stem cells. Hum Mol Genet. 2011;20(4):752-762.##20.	Subramanian A, Shu-Uin G, Kae-Siang N, Gauthaman K, Biswas A, Choolani M, et al. Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. J Cell Biochem. 2012;113(6):1886-1895.##21.	Malekshah AK, Moghaddam AE. Follicular fluid and cumulus cells synergistically improve mouse early embryo development in vitro. J Reprod Dev. 2005;51(2):195-199.##22.	Hua J, Qiu P, Zhu H, Cao H, Wang F, Li W. Multipotent mesenchymal stem cells (MSCs) from human umbilical cord: potential differentiation of germ cells. Afr J Biochem. Res. 2011;5(4):113-123.##23.	Latifpour M, Shakiba Y, Amidi F, Mazaheri Z, Sobhani A. Differentiation of human umbilical cord matrix-derived mesenchymal stem cells into germ-like cells. Avicenna J Med Biotechnol. 2014;6(4):218 -227.##24.	Asgari HR, Akbari M, Abbasi M, Ai J, Korouji M, Aliakbari F, et al. Human Wharton’s jelly-derived mesenchymal stem cells express oocyte developmental genes during co-culture with placental cells. Iran J Basic Med Sci. 2015;18(1):22-29.##25.	Xie L, Lin L, Tang Q, Li W, Huang T, Huo X, et al. Sertoli cell-mediated differentiation of male germ cell-like cells from human umbilical cord Wharton's jelly-derived mesenchymal stem cells in an in vitro co-culture system. Eur J Med Res. 2015;20:9.#### ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>سنتز، بررسی اثرات سیتوتوکسیک و مطالعه داکینگ دو مشتق ایندول-چالکون</TitleF>
		<TitleE>Synthesis, Cytotoxic Activity and Docking Study of Two Indole-Chalcone Derivatives

</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: چالکون&#8204;ها الگویی برای طراحی و کشف داروهای ضدسرطان هستند و با مکانیسم&#8204;های مختلف از جمله مهار پلیمریزاسیون توبولین باعث القای آپوپتوز و مهار رشد سلول&#8204;های سرطانی می&#8204;گردند. مطالعه حاضر در راستای سنتز دو ترکیب چالکونی، ارزیابی سمیت سلولی آن ها روی سلول&#8204;های سرطانی و سلول&#8204;های نرمال و هم&#8204;چنین مطالعه داکینگ ملکولی این ترکیبات به انجام رسیده است.
مواد و روش&#8204;ها: در این مطالعه تجربی، از واکنش 4-متوکسی بنزآلدهید با 3- استیل ایندول یا N-متیل-3-استیل ایندول در حضور لیتیم هیدروکسید به عنوان کاتالیست ترکیبات چالکونی تهیه شدند و ساختار آن&#8204;ها با استفاده از طیف&#8204;های NMR، IR و Mass مورد تایید قرار گرفت. سمیت سلولی این ترکیبات با روش MTT بر روی رده&#8204;های سلول سرطانی HepG2، MCF7، A549 و SKOV3 و هم&#8204;چنین روی رده سلولی نرمال NIH3T3 و در مقایسه با اتوپوزید بررسی شد. سپس برای بررسی مکانیسم احتمالی این ترکیبات، با بهره&#8204;گیری از روش داکینگ ملکولی و با استفاده از نرم افزار AutoDock 4.2 برهمکنش&#8204;های این ترکیبات با جایگاه اتصال کلشی&#8204;سین در پروتئین توبولین (1SA0) ارزیابی گردید.
یافته&#8204;ها: بر اساس طیف سنجی1H NMR و با توجه به ثابت کوپلاژ هیدروژن&#8204;های وینیلی (J= 15.6 Hz)، چالکون&#8204;های سنتز شده از کانفیگوراسیون ترانس برخوردار هستند. نتایج حاصل از آزمون سمیت سلولی نشان داد که این ترکیبات اثر قابل توجهی در مهار سلول&#8204;های سرطانی دارند. ترکیب 3b با IC50 برابر با 1/8 میکروگرم در میلی&#8204;لیتر، بیش ترین فعالیت را روی رده سلولی HepG2 داشت. ضمن این که ترکیب فوق&#8204;الذکر فاقد اثر سمی قابل توجه روی رده سلولی نرمال NIH3T3 بود. هم چنین آنالیز داکینگ نشان داد که ترکیب 3b با برهمکنش&#8204;های هیدروژنی و هیدروفوبیک با ریشه&#8204;های اسید&#8204;آمینه موجود در جایگاه اتصال کلشی&#8204;سین در پروتئین توبولین (1SA0) ارتباط برقرار می&#8204;کند.
استنتاج: ترکیبات ایندول-چالکونی سنتز شده می&#8204;توانند به صورت اختصاصی رشد سلول&#8204;های سرطانی را مهار نمایند. آنالوگ N-متیل ایندول (ترکیب 3b) پروفایل اثر بهتری را روی سلول&#8204;های سرطانی مورد آزمایش نشان داد. این ترکیب می&#8204;تواند به&#8204;عنوان الگویی ساختاری برای بهینه سازی و توسعه ترکیبات قوی ضدسرطان مورد توجه قرار گیرد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Chalcones are promising lead for anticancer drug design and discovery. Chalcones with different mechanisms including tubulin polymerization inhibition induce apoptosis in cancer cells. The aim of current work was synthesis of two indole-chalcone derivatives and investigation of their cytotoxic activity against cancer and normal cell lines, as well as molecular docking study with the proposed target tubulin.
Materials and methods: In this study, the indole-chalcone derivatives (3a and 3b) were prepared by the reaction of 4-methoxybenzaldehyde with 3-acetylindole or N-methyl-3-acetyl-indole in the presence of LiOH as catalyst. The pure compounds obtained were characterized by 1H NMR, IR, and Mass spectroscopy. The cytotoxic activity of synthesized compounds was tested using MTT assay toward four cancer cell lines (A549, MCF7, HepG2 and SKOV3) and a normal cell line (NIH3T3) in comparison with etoposide. Molecular docking was performed by using AutoDock 4.2 software to evaluate potential mechanism and interactions of chalcone compounds with the tubulin (1SA0) binding site.
Results: The 1H NMR spectra of compounds showed two doublets related to the vinylic protons with coupling constant value of 15.6 Hz, demonstrating trans configuration of the compounds. Cytotoxicity assay showed that these compounds had a significant effect against viability of cancer cells. The compound 3b with IC50 value of 8.1 &#956;g/ml against HepG2 had the most potent cytotoxic effect. Furthermore, this compound had no significant cytotoxic effect against normal cell line. Docking analysis showed that compound 3b is bound to the colchicine binding site of tubulin via hydrogen and hydrophobic interactions.
Conclusion: The indole-derived chalcones had a significant selective cytotoxic effect against cancer cells. The N-methyl-indole analog 3b showed better profile of activity against tested cell lines. This analog can be considered as a lead compound for further optimization and development of potent anticancer agents.
&#160;
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>12</FPAGE>
			<TPAGE>25</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/23
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/4/2
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/23
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/7/1
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>حسن</Name>
				<MidName></MidName>
				<Family>میرزایی</Family>
				<NameE>Hassan</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mirzaei</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکترای پژوهشی، مرکز تحقیقات علوم دارویی، کمیته تحقیقات دانشجویی، دانشکده داروسازی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد</Name>
				<MidName></MidName>
				<Family>شکرزاده</Family>
				<NameE>Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shokrzadeh</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه سم شناسی و داروشناسی، دانشکده داروسازی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سعید</Name>
				<MidName></MidName>
				<Family>امامی</Family>
				<NameE>Saeed</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Emami</FamilyE>
				<Organizations>
				<Organization>استاد، گروه شیمی دارویی، مرکز تحقیقات علوم دارویی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sd_emami@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>chalcone</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>anticancer agents</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>MTT assay</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>tubulin polymerization</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>docking</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>چالکون</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>ترکیبات ضدسرطان</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>تست MTT</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پلیمریزاسیون توبولین</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>داکینگ</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Sonnenschein C, Soto AM. Theories of carcinogenesis: an emerging perspective. Semin Cancer Biol 2008; 18(5): 372-377.##2.	William Jr, William N, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009; 8(3): 213-225.##3.	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): 359-386.##4.	Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009; 20(3): 556-563.##5.	Larsen ME, Rowntree J, Young AM, Pearson S, Smith J, Gibson OJ, et al. Chemotherapy side-effect management  using mobile phones. Conf Proc IEEE Eng Med Biol Soc 2008; 5152-5155##6.	Ansari M, Emami S. β-Ionone and its analogs as promising anticancer agents. Eur J Med Chem 2016; 123: 141-154.##7.	Mirzaei H, Emami S. Recent advances of cytotoxic chalconoids targeting tubulin polymerization: Synthesis and biological activity. Eur J Med Chem 2016; 121: 610-639.##8.	Nakhjiri M, Safavi M, Alipour E, Emami S, Atash AF, Jafari-Zavareh M, et al. Asymmetrical 2,6-bis(benzylidene)cyclohexanones: Synthesis, cytotoxic activity and QSAR study. Eur J Med Chem 2012; 50: 113-123.##9.	Molaverdi F, Khoobi M, Emami S, Alipour M, Firuzi O, Foroumadi A, et al. Polyoxygenated cinnamoylcoumarins as conformationally constrained analogs of cytotoxic diarylpentanoids: synthesis and biological activity. Eur J Med Chem 2013; 68: 103-110.##10.	Matos MJ, Vazquez-Rodriguez S, Uriarte E, Santana L. Potential pharmacological uses of chalcones: a patent review (from June 2011 - 2014). Expert Opin Ther Pat 2015; 25(3): 351-366.##11.	Mirzaei H, Keighobadi M, Emami S. An overview of anticancer chalcones with apoptosis inducing activity. J Mazand Univ Med Sci 2017; 26(146): 254-268.(persian)##12.	Sharma V, Kumar V, Kumar P. Heterocyclic chalcone analogues as potential anticancer agents. Anticancer Agents Med Chem 2013; 13(3): 422-432.##13.	Zahran MAH, Ibrahim AM. Synthesis and cellular cytotoxicities of new N-substituted indole-3-carbaldehyde and their indolylchalcones. J Chem Sci 2009; 121(4): 455-462.##14.	Bhagat S, Sharma R, Sawant DM, Sharma L, Chakraborti AK. LiOH• H2O as a novel dual activation catalyst for highly efficient and easy synthesis of 1, 3-diaryl-2-propenones by Claisen–Schmidt condensation under mild conditions. J Mol Catal A: Chem 2006; 244(1-2): 20-24.##15.	Sakhteman A, Zare B. Modelface: an application programming interface (API) for homology modeling studies using Modeller software. Iran J Pharm Res 2016; 15(4): 801-807.##16.	Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017, San Diego: Dassault Systèmes, 2016##17.	Aryapour H, Riazi GH, Ahmadian S, Foroumadi A, Mahdavi M, Emami S, Induction of apoptosis through tubulin inhibition in human cancer cells by new chromene-based chalcones. Pharm Biol 2012; 50(12): 1551-1560.##18.	Firoozpour L, Edraki N, Nakhjiri M, Emami S, Safavi M, Kabudanian ,etal. Cytotoxic activity evaluation and QSAR study of chromene-based chalcones. Arch Pharm Res 2012; 35(12): 2117-2125.##19.	Sharma V, Kumar P, Pathak D. Biological importance of the indole nucleus in recent years: a comprehensive review. J Heterocyclic Chem 2010; 47(3): 491-502.##20.	Kumar D, Kumar NM, Akamatsu K, Kusaka E, Harada H, Ito T. Synthesis and biological evaluation of indolyl chalcones as antitumor agents. Bioorg Med Chem Lett 2010; 20(13): 3916-3919.##21.	Wang G, Li C, He L, Lei K, Wang F, Pu Y, et al. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents. Bioorg Med Chem 2014; 22(7): 2060-2079.##22.	Boumendjel A, McLeer-Florin A, Champelovier P, Allegro D, Muhammad D, Souard F, et al. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer 2009; 9: 242.##23.	Ducki S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. Anti-Cancer Agents in Med Chem 2009; 9(3): 336-347.##24.	Ducki S, Rennison D, Woo M, Kendall A, Chabert JF, McGown AT, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg Med Chem 2009; 17(22): 7698-7710.#### ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>بررسی اثر عصاره گیاه شیرین‌بیان Glycyrrhiza glabra بر بلوغ آزمایشگاهی تخمک‌های نارس موش نژاد NMRI و تکوین جنین‌های حاصل از آن</TitleF>
		<TitleE>Effect of Licorice Plant (Glycyrrhiza glabra ) on In vitro Maturation of Immature Oocytes and Embryonic Development in NMRI Mice</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: گیاه شیرین&#8204;بیان گیاهی چندساله است که به &#8204;واسطه دارا بودن ترکیبات دارویی و غذایی مهم، در دنیا حائز اهمیت بوده و مورد توجه صنایع دارویی و غذایی قرار گرفته است. هدف از این تحقیق، بررسی تاثیر عصاره شیرین بیان بر بلوغ آزمایشگاهی تخمک&#8204;های نارس موش نژاد NMRI می&#8204;باشد.
مواد و روش&#8204;ها: در این مطالعه&#8204;ی تجربی، حیوانات به&#8204;صورت تصادفی به پنج گروه کنترل، شم، تجربی 1، 2 و 3 تقسیم&#8204;بندی شدند. جهت تحریک تخمک&#8204;گذاری از هورمون PMSG به میزان ۵/۷ واحد بین&#8204;المللی برای هر موش به&#8204;صورت تزریق داخل صفاقی استفاده شد. موش&#8204;های گروه کنترل فقط آب و غذای مخصوص موش&#8204;ها دریافت کردند. به موش&#8204;های گروه شم در طی 7 روز، روزانه 002/0 میلی&#8204;گرم بر کیلوگرم وزن بدن آب مقطر به&#8204;صورت گاواژ و به موش&#8204;های سه گروه تجربی 1 و 2 و 3 در طی 7 روز، روزانه به ترتیب 001/0، 002/0 و 005/0میلی&#8204;گرم بر کیلوگرم وزن بدن عصاره ی شیرین بیان از راه دهان به آن&#8204;ها گاواژ شد. سپس موش&#8204;های در روز 8 تشریح شدند. تخمدان&#8204;های آن&#8204;ها جدا شده وتخمک&#8204;ها جهت رسیدن به مرحله&#8204;ی متافاز دو، طی 24 ساعت بررسی شدند. اووسیت&#8204;هایی که در متافاز دو با اسپرمی که از موش نر به دست آورده شد، لقاح داده شد و بعد از 24 و 48 ساعت نتایج لقاح آزمایشگاهی تخمک (IVF) بررسی شد.
یافته&#8204;ها: به دنبال مصرف عصاره&#8204;ی گیاه شیرین&#8204;بیان، تأثیرات مثبتی بر روی تعداد فولیکول&#8204;ها، بلوغ تخمک&#8204;ها، تعداد جنین دوسلولی و چهار سلولی در گروه تجربی دو و سه نسبت به گروه کنترل مشاهده شد.
استنتاج: نتایج فوق به دلیل خواص فیتواستروژنیک شیرین بیان نشان&#8204;دهنده&#8204;ی تأثیرات مفید این عصاره&#8204; بر بلوغ تخمک و باروری می&#8204;باشد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Glycyrrhiza glabra is a perennial plant with some major food and medicinal compounds that has received attention by food and pharmaceutical industries. The aim of this study was to investigate the effect of licorice on in vitro maturation of immature oocytes on NMRI mice.
Materials and methods: In this experimental study, the animals were randomly divided into five groups: a control, a sham and three experimental groups. The mice were injected intraperitoneally with 7.5 IU PMSG to stimulate ovulation. The control group, received only water and food. The sham animals were gavaged with 200 ml of distilled water for 7 days. The three experimental groups were given daily injection of 100, 200, and 500 &#956;L licorice by oral gavage for 7 days. The mice were sacrificed on day 8, the ovaries were then removed and investigated for oocytes reaching metaphase II (MII) within 24 hours. The oocytes were fertilized by the sperm of male mice and investigated after 24 and 48 hours after in vitro fertilization (IVF).
Results: Compared with the control group, consumption of licorice extract in experimental groups (II and III) was found to have a positive effect on the number of follicles, oocytes, and number of 2 and 4 cell embryos.
Conclusion: This study showed the beneficial effects of licorice extract due to its Phyto-estrogenic properties on oocyte maturation and infertility.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>26</FPAGE>
			<TPAGE>37</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/17
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/9/27
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/25
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/4/4
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>زکیه</Name>
				<MidName></MidName>
				<Family>اسمعیلی</Family>
				<NameE>Zakieh Esmailii</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Esmailii</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد، گروه زیست شناسی، دانشکده ی علوم پایه، دانشگاه آزاد اسلامی واحد علوم و تحقیقات، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>نسیم</Name>
				<MidName></MidName>
				<Family>حیاتی رودباری</Family>
				<NameE>Nasim</NameE>
				<MidNameE></MidNameE>
				<FamilyE>hayati roodbari</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه زیست شناسی، دانشکده ی علوم پایه، دانشگاه آزاد اسلامی واحد علوم و تحقیقات، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nasimhayati@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سیمین</Name>
				<MidName></MidName>
				<Family>محمدی گرجی</Family>
				<NameE>Simin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>mohammady gorji</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه زیست شناسی، دانشکده ی علوم پایه، دانشگاه آزاد اسلامی واحد ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>کاظم</Name>
				<MidName></MidName>
				<Family>پریور</Family>
				<NameE>Kazem</NameE>
				<MidNameE></MidNameE>
				<FamilyE>parivar</FamilyE>
				<Organizations>
				<Organization>استاد، گروه زیست شناسی، دانشکده ی علوم پایه، دانشگاه آزاد اسلامی واحد علوم و تحقیقات، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Glycyrrhiza glabra</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>NMRI mice</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>in vitro maturation of oocytes</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>fertilized oocytes</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>گیاه شیرین‌بیان</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>موش نژاد NMRI</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>بلوغ آزمایشگاهی تخمک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>لقاح آزمایشگاهی تخمک</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Albert-Puleo M. Fennel and anise as estrogenic agents.J. Ethnopharmacol. 1980; 2(4): 337 - 344.##2.	Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, Bertoldo A, Fiore C, Moghetti P. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol. 2007;131(1):61-67.##3.	Armanini D, Mattarello MJ, Fiore C, Bonanni G, Scaroni C, Sartorato P, et al. Licorice reduces serum testosterone in healthy women. Steroids 2004;69(11-12):763–766.##4.	Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22(6):709–724.##5.	Bates RB, Haber WA, Setzer WN, Stessman CC. Cyclic Hemiacetals with Seven Membered Rings from an Undescribed Salacia Species from Monteverde, Costa Rica. J Nat Prod. 1999; 62(2): 340-341.##6.	Brzezinski A, Adlercreutz H, Shaoul R, Rosier A, Shmueli A, Tanos V, Schenker JG. Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause. 1997;4(2):89-94.##7.	Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord. 2007;8(2):127-141.##8.	Irani M, Sarmadi M, Bernard F,Ebrahimi pour GH, Shaker H. Leaves Antimicrobial Activity of Glycyrrhiza glabra L. Iran J Pharm Res. 2010;9(4):425–428.(persian)##9.	Kim BK, Lee SC, Kim KJ, Han CH, Kim JH. Invitro maturation, fertilization, and development ofh human germinal vesicle oocytes collected from stimulated cycles. Fertil Steril 2000; 74(6): 1153-1158.##10.	Liu H, Wang J, Zhou W, Wang Y, Yang L. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol. 2013;146(3):773-793.##11.	Dumesic DA, Padmanabhan V, Abbott DH. Polycystic ovary syndrome and oocyte developmental competence. Obst Gyn Surv .2008; 63(1): 39–48.##12.	Nabavi SM, Nabavi SF, Ebrahimzadeh MA, Eslami B. In Vitro Antioxidant Activity ofPyrus Boissieriana, Diospyros Lotus, Eryngium Caucasicum and Froriepia Subpinnata. J Rafsenjan Univ Med Sci 2009; 8(2): 139-150 (Persian).##13.	Nogueira D, Ron-El R, Friedler S, Schachter M, Raziel A, Cortvrindt R, et al. Meiotic arrest in vitro by phosphodiesterase 3-inhibitor enhances maturation capacity of human oocytes and allows subsequent embryonic development. Biol Reprod. 2006;74(1):177-184.##14.	Ozen T, Korkmaz H. Modulatori effect of urtica dioica L(urticacea) leaf extract on biotransformation enzyme systems, antioxsidant enzymes, lactate dehydrogenase and lipid peroxidation in mice. Phytomedicine. 2003;10(5):405 -415.##15.	Pincus G, Enzmann EV. The comparative behavior of mammalian eggs in vivo and in vitro I. The activation of ovarian eggs. J Exp Med. 1935;62(5):665-675.##16.	Sharma V, Agrawal R. Glycyrrhiza glabra-a plant for the future. Mint J Pharm Med Sci. 2013;2(3):15-20.##17.	Suzuki M, Misumi K, Ozawa M, Noguchi J, Kaneko H, Ohnuma K, et al. Successful piglet production by IVF of oocytes matured in vitro using NCSU-37 supplemented with bovine serum. Theriogenology. 2006; 65(2): 374-386.##18.	Tamaya T, Sato S, Okada HH. Possible mechanism of steroid action of the plant herb extracts glycyrrhizin, glycyrrhetinic acid, and paeoniflorin: inhibition by plant herb extracts of steroid protein binding in the rabbit. Am J Obstet Gynecol. 1986;155(5):1134-1139.##19.	Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogenlikeactivity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol 2001; 78(3): 291-298.##20.	Vaya J, Belinky PA, Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic Biol Med 1997; 23(2): 302-313.##21.	Trounson A, Anderiesz C, Jones G. Maturation of human oocytes in vitro and their developmental competence. Reproduction .2001; 121(1): 51-75.##22.	Yaginuma T, Izumi R, Yasui H, Arai T, Kawabata M. Effect of traditional herbal medicine on serum testosterone levels and its induction of regular ovulation in hyperandrogenic and oligomenorrheic women (author's transl). Nihon Sanka Fujinka Gakkai Zasshi. 1982;34(7):939-944## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>القاء بیان مداوم سیکلواکسیژناز-2 در رده سلولی سرطان سینه از طریق ترانسفکشن آن ها با پلاسمید pSG5-COX-2</TitleF>
		<TitleE>Induction of Continuous Expression of Cyclooxygenase -2 in Human Breast Cancer Cell Line Using COX-2 cDNA Plasmid Transfection</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: یکی از مشکلات عمده مربوط به شیمی&#8204;درمانی، بروز مقاومت در برابر داروهای ضد سرطان است. گزارش&#8204;های اخیر، وجود ارتباط میان بروز سیکلواکسیژناز- 2 (COX-2) (Cyclooxygenase-2) و توسعه فنوتیپ مقاومت چند دارویی (MDR) (Multidrug resistance) را نشان داده&#8204;اند. COX-2 به طور مداوم در سلول&#8204;ها بیان نمی&#8204;شود، بلکه بیان آن توسط سیگنال&#8204;های التهابی، فاکتورهای رشد و سیتوکین&#8204;ها در محل التهاب القاء می&#8204;شود. جهت بررسی ارتباط میان بیان COX-2 و ترانسپورترهای MDR در شرایط in vitro به سلول&#8204;هایی نیاز است که این پروتئین را به صورت مداوم بیان کنند. این مطالعه با هدف القاء بیان مداوم COX-2 در رده سلولی سرطان پستان انسان MCF7 و MCF7/MX انجام گرفت.
مواد و روش&#8204;ها: در این مطالعه تجربی، پلاسمید حاوی توالی COX-2 در سلول های باکتری اشرشیا کولی کلون شد، سپس پلاسمید خالص سازی شده توسط فرآیند لیپوفکشن با کمک معرف فیوژن 6 به رده سلولی MCF7 و MCF7/MX انتقال یافت. در آخر محتوی پروتئینی به دست آمده از سلول&#8204;های ترانسفکت شده طی فرآیند وسترن بلات جداسازی و بیان پروتئین COX-2 در آن&#8204;ها مورد بررسی قرار گرفت.
یافته&#8204;ها: نتایج نشان داد که سلول&#8204;های MCF7 ترانسفکت شده&#8204;ای که نسبت حجم فیوژن 6 به DNA در آن&#8204;ها 3:1 است و محیط حاوی جنتیسین 24 ساعت بعد از پاساژ به آن&#8204;ها افزوده شده است، بیش&#8204;ترین میزان بیان پروتئین COX-2 را داشت. هم&#8204;چنین در سلول&#8204;های MCF7/MX نیز بیان COX-2 در سلول&#8204;های ترانسفکت شده&#8204;ای که نسبت حجم فیوژن 6 به DNA در آن&#8204;ها 3:2 بود، نسبت به کنترل افزایش یافت (P&#60;0.05).
استنتاج: در حقیقت سطح بیان ژن مورد نظر بسته به رده سلولی و شرایط کشت متفاوت است و افزایش میزان DNA لزوما منجر به افزایش کارایی ترانسفکشن نمی&#8204;شود.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: One of the major problems in chemotherapy is resistance to anti-cancer drugs. Recent studies have demonstrated a relationship between cyclooxygenase-2 (COX-2) expression and progression of multidrug resistance (MDR). One of the proteins involved in drug resistance is ABCG2 (ATP-binding cassette sub-family G member 2) that is often overexpressed in patients with cancer. This study was performed to develop the MCF7 and MCF7/MX human breast cancer cell line which continuously expressed COX-2 in order to evaluate the effect of induction of COX-2 expression on ABCG2 expression.
Materials and methods: For this purpose, a plasmid containing the sequence of cyclooxygenase-2 was cloned in E. coli. The purified plasmid was then transferred into the MCF7 and MCF7/MX cell lines by transfection process. Finally, the protein content of transfected cells were extracted and analyzed by Western blotting. The COX-2 expression was compared between transfected cells.
Results: The results showed that COX-2 protein levels were the highest in MCF7 cells transfected with a DNA and Fusion 6 ratio of 3:1 and the medium containing genticine added after 24 hours. Also, compared to the control cell line, in MCF7/MX cells the expression of COX-2 gene increased in transfected cells with a DNA and Fusion 6 ratio of 3:2 (P&#60;0.05).
Conclusion: In fact, the level of target gene expression may vary based on the cell line and culture conditions. Increase in the amount of DNA does not necessarily lead to increase in transfection efficiency.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>38</FPAGE>
			<TPAGE>50</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/10
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1394/9/19
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/22
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/7/30
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>سعیده</Name>
				<MidName></MidName>
				<Family>واحدی</Family>
				<NameE>Saeedeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Vahedi</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد ژنتیک، دانشکده علوم پایه، واحد علوم و تحقیقات، دانشگاه آزاد اسلامی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>بی بی فاطمه</Name>
				<MidName></MidName>
				<Family>کلالی نیا</Family>
				<NameE>BiBi Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Kalalinia</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات بیوتکنولوژی، دانشکده داروسازی، دانشگاه علوم پزشکی، مشهد، مشهد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>KalaliniaF@mums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>زهرا</Name>
				<MidName></MidName>
				<Family>نورمحمدی</Family>
				<NameE>Zahra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Noormohamadi</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه زیست شناسی، دانشکده علوم پایه، واحد علوم و تحقیقات، دانشگاه آزاد اسلامی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فاطمه</Name>
				<MidName></MidName>
				<Family>مصفا</Family>
				<NameE>Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mosaffa</FamilyE>
				<Organizations>
				<Organization>دانشیار، مرکز تحقیقات بیوتکنولوژی، دانشکده داروسازی، دانشگاه علوم پزشکی، مشهد، مشهد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>جواد</Name>
				<MidName></MidName>
				<Family>بهروان</Family>
				<NameE>Javad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Behravan</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات بیوتکنولوژی، دانشکده داروسازی، دانشگاه علوم پزشکی، مشهد، مشهد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>multidrug resistance</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>COX-2</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>MCF7 cell line</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>مقاومت چند دارویی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>ژن COX-2</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>رده سلولی MCF7</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005; 5: 1-13.##2.	Sarkadi B, Ozvegy-Laczka C, Német K, Váradi A. ABCG2 a transporter for all seasons. FEBS Lett 2004; 567: 116-120.##3.	Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J .2005; 7 (1): 118-133.##4.	Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22(47): 7340-7358.##5.	Diestra JE, Scheffer GL, Català I, Maliepaard M, Schellens JH, Scheper RJ, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol .2002; 198(2):  213-219.##6.	Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000; 96(1): 365-368.##7.	Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62: 167-215.##8.	Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J .1998. 12(12): 1063-1073.##9.	Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol .2002; 190(3): 279-286.##10.	Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, et al. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res. 2001; 21(3c): 2141-2147.##11.	Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 2002; 35(4): 843-852.##12.	Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, et al. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther .2005; 312(1): 346-354.##13.	Ejendal KF, Hrycyna CA. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 2002; 3(5): 503-511.##14.	Hofer M, Pospíšil M, Hoferová Z, Weiterová L, Komůrková D. Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review. Molecules 2012; 17(5): 5615-5625.##15.	Kang HK, Lee E , Pyo H, Lim SJ. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005; 4(9): 1358-1363.##16.	Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich1 M. The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies. Int J Cell Bio .2010; 2010.##17.	Gajraj NM. Cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96(6): 1720-1738.##18.	Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002; 277(41): 38915-38920.##19.	Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 2004; 10(6): 647-657.##20.	Surowiak  P, Materna V, Denkert C, Kaplenko I, Spaczyński M, Dietel M,et al. Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Letters 2006; 235(2): 272-280.##21.	Surowiak P, MaternaV, Matkowski R, Szczuraszek K,  Kornafel J, Wojnar A,  et al. Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 2005; 7(5): R862-R870.##22.	Surowiak P, Pawełczyk K, Maciejczyk A, Pudełko M, Kołodziej J, Zabel M, et al. Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res. 2008; 28(5B): 2967-2974.##23.	Lee JY, Tanabe S, Shimohira H, Kobayashi Y, Oomachi T, Azuma S, et al . Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. Res Vet Sci 2007; 83(2): 210-216.##24.	Kalalinia F, Elahian F, Behravan J. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J Cancer Res Clin Oncol .2011; 137(2): 321-330.##25.	Kalalinia F, Elahian F, Hassani M, Kasaeeian J, Behravan J. Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2. Asian Pac J Cancer Prev. 2012; 13(6): 2979-2984.##26.	Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001; 276(52): 48997-49002.##27.	Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene 2007; 26(26): 3789-3796.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>بررسی فراوانی ژن های exoT وexoS در سودوموناس آئروژینوزا و ارتباط آن ها با مقاومت آنتی بیوتیکی در بیماران سوختگی بیمارستان زارع ساری</TitleF>
		<TitleE>Frequency of exoT and exoS Genes among Pseudomonas Aeruginosa Isolates and Antibiotic Resistance in Burn Patients in Sari Zare Hospital, Iran</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: سودوموناس آئروژینوزا، یکی از عوامل مهم عفونت زخم سوختگی در بیمارستان&#8204;ها می&#8204;باشد که با تولید برخی فاکتور&#8204;های بیماری&#8204;زا (سیتوتوکسین&#8204;هایExoT و ExoS ) باعث ایجاد عفونت می&#8204;شود. هدف مطالعه حاضر بررسی فراوانی ژن&#8204;هایexoT وexoS در سودوموناس آئروژینوزای جدا شده از عفونت زخم سوختگی و ارتباط مقاومت آنتی بیوتیکی با حضور این ژن&#8204;ها می&#8204;باشد.
مواد و روش&#8204;ها: در این مطالعه توصیفی-مقطعی، در طی سه ماه اول سال 1395، از زخم 80 بیمار سوختگی بیمارستان زارع ساری نمونه&#8204;برداری شد. و با تست&#8204;های بیوشیمیایی، 18 ایزوله سودوموناس آئروژینوزا شناسایی گردید. وجود ژن&#8204;های exoT وexoS، با روشPCR و هم&#8204;چنین مقاومت به 8 آنتی&#8204;بیوتیک با روش دیسک آگار دیفیوژن بررسی شد. داده&#8204;ها با نرم&#8204;افزار SPSS نسخه 21 و روش آماری کای اسکوئر آنالیز شدند. و سطح معنی&#8204;دار، 05/0 &#60; p در نظر گرفته شد.
یافته&#8204;ها: از 18 ایزوله سودوموناس آئروژینوزا، 15 نمونه (5/83 درصد ) ژنexoT ، 14 نمونه (8/77 درصد ) ژنexoS و 13 نمونه (5/72 درصد ) هم&#8204;زمان هر دو ژن را دارا بودند. از لحاظ آماری بین حضور ژن&#8204;های exoT وexoS و مقاومت به آمپی سیلین، سفازولین و تری متوپریم به ترتیب (0184/0p=) و(0047/0p=) ، و هم&#8204;چنین مقاومت به ایمی پنم و حضور exoT (0489/0p=) اختلاف معناداری مشاهده گردید.
استنتاج: حضور بالای ژن&#8204;هایexoT وexoS در اکثر ایزوله&#8204;های سودوموناس آئروژینوزا و مشاهده اختلاف معنادار بین وجود این ژن&#8204;ها و مقاومت آنتی&#8204;بیوتیکی، اهمیت این ژن&#8204;ها را در عفونت زخم سوختگی نشان می&#8204;دهد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Pseudomonas aeruginosa is one of the most important pathogens of burn infections in hospitals. It causes infection by producing some virulence factors such as exoS and exoT cytotoxins. The aim of this study was to evaluate the frequency of exoS and exoT genes among P.aeruginosa isolated from wound infections in burn patients and the relationship between the presences of these genes and antibiotic resistance.
Materials and methods: In this descriptive cross-sectional study, the wounds of 80 burned patients in Sari Zare Hospital were sampled during April, May, and June 2016. After identification by biochemical tests, 18 isolates of P.aeruginosa were obtained. Antimicrobial susceptibility to 8 antibiotics was determined by disk diffusion method. PCR was performed for detection of exoS and exoT genes. Data was analyzed in SPSS V21 applying Chi-square. The significance level was considered at P&#60;0.05.
Results: A total of 18 isolates was investigated from which 15 (83.5%) had exoT gene and 14 isolates (77.8%) had exoS gene. Simultaneous presence of these genes was seen in 13 (72.5%) isolates. Statically, resistance against Ampicillin, Cephalexin, Co-trimoxazol, and Cefazolin was significantly correlated with the presence of exoS and exoT genes (P = 0.0184, P =0.0047, respectively). In addition, resistance against Imipenem was significantly correlated with the presence of exoT (P=0.0489).
Conclusion: High prevalence of exoS and exoT among Pseudomonas aeruginosa isolates (72.5%) and the significant differences between presence of these genes and antibiotic resistance indicate the importance of these two genes in burn infections.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>51</FPAGE>
			<TPAGE>59</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/5
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/1/16
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/12
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/6/21
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>محمد</Name>
				<MidName></MidName>
				<Family>شکرزاده</Family>
				<NameE>Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shokrzadeh</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه سم شناسی و فارماکولوژی، مرکز تحقیقات علوم دارویی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>پروانه</Name>
				<MidName></MidName>
				<Family>رهبری جید</Family>
				<NameE>Parvaneh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rahbari Jeyd</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد، دانشکده پیراپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Rahbariparvaneh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>عباس</Name>
				<MidName></MidName>
				<Family>محمدپور</Family>
				<NameE>Abbas</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohammadpour</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری سلولی و مولکولی، مرکز تحقیقات علوم دارویی، گروه سم شناسی و فارماکولوژی، دانشکده داروسازی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فاطمه</Name>
				<MidName></MidName>
				<Family>زابلی</Family>
				<NameE>Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zaboli</FamilyE>
				<Organizations>
				<Organization>استادیار، دانشکده کشاورزی و صنایع غذایی، دانشگاه آزاد واحد آیت الله آملی، آمل، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فاطمه زهرا</Name>
				<MidName></MidName>
				<Family>محمدنژاد</Family>
				<NameE>Fatemeh Zahra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohammadnejad</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد، دانشکده پیراپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مریم</Name>
				<MidName></MidName>
				<Family>غفاری چراتی</Family>
				<NameE>Maryam</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ghaffari Charati</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد، دانشکده پیراپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>یحیی</Name>
				<MidName></MidName>
				<Family>صالح طبری</Family>
				<NameE>Yahya</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Saleh Tabari</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری سم شناسی، مرکز تحقیقات علوم دارویی، گروه سم شناسی و فارماکولوژی، دانشکده داروسازی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Pseudomonas aeruginosa</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>burn infection</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>exoS</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>exoT</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>antibiotic resistance</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سودوموناس آئروژینوزا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>عفونت سوختگی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>exoS</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>exoT</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>مقاومت آنتی‌بیوتیکی</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Quinn PJ, Markey BK, Leonard FC, Hartigan P, Fanning S, FitzPatrick ES. Veterinary microbiology and microbial disease. New Jersey, John Wiley &#38; Sons; 2011.##2.	Jabalameli F, Mirsalehian A, Sotoudeh N, Jabalameli L, Aligholi M, Khoramian B, etal. Multiple-locus variable number of tandem repeats (VNTR) fingerprinting (MLVF) and antibacterial resistance profiles of extended spectrum beta lactamase (ESBL) producing Pseudomonas aeruginosa among burnt patients in Tehran. Burns. 2011;37(7):1202-1207.##3.	Ramos JL, Filloux A. Pseudomonas: vol6 ;Molecular Microbiology, Infection and Biodiversity. Netherlands ,Springer 2010.##4.	Jefferies JM, Cooper T, Yam T, Clarke SC. Pseudomonas aeruginosa outbreaks in the neonatal intensive care unit–a systematic review of risk factors and environmental sources. J Med Microbiol. 2012;61(8):1052-1061.##5.	Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol.  2009; 12(1): 61-66.##6.	Galle M, Carpentier I, Beyaert R. Structure and function of the Type III secretion system of Pseudomonas aeruginosa. Curr Protein Pept Sci. 2012;13(8):831-842.##7.	Sun Y, Karmakar M, Taylor PR, Rietsch A, Pearlman E. ExoS and ExoT ADP ribosyltransferase activities mediate Pseudomonas aeruginosa keratitis by promoting neutrophil apoptosis and bacterial survival. J Immunol .2012; 188: (4):1884-1895.##8.	Galle M, Carpentier I, Beyaert R. Structure and function of the Type III secretion system of Pseudomonas aeruginosa. Curr Protein Pept Sci. 2012  ;13(8):831-842.##9.	Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol  2009; 7(9): 654-665.##10.	Shen DK , Quenee L, Bonnet M, Kuhn L, Derouazi M, Lamotte D,etal. Orf1/SpcS chaperones ExoS  for type three secretion by Pseudomonas aeruginosa. Biomed Environ Sci.  2008; 21(2): 103-109.##11.	Azargoon R, Doustdar F, Khanbabaei G, Ghazi M, Mehrnejad F, Goudarzi H. Type III secretion system characterization of Pseudomonas aeruginosa isolates associated with cystic fibrosis. Research in Medicine 2013; 37 (3): 1890-1193.(persian)##12.	Sun Y, Karmakar M, Taylor PR, Rietsch A, Pearlman E. ExoS and ExoT ADP ribosyltransferase activities mediate Pseudomonas aeruginosa keratitis by promoting neutrophil apoptosis and bacterial survival. J Immunol. 2012;188(4):1884-1895.##13.	Jabalameli F, Mirsalehian A, Khoramian B, Aligholi M, Khoramrooz SS, Asadollahi P, etal. Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients. Burns 2012; 38(8): 1192-1197.##14.	Saleh P, Afsharjoo HR, Noshad H, Mallah F. Bacteriology of Burned Patients Admitted to Burn Unit in Northwest of Iran. Med J Tabriz Univ MedSci Health Services.  2016; 38(4): 38-43.##15.	Habibi A, Amir Mozafari N, Fallah Mehrabadi J, Kazemi Darsanky R. The frequency and antibiotic resistance modeling in clinical strains of Pseudomonas aeruginosa isolated from different parts of Tehran hospitals. RJMS 2016, 23(146): 10-16.##16.	Khoramrooz S, Rahbari N, Parhizgari N, Sharifi A, Yazdanpanah M, Gharibpour F, et al  Frequency of type III Secretion System Cytotoxins -Encoding Genes among Pseudomonas Aeruginosa Isolated from Burn Patients. ZUMS Journal 2015; 23(99): 52-63.##17.	Aghaei SS, Javadi A, Sharifi Y, Morovvati A. Detection of ExoT oxin A, Y, T, U, S genes of Pseudomonas aeruginosa Isolates Resistant to Third-Generation Cephalosporins in Clinical Samples of Hospitalized Patients in Hospitals of Qom City, Iran. Qom Univ Med Sci J 2016, 10(1): 48-55.##18.	Strateva T, Markova B, Ivanova D, Mitov I. Distribution of the type III effector proteins-encoding genes among nosocomial Pseudomonas aeruginosa isolates from Bulgaria. Ann Microbiol .2010; 60(3): 503- 509.#### ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>وجود ژن cagA و ارتباط آن با الگوی مقاومت به آنتی بیوتیک در هلیکوباکتر پیلوری جدا شده ازبیماران</TitleF>
		<TitleE>Presence of CagA Gene and Its Antibiotic Resistance Pattern in Helicobacter Pylori Isolates 

</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>مقدمه:یکی ازعوامل شایع عفونت معده هلیکوباکترپیلوری&#160; می باشد. مشخص شده است که سویه های تایپ I ، که در ژنوم آنها جزیره پاتوژنیسیته cag وجود دارد، بیشتر منجر به زخم&#8204;های پپتیک و سرطان می گردند.استفاده از آنتی بیوتیک ها یکی از راههای درمان این عفونت می باشد و مقاومت دارویی یکی از مهم ترین عوامل شکست این روش درمانی می باشد.هدف از این مطالعه بررسی الگوی مقاومت آنتی بیوتیکی و وجود ژن cagA درسویه های هلیکوباکترپیلوری جداشده از بیماران می باشد.

موادوروش ها: این مطالعه برروی 86 بیمار مراجعه کننده انجام شد.نمونه اندوسکوپی جهت انجام تست اوره آز سریع وکشت وتهیه بلوک پارافینه به منظور مشاهده ی لام بافتی و انجامPCR &#160;صورت گرفت. نمونه در محیط کشت مختلف و ایجاد کلنی حاصل ،با استفاده از تست کاتالازواکسیداز تایید گردیدند. سپس آنتی بیوگرام از نمونه ها انجام گردید.

یافته ها:نتایج نشان &#160;که درتست اوره آز سریع3/45% افراد ،مشاهده ی لام بافتی 4/53% وانجام کشت نفر9/55% مثبت می باشند.وتست PCR 2/80% بیماران را به خود اختصاص می دهد. بررسی نمونه هااز نظرژنcagA به میزان (56/69%) دارای ژن cagA مثبت می باشند. از بین بیماران مراجعه کننده کشت مثبت به ترتیب بیشترین مقاومت،به مترونیدازول وآموکسیسیلین وسیپروفلوکسازین وکلاریترومایسین و فورازولیدین و کمترین تتراسایکلین می باشند.

نتیجه گیری:روش PCR روش مناسب تری از روش های دیگر در این مطالعه می باشد. درکشور های در حال توسعه میزان شیوع این میکروارگانیسم بالا است از جمله کشور ایران و مقاومت به مترونیدازول ازهمه ی آنتی بیوتیک ها بیشتر می باشد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Helicobacter pylori is one of the most prevalent agents causing gastric infection.&#160; Most of the type I strains genome containing cag pathogenicity island (i.e. cagA) result in peptic ulcer and gastric cancer. Antibiotics are amongst the main treatments but drug resistance may cause treatment failure. The aim of current research was to investigate the presence of cagA in H. pylori samples and their antibiotic resistance patterns.
Materials and methods: A descriptive study was performed in 86 patients. The endoscopy specimen was used fosr rapid urease test and culture and preparation of paraffin blocks to observe lam of tissue and performing PCR method. Samples were grown in standard media and grown colonies in culture medium were identified using catalase and oxidase tests. Antibiotic susceptibility tests were performed by antibiogram.
Results: In this study, the rapid urease test, tissue lam observation, culture results and PCR analysis were positive in 45.3%, 53.4%, and 55.9%, and 80.2%, respectively. CagA gene was detected in 69.56% of the samples. Among patients with positive culture, highest rates of resistance were found to metronidazole, amoxicillin, ciprofloxacin, clarithromycin, and furazolidone, while the lowest rate of resistance was to tetracycline.
Conclusion: Compared with other methods, PCR analysis was found to be more appropriate. Current study showed that H. pylori strains in Iran are increasingly resistant to clarithromycin, and furazolidone, and metronidazole.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>60</FPAGE>
			<TPAGE>72</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/1
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/11/13
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/1
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/8/10
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>محمد</Name>
				<MidName></MidName>
				<Family>شکرزاده</Family>
				<NameE>Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shokrzadeh</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه سم شناسی و فارماکولوژی، مرکز تحقیقات علوم دارویی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>اسماعیل</Name>
				<MidName></MidName>
				<Family>فتاحی</Family>
				<NameE>Ismail</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Fattahi</FamilyE>
				<Organizations>
				<Organization>استادیار، دانشکده کشاورزی و صنایع غذایی، دانشگاه آزاد واحد آیت الله آملی، آمل، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>عباس</Name>
				<MidName></MidName>
				<Family>محمدپور</Family>
				<NameE>Abbas</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohammadpour</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری سلولی ومولکولی، دانشکده داروسازی، دانشگاه علوم پزشکی مازندران، ساری</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>امیرحسین</Name>
				<MidName></MidName>
				<Family>مشهدبان</Family>
				<NameE>Amir Hosein</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mashhadban</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد میکروبیولوژی، بیمارستان امام خمینی (ره)، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>amirhosein.mashhadban@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>gastric cancer</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>antibiotic resistance</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Microaerophile</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Helicobacter pylori</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>CagA</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سرطان معده</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>مقاومت آنتی بیوتیکی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروآئروفیل</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>هلیکوباکترپیلوری</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>cagA</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Czesnikiewicz-Guzik, Bielanski W, Guzik TJ, Loster B, Konturek SJ. Helicobacter pylori in the oral cavity and its implications for gastric infection, periodontal health, immunology and dyspepsia. J Physiol Pharmacol. 2005. 56(6): 7-89.##2.	Gebara EC, Faria CM, Pannuti C, Chehter L, Mayer MP, Lima LA. Persistence of Helicobacter pylori in the oral cavity after systemic eradication therapy. J clin periodontol. 2006. 33(5): 329-333.##3.	Gebara EC, Pannuti C, Faria CM, Chehter L, Mayer MP, Lima LAet al. Prevalence of Helicobacter pylori detected by polymerase chain reaction in the oral cavity of periodontitis patients. Oral microbiol Immunol. 2004. 19(4): 277-280.##4.	Kignel S, de Almeida Pina F, André EA, Alves Mayer MP, Birman EG. Occurrence of Helicobacter pylori in dental plaque and saliva of dyspeptic patients. Oral Dis. 2005. 11(1): 17-21.##5.	Cześnikiewicz-Guz M, Karczewska E, Bielański W, Guzik TJ, Kapera P, Targosz A, Konturek SJ, Loster B. Association of the presence the Helicobacter pylori in the oral cavity and in the stomach. J Physiol Pharmacol. 1(55): 105-115.##6.	Umeda, M., et al., High prevalence of Helicobacter pylori detected by PCR in the oral cavities of periodontitis patients. J periodontol. 2003. 74(1): 129-134.##7.	Anand PS, Nandakumar K, Shenoy KT. Are dental plaque, poor oral hygiene, and periodontal disease associated with Helicobacter pylori infection?.  J periodontol. 2006. 77(4): 692-698.##8.	Berroteran, A, Perrone M, Correnti M, Cavazza ME, Tombazzi C, Goncalvez R, Lecuna V. Detection of Helicobacter pylori DNA in the oral cavity and gastroduodenal system of a Venezuelan population. J Med Microbiol. 2002. 51(9): 764-770.##9.	Özdemir A, Mas MR, Sahin S, Sağlamkaya U, Ateşkan U. Detection of Helicobacter pylori colonization in dental plaques and tongue scrapings of patients with chronic gastritis. Quintessence Int. 2001. 32(2): 131-134.##10.	Chitsazi MT, Fattahi E, Farahani RM, Fattahi S. Helicobacter pylori in the dental plaque: is it of diagnostic value for gastric infection? Med Oral Patol Oral Cir Bucal. 2006. 11(4): 325-328.##11.	Saxena A, Shukla S, Prasad KN, Ghoshal UC. Virulence attributes of Helicobacter pylori isolates &#38; their association with gastroduodenal disease. Indian J Med Res. 2011. 133(5): 514-520.##12.	Goudarzi H, Rezaie H,Rafiezadeh M, Mir samadi E, Mir samadi A. The frequency of cagA gene of H.pylori isolated from biopsy specimen in Tehran during 2008-2010. amuj. 2012;15 (5): p. 42-48.##13.	Argent RH, Thomas RJ, Letley DP, Rittig MG, Hardie KR, Atherton JC. Functional association between the Helicobacter pylori virulence factors VacA and CagA. J Med Microbiol. 2008. 57(2): 145-150.##14.	Nagiyev T, Yula E,Abayli B,Koksal F. Prevalence and genotypes of Helicobacter pylori in gastric biopsy specimens from patients with gastroduodenal pathologies in the Cukurova region of Turkey. J Clin Microbiol. 2009. 47(12): 4150-4153.##15.	Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, Shiratori Y, Omata M. Major virulence factors, VacA and CagA, are commonly positive inHelicobacter pylori isolates in Japan. Gut. 1998. 42(3): 338-343.##16.	Nguyen TL, Uchida T, Tsukamoto Y, Trinh DT, Ta L, Mai BH,et al. Helicobacter pylori infection and gastroduodenal diseases in Vietnam: a cross-sectional, hospital-based study. BMC gastroenterol. 2010. 10(1): 114.##17.	Uchida T, Nguyen LT, Takayama A, Okimoto T, Kodama M, Murakami K, et al. Analysis of virulence factors of Helicobacter pylori isolated from a Vietnamese population. BMC Microbiol. 2009. 9.##18.	Paniagua GL, Monroy E, Rodríguez R, Arroniz S, Rodríguez C, Cortés JL, et al. Frequency of vacA, cagA and babA2 virulence markers in Helicobacter pylori strains isolated from Mexican patients with chronic gastritis. Ann Clin Microbiol Antimicrob. 2009. 8(1): 14.##19.	Yakoob J, Abid S, Abbas Z, Jafri W, Ahmad Z, Ahmed R, et al. Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. BMC Gastroenterol. 2009. 9: 87.##20.	Wang, Y.-C., et al., In Vitro Activity of 2-methoxy-1, 4-naphthoquinone and Stigmasta-7, 22-diene-3β-ol from Impatiens balsamina L. against Multiple Antibiotic-Resistant Helicobacter pylori. Evid Based Complement Alternat Med. 2011. 2011.##21.	De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C , et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010. 19(4): 409-414.##22.	Chu YT, Wang YH,Wu JL,Lei HY. Invasion and multiplication of Helicobacter pylori in gastric epithelial cells and implications for antibiotic resistance. Infect Immun. 2010. 78(10): 4157-4165.##23.	Kato M, Asaka M. Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol. 2010. 40(9): 828-837.##24.	Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C, et al. Clinical trial: clarithromycin vs. levofloxacin in first‐line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2010. 31(10): 1077-1084.##25.	Rick JR1, Goldman M, Semino-Mora C, Liu H, Olsen C, Rueda-Pedraza E, et al. In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori infected children. J Pediatr Gastroenterol Nutr. 2010. 50(2): 167-172.##26.	Amjad N, Osman HA, Razak NA, Kassian J, Din J, bin Abdullah N. Clinical significance of Helicobacter pylori cagA and iceA genotype status. World J Gastroenterol. 2010. 16(35): 4443-4447.##27.	maleki P, Saeid Latifi N, Zuhri S. Allelic Variation of Helicobacter pylori babA and cagA Genes and their Association with Clinical Consequences. Govaresh. 2013;17(4):203-212.##28.	Shirazi MH,Ghasemi A, Khorammizadeh MR, Daryani NE, Hosseini M, Sadeghifard N. A Study of CagA Gene in Helicobacter Pylori Strains Isolated from Patients with NUD, Peptic Ulcer and Gastric Cancer by PCR method. J Ilam Univ Med Sci.2007;14(3):22-28.##29.	John T. Loh, Carrie L. Shaffer, M. Blanca Piazuelo, Luis E. Bravo, Mark S. McClain1,Pelayo Correa, and Timothy L. Cover,2011. Analysis of cagA in Helicobacter pylori Strains fromColombian Populations with Contrasting Gastric Cancer RiskReveals a Biomarker for Disease Severity. Journal of CancerEpidemiology,Biomarkers&#38; Prevention, Volume 11(548) pages2237-2249.##30.	Rezaeaian A, Kargar M,Saud N,Ghorbani Dalini S. high-rise honest journalist victim of Dalyny, 1391, Genetic polymorphism of cagA and vacA in Helicobacter pylori strains isolated from gastrointestinal disease in the province of Chahar Mahal and Bakhtiari. J Isfahan Med School.2012;30(197):1027-1019.##31.	Baghaee K, Shokrzadeh L, Jafari F, Bolfion M, MASHAYEKHI R, Zojaji H,et al. Association between gastric disorders and cagA or cagE in Iranian patients. Pajuhandeh:2011;4(76):137-142.##32.	Peter Malfertheiner, Francis Megraud, Colm A O'Morain, John Atherton, Anthony T R Axon, Franco Bazzoli, Gian Franco Gensini, Javier P Gisbert, David Y Graham, Theodore Rokkas, Emad M El-Omar and  Ernst J Kuipers ,2015. Management of Helicobacter pylori infectiondtheMaastricht IV/ Florence Consensus Report,journal of gastroenterology and hepatology, Volume 61( 5( ,pages  646-664.##33.	Talebi Bazemanabadi A, Mohabbani Mobarez A, Ajami A, Rafiee A, Taghvai T. Evaluation of Antibiotic resistance of Helicobacter pylori isolated from patients referring to Tooba Sari medical center 2008. J Mazandaran Univ Med Sci. 2009; 19 (70) :26-32.##34.	Nasrabadi NN, Ataee R, Abediankenari S, Shokrzadeh M, Najafi M, Hoseini SV, et al. Expression of MT2 receptor in patients with gastric adenocarcinoma and its relationship with clinicopathological features. Journal of gastrointestinal cancer. 2014;45(1):54-60.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>عدم ارتباط بین پلی مورفیسم تک نوکلئوتیدی (rs6887695G/C) در ژن IL12B با عفونت هپاتیت B مزمن در جمعیت ایرانی</TitleF>
		<TitleE>Lack of Association between IL12B Gene Single Nucleotide Polymorphism (rs6887695G/C) and Chronic Hepatitis B Virus Infection in an Iranian Population</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;سابقه و هدف: ویروس هپاتیت B یکی از مهم&#8204;ترین علل ضایعات کبدی در سراسر جهان است پاسخ سیستم ایمنی میزبان و ویروس هپاتیت B، نقش مهمی در نتیجه عفونت دارند. اینترلوکین 12 (IL12) در نقش یک سایتوکاین پیش التهابی باعث تحریک سلول&#8204;های کشنده طبیعی و لنفوسیت T برای تولید اینترفرون گاما (IFN- &#947;)، تقویت لنفوسیت&#8204;های &#160;Th1و افزایش فعالیت سلول&#8204;های T سایتوتوکسیک می&#8204;شود. این خصوصیات منحصر به فرد IL12، نشان می&#8204;دهد که این سایتوکین &#160;ممکن است نقش مهمی در پاکسازی و کنترل HBV داشته باشد. از طرف دیگر پلی&#8204;مورفیسم&#8204;های تک نوکلئوتیدی با تولید متفاوت سایتوکاین&#8204;ها همراه است. در این مطالعه، ارتباط پلی&#8204;مورفیسم (rs6887695) ژن IL12B با عفونت مزمن HBV مورد بررسی قرار خواهد گرفت.
مواد و روش&#8204;ها: توزیع ژنوتیپ&#8204;های (rs6887695) ژن IL12B در ۱٢٠ بیمار مزمن مبتلا به ویروس هپاتیت B مزمن و ۱٢٠ فرد سالم با استفاده از واکنش زنجیره پلیمراز و متعاقب آن هضم آنزیمی RFLP در روی نمونه&#8204;های جمع&#8204;آوری شده بین سال&#8204;های ١٣٩٢ تا ١٣٩٤ انجام شد.
یافته&#8204;ها: فراوانی ژنوتیپ&#8204;های GG، GC و CC به ترتیب در بیماران ٧̸٥٦ درصد، ٧/٣٦ درصد و ٦/٦ درصد و در میان افراد شاهد به ترتیب ٧/٥١ درصد، ٥/٤٢ درصد و ٨/٥ درصد است (٦٥/٠P value=) 
استنتاج: یافته&#8204;های مطالعه حاضر نشان می&#8204;دهد که میان پلی&#8204;مورفیسم تک نوکلئوتیدی (rs6887695) ژن IL12B و ابتلا به عفونت ویروس هپاتیت B مزمن در جمعیت ایرانی تحت مطالعه، رابطه معناداری وجود ندارد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Hepatitis B virus (HBV) is considered to be one of the most important etiological factors of liver complication around the world. Interactions of host immune responses with HBV have a crucial role in the outcome of the infection. IL12 is an important pro-inflammatory cytokine that stimulates natural killer cells and T-lymphocytes to produce IFN-&#947;, promotes T-helper 1 responses, and expands CD8+cytotoxic T-cell activity. These unique properties of IL12 indicate that it might play an important role in control and clearance of HBV. In addition, single nucleotide polymorphisms (SNPs) are presumed to be linked to differential production of cytokines levels. This study investigated the association of IL12B rs6887695 G/C polymorphism with chronic HBV infection.
Materials and methods: Genotypes distribution of IL12B rs6887695 was determined in 120 chronic HBV infected patients and 120 healthy controls using polymerase chain restriction fragment length polymorphism (PCR-RFLP) method between 2013 and 2015.
Results: The frequencies of rs6887695 GG, GC and CC genotypes in the patients with chronic infection were 56.7%, 36.7% and 6.6%, respectively and in healthy controls were 51.7%, 42.5%, and 5.8%, respectively. No statistically significant difference was detected in IL12B rs6887695 genotypes between the patients and controls (P =0.65).
Conclusion: IL12 plays an essential role in immune response against HBV infection; however, present findings suggest that IL12B rs6887695 SNP was not associated with chronic HBV in the Iranian population studied.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>73</FPAGE>
			<TPAGE>82</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/8
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/10/19
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/11
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/4/20
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>صدیقه</Name>
				<MidName></MidName>
				<Family>حیدریان</Family>
				<NameE>Sediqeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Heidarian</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد ویروس شناسی، مرکز تحقیقات بیماریهای گوارش و کبد، پژوهشکده بیماریهای گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فرزانه</Name>
				<MidName></MidName>
				<Family>صباحی</Family>
				<NameE>Farzaneh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sabahi</FamilyE>
				<Organizations>
				<Organization>استاد، گروه ویروس شناسی، دانشگاه تربیت مدرس، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید رضا</Name>
				<MidName></MidName>
				<Family>محبی</Family>
				<NameE>Seyed Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohebbi</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات علوم پایه و اپیدمیولوژی بیماریهای گوارش، پژوهشکده بیماری های گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sr.mohebbi@sbum.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مریم</Name>
				<MidName></MidName>
				<Family>کارخانه</Family>
				<NameE>Maryam</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Karkhane</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد، مرکز تحقیقات بیماریهای گوارش و کبد، پژوهشکده بیماریهای گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>پدرام</Name>
				<MidName></MidName>
				<Family>عظیم زاده</Family>
				<NameE>Pedram</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Azimzadeh</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری، مرکز تحقیقات بیماری‌های منتقله از آب و غذا، پژوهشکده بیماری‌های گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مهسا</Name>
				<MidName></MidName>
				<Family>سعیدی نیاسر</Family>
				<NameE>Mahsa</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Saeedi Niasar</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد، مرکز تحقیقات بیماریهای گوارش و کبد، پژوهشکده بیماریهای گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>شقایق</Name>
				<MidName></MidName>
				<Family>درخشانی</Family>
				<NameE>Shaqaeyeq</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Derakhshani</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد، مرکز تحقیقات بیماریهای گوارش و کبد، پژوهشکده بیماریهای گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>افسانه</Name>
				<MidName></MidName>
				<Family>شریفیان</Family>
				<NameE>Afsaneh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sharifian</FamilyE>
				<Organizations>
				<Organization>دانشیار، مرکز تحقیقات بیماریهای گوارش و کبد، پژوهشکده بیماریهای گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد رضا</Name>
				<MidName></MidName>
				<Family>زالی</Family>
				<NameE>Mohammadreza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zali</FamilyE>
				<Organizations>
				<Organization>. استاد، مرکز تحقیقات بیماریهای گوارش و کبد، پژوهشکده بیماریهای گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران ایراان</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Hepatitis B virus</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>single nucleotide polymorphism</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Interleukin-12</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>chronic infection</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>ویروس هپاتیت B مزمن</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پلی‌مورفیسم تک نوکلئوتیدی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>اینترلوکین 12</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>عفونت مزمن</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Zuckerman A. More than third of world’s population has been infected with hepatitis B virus. BMJ: British Medical Journal. 1999;318(7192):1213.##2.	Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences. 1987;84(4):1005-9.##3.	Yan Z-H, Fan Y, Wang X-H, Mao Q, Deng G-H, Wang Y-M. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World journal of gastroenterology: WJG. 2012;18(24):3119.##4.	Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection. Transplant immunology. 2005;14(3):183-6.##5.	Abbas A, Lichtman A. Cellular and molecular immunology. Philadelphia: Saunders; 2009. Acceso Marzo. 2010;9.##6.	Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, et al. Interleukin‐12 is produced by dendritic cells and mediates T helper 1 development as well as interferon‐γ production by T helper 1 cells. European journal of immunology. 1996;26(3):659-68.##7.	Komastu T, Ireland DD, Reiss CS. IL-12 and viral infections. Cytokine &#38; growth factor reviews. 1998;9(3):277-85.##8.	Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomedicine &#38; pharmacotherapy. 2001;55(2):111-6.##9.	Bancroft AJ, Else KJ, Sypek JP, Grencis RK. Interleukin‐12 promotes a chronic intestinal nematode infection. European journal of immunology. 1997;27(4):866-70.##10.	Orange JS, Wolf SF, Biron CA. Effects of IL-12 on the response and susceptibility to experimental viral infections. The Journal of Immunology. 1994;152(3):1253-64.##11.	Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology. 2005;5(3):215-29.##12.	McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(S5).##13.	Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002;35(5):1274-6.##14.	Li X, Bai L, Fang J, Hou S, Zhou Q, Yu H, et al. Genetic Variations of IL-12B, IL-12Rβ1, IL-12Rβ2 in Behcet's Disease and VKH Syndrome. PloS one. 2014;9(5):e98373.##15.	Pravica V, Perrey C, Stevens A, Lee J-H, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-γ gene:: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ production. Human immunology. 2000;61(9):863-6.##16.	Montazer Haghighi M, Taleghani Y, Yaghoob M, Irani Shemirani A, Akbari Z, Vahedi M, et al. Association of C&#62; T p757l polymorphism in EXO1 gene and risk of sporadic colorectal cancer in an Iranian population. Scientific Journal of Hamadan University of Medical Sciences. 2011;18(2):45-9.##17.	Huang D, Cancilla M, Morahan G. Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit. Genes and immunity. 2000;1(8):515.##18.	Adorini L. Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases. Cellular and molecular life sciences. 1999;55(12):1610-25.##19.	Heidarian S, Sabahi F, Mohebbi SR, Zali MR. Lack of association between Interleukin-12 gene polymorphism (rs568408 G/A) and susceptibility to chronic hepatitis B virus infection. Journal of Kermanshah University of Medical Sciences (J Kermanshah Univ Med Sci). 2016;20(1):21-5.##20.	Tayefinasrabadi H, Hosseini SM, Mohebbi SR, Azimzadeh P, Zali MR. Association between rs763780 polymorphism in IL-17 gene and chronic hepatitis B infection in the patients referring to Taleghani Hospital, in Tehran, Iran. Scientific Journal of Kurdistan University of Medical Sciences. 2015;20(6).##21.	Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high‐risk Chinese population. International journal of cancer. 2011;128(7):1692-6.##22.	Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, et al. Effect of cytokine genotypes on the hepatitis B virus‐hepatocellular carcinoma association. Cancer. 2005;103(4):740-8.##23.	Naghoosi H, Mohebbi SR, Tahaei S, Azimzadeh P, Romani S, Sanati A, et al. Lack of association of interleukin 12 p40 subunit polymorphism (IL-12B+ 1188) and risk of chronic hepatitis B infection in Iranian patients. Zahedan Journal of Research in Medical Sciences. 2012;14(3):34-8.##24.	Azimzadeh P, Mohebbi SR, Romani S, Naghoosi H, Vahedi M, Kazemian S, et al. Effect of interleukin-12 p40 subunit gene 3’-untranslated region polymorphism in chronic HCV infection. Scientific Journal of Kurdistan University of Medical Sciences. 2011;16(1):10-9.##25.	Shokrgozar MA, Sarial S, Amirzargar A, Shokri F, Rezaei N, Arjang Z, et al. IL-2, IFN-γ, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis. Journal of clinical immunology. 2009;29(6):747.##26.	Walsh JP, Berry J, Liu S, Panicker V, Dayan CM, Brix TH, et al. The clinical presentation of autoimmune thyroid disease in men is associated with IL12B genotype. Clinical endocrinology. 2011;74(4):508-12.##27.	Wu Y, Lu Z, Chen Y, Xue F, Chen X, Pan M, et al. Association of IL-12B gene rs6887695 polymorphism with hereditary susceptibility and clinical characterization of psoriasis vulgaris in the Chinese Han population. Archives of dermatological research. 2013;305(6):477-82.##28.	Morahan G, Huang D, Ymer SI, Cancilla MR, Stephen K, Dabadghao P, et al. Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nature genetics. 2001;27(2):218-21.##29.	Morahan G, Huang D, Wu M, Holt BJ, White GP, Kendall GE, et al. Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children. The Lancet. 2002;360(9331):455-9.##30.	Fang S, Fang X, Xiong M. Psoriasis prediction from genome-wide SNP profiles. BMC dermatology. 2011;11(1):1.##31.	Razavi AH, Azimzadeh P, Mohebbi SR, Hosseini SM, Romani S, Khanyaghma M, et al. Lack of association between transforming growth factor Beta 1-509C/T and+ 915G/C polymorphisms and chronic hepatitis B in Iranian patients. Hepatitis monthly. 2014;14(4).##32.	Amani D, Dehaghani AS, Zolghadri J, Ravangard F, Niikawa N, Yoshiura K-i, et al. Lack of association between the TGF-β1 gene polymorphisms and recurrent spontaneous abortion. Journal of reproductive immunology. 2005;68(1):91-103.##33.	Masood M, Salehi E, Sheykh Bahayi N, Rajab A, Vojgani M, Massoud A. Survey the Single Nucleotide Polymorphism of TGFβ at Codon 25 in Type 1 Diabetic Patients. Journal of Guilan University of Medical Sciences. 2007;16(62):1-6.##34.	Navikas V, Link H. Cytokines and the pathogenesis of multiple sclerosis. Journal of neuroscience research. 1996;45(4):322-33.##35.	Yin L-M, Zhu W-F, Wei L, Xu X-Y, Sun D-G, Wang Y-B, et al. Association of interleukin-12 p40 gene 3’-untranslated region polymorphism and outcome of HCV infection. World Journal of Gastroenterology: WJG. 2004;10(16):2330.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>بررسی تاثیر تمرینات ورزشی حین دیالیز و پیاده‌روی در منزل بر توانایی جسمانی و کفایت دیالیز بیماران همودیالیزی

</TitleF>
		<TitleE>Effect of Intradialytic and Home-Based Walking Exercises on Physical Function and Dialysis Adequacy in Hemodialysis Patients</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: بیماران تحت درمان با همودیالیز، صرف نظر از سن، از اختلال در عملکرد جسمانی و سبک زندگی کم تحرک رنج می&#8204;برند و مشکلات گوناگون ناشی از کم&#8204;تحرکی بر ابعاد مختلف زندگی آن&#8204;ها اثر می&#8204;گذارد. تمرینات ورزشی متناسب با توانایی&#8204; و تمایل بیماران همودیالیزی می&#8204;تواند به&#8204;عنوان راه&#8204;حلی برای مقابله با کم&#8204;تحرکی مطرح شود. مطالعه حاضر با هدف بررسی تاثیر تمرینات ورزشی حین دیالیز و پیاده&#8204;روی در منزل بر توانایی جسمانی و کفایت دیالیز بیماران همودیالیزی انجام شد.
مواد و روش&#8204;ها: در این کارآزمایی بالینی، 60 بیمار همودیالیزی به صورت تصادفی از دو بیمارستان تحت پوشش دانشگاه علوم پزشکی مازندران انتخاب شدند. بیماران گروه آزمون، برنامه ورزشی را به مدت هشت هفته (دو هفته حین دیالیز و شش هفته در منزل) انجام دادند. از آزمون پیاده&#8204;روی شش دقیقه&#8204;ای (6MWT) جهت سنجش عملکرد جسمانی و از مقادیرKT/V&#160; و URR برای سنجش کفایت دیالیز استفاده شد. جهت آنالیز داده&#8204;ها از نرم افزار SPPS20 استفاده شد و 05/0&#8805;p معنادار در نظر گرفته شد.
یافته&#8204;ها: در تست پیاده&#8204;روی شش دقیقه&#8204;ای، میانگین مسافت طی شده توسط گروه آزمون در مقایسه با گروه کنترل تغییر معناداری داشت (015/0 P ꞊). سطح کفایت دیالیز بیماران گروه آزمون با توجه به فرمول KT/V و URR، در مقایسه با گروه کنترل افزایش داشت، اگرچه این افزایش از نظر آماری معنادار نبوده است.
استنتاج: فعالیت&#8204;های ورزشی از جمله برنامه طراحی شده سبب بهبود وضعیت جسمانی بیماران همودیالیزی می&#8204;شود. انجام این فعالیت&#8204;ها به علت سهولت کاربرد، نداشتن عارضه، پایین بودن هزینه، قابل اجرا بودن در هر زمان و مکان و عدم نیاز به تجهیزات خاص به بیماران همودیالیزی توصیه می&#8204;شود.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Background and purpose: Patients undergoing hemodialysis, regardless of age, suffer from impaired physical function. Many problems caused by lack of mobility affect different dimensions of their lives. Exercise training, commensurate with the ability and willingness of hemodialysis patients could be of great benefit in dealing with the lack of physical activity. The aim of this study was to investigate the effect of intradialytic and home-based walking exercises on physical function and adequacy of hemodialysis patients.
Materials and methods: In a clinical trial, 60 hemodialysis patients were randomly selected from two hospitals affiliated to Mazandaran University of Medical Sciences. Patients in the exercise group performed the exercise program for eight weeks (two weeks during dialysis and six weeks at home). The six-minute walk test (6MWt) was used to measure physical function and KT/V and URR values were used to measure the dialysis adequacy.
Results: In the six-minute walk test, the mean distance walked by the exercise group was significantly different from that in the control group (P˂ 0.015).&#160; According to the KT/V and URR values, the adequacy of dialysis in patients in the exercise group increased, although this increase was not statistically significant.
Conclusion: Exercise activities such as the program designed can improve physical function in hemodialysis patients. These activities are recommended for such patients since they are easily done at any time and place without any special equipment, have no complications, and are low cost.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>83</FPAGE>
			<TPAGE>93</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/17
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/4/26
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/27
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/7/5
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>مرضیه</Name>
				<MidName></MidName>
				<Family>هاتف</Family>
				<NameE>Marzieh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hatef</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد پرستاری مراقبت ویژه، کمیته تحقیقات دانشجویی، دانشکده پرستاری و مامایی نسیبه، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>روانبخش</Name>
				<MidName></MidName>
				<Family>اسماعیلی</Family>
				<NameE>Ravanbakhsh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Esmaeili</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه پرستاری، مرکز تحقیقات ارتوپدی مازندران، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>نورالدین</Name>
				<MidName></MidName>
				<Family>موسوی نسب</Family>
				<NameE>Noroddin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mousavinasab</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه آمار، دانشکده بهداشت، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>زهرا</Name>
				<MidName></MidName>
				<Family>مدنی</Family>
				<NameE>Zahra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Madani</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه طب ورزشی، دانشکده پزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فاطمه</Name>
				<MidName></MidName>
				<Family>اسپهبدی</Family>
				<NameE>Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Spahbodi</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه نفرولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ویدا</Name>
				<MidName></MidName>
				<Family>شفیع‌پور</Family>
				<NameE>Vida</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shafipour</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه پرستاری، مرکز تحقیقات ارتوپدی مازندران، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>vidashafipour@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>exercise training</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>hemodialysis adequacy</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>physical function</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>hemodialysis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>تمرینات ورزشی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>کفایت دیالیز</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>توانایی جسمانی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>همودیالیز</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	United Stage Renal Data System . Annual Data Report: Atlas of End-Stage Renal Disease [Internet]. Bethesda (ASRD): 2014.##2.	Mousavi SS, Soleimani A, Mousavi MB. Epidemiology of end-stage renal disease in Iran: a review article. Saudi J Kidney Dis Transpl. 2014;25(3):697-702.##3.	Johansen KL. Exercise in the end-stage renal disease population. J Am Soc Nephrol. 2007;18(6):1845-1854.##4.	Altintepe L, Levendoglu F, Okudan N, Guney I, Savas CILLI A, Ugurlu H, et al. Physical disability, psychological status, and health‐related quality of life in older hemodialysis patients and age‐matched controls. Hemodial Int . 2006;10(3):260-266.##5.	Peng YS, Chiang CK, Hung KY, Chang CH, Lin CY, Yang CS, et al. Are both psychological and physical dimensions in health-related quality of life associated with mortality in hemodialysis patients: a 7-year Taiwan cohort study. Blood Purif. 2010;30(2):98-105.##6.	Gomes EP, Reboredo MM, Carvalho EV, Teixeira DR, Carvalho Filho L, Sanders-Pinheiro H, et al. Physical activity in hemodialysis patients measured by triaxial accelerometer. Biomed Res Int. 2015;2015:645645.##7.	Cheema BS, Singh MA. Exercise training in patients receiving maintenance hemodialysis: a systematic review of clinical trials. Am J Nephrol. 2005;25(4):352-364.##8.	Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;64(3):383-393.##9.	Ouzouni S, Kouidi E, Sioulis A, Grekas D, Deligiannis A. Effects of intradialytic exercise training on health-related quality of life indices in haemodialysis patients. Clin Rehabil. 2009;23(1):53-63.##10.	Segura-Orti E, Kouidi E, Lisón J. Effect of resistance exercise during hemodialysis on physical function and quality of life: randomized controlled trial. Clin Nephrol. 2009;71(5):527-537.##11.	Tao X, Chow SK, Wong FK. A nurse-led case management program on home exercise training for hemodialysis patients: A randomized controlled trial. Int J Nurs Stud. 2015;52(6):1029-1041.##12.	Kosmadakis GC, Bevington A, Smith AC, Clapp EL, Viana JL, Bishop NC, et al. Physical exercise in patients with severe kidney disease. Nephron Clin Pract. 2010;115(1):c7-c16.##13.	Delgado C, Johansen KL. Barriers to exercise participation among dialysis patients. Nephrol Dial Transplant. 2012;27(3):1152-1157.##14.	Heiwe S, Tollin H. Patients’ perspectives on the implementation of intra-dialytic cycling—a phenomenographic study. Implement Sci. 2012;7(1):68.##15.	Bennett PN, Breugelmans L, Barnard R, Agius M, Chan D, Fraser D, et al. Sustaining a hemodialysis exercise program: a review. Semin Dial. 2010; 23(1):62-73.##16.	Ceballos O ML, Rojo L, Azócar PM, Ibacache M MJ, Delucchi BA, Quiroz ZL, et al. Mineral metabolism in patients on chronic peritoneal dialysis. Rev Chil Pediatr. 2014;85(1):31-39.##17.	Jhamb M, McNulty ML, Ingalsbe G, Childers JW, Schell J, Conroy MB, et al. Knowledge, barriers and facilitators of exercise in dialysis patients: a qualitative study of patients, staff and nephrologists. BMC Nephrol. 2016;17(1):192.##18.	Chien CL, Lee CM, Wu YW, Wu YT. Home-based exercise improves the quality of life and physical function but not the psychological status of people with chronic heart failure: a randomised trial. J Physiother. 2011;57(3):157-163.##19.	Tamura S. Relationshps Between Exercise Behavior, Self-Efficacy and Affect.USA:  University of Colorado Boulder , 2014.( Thesis)##20.	Basiri Moghaddam M, Mohamadpour A, Mottaghi M, Jahani Maghani F. Impact of Isometric and Isotonic Movements during Hemodialysis on Dialysis Adequacy. Horizon Med Sci. 2016;22(1):35-41.##21.	Mohseni R, Zeydi AE, Ilali E, Adib-Hajbaghery M, Makhlough A. The effect of intradialytic aerobic exercise on dialysis efficacy in hemodialysis patients: a randomized controlled trial. Oman Med J. 2013;28(5):345-349.##22.	Aliasgharpour M, Hadiyan Z. Assessment of a Designed Exercise Program on Physical Capacity using Six-Minute Walking Test (6MWT) in hemodialysis patients.J Hayat. 2011;17(3):59-68.(persian)##23.	Qiu Z, Zheng K, Zhang H, Feng J, Wang L, Zhou H. Physical Exercise and Patients with Chronic Renal Failure: A Meta-Analysis. Biomed Res Int.  2017;2017:7191826.##24.	Koh KP, Fassett RG, Sharman JE, Coombes JS, Williams AD. Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients: a randomized pilot study. Am J Kidney Dis. 2010;55(1):88-99.##25.	Parsons TL, Toffelmire EB, King-VanVlack CE. Exercise training during hemodialysis improves dialysis efficacy and physical performance. Arch Phys Med Rehabili. 2006;87(5):680-687.##26.	Pescatello L, Arena R, Riebe D, Thompson P. ACSM's guidelines for exercise testing and prescription.Philadelphia:  Lippincott Williams &#38; Wilkins; 2014.  p. 80.##27.	Britto RR, Probst VS, Andrade AF, Samora GA, Hernandes NA, Marinho PE, et al. Reference equations for the six-minute walk distance based on a Brazilian multicenter study. Braz J Phys Ther. 2013;17(6):556-563.##28.	Bulckaen M, Capitanini A, Lange S, Caciula A, Giuntoli F, Cupisti A. Implementation of exercise training programs in a hemodialysis unit: effects on physical performance. J Nephrol. 2011;24(6):790-797.##29.	Malagoni AM, Catizone L, Mandini S, Soffritti S, Manfredini R, Boari B, et al. Acute and long-term affects of an exercise program for dialysis patients prescribed in hospital and performed at home. J Nephrol. 2008;21(6):871-878.##30.	Bohm C, Stewart K, Onyskie-Marcus J, Esliger D, Kriellaars D, Rigatto C. Effects of intradialytic cycling compared with pedometry on physical function in chronic outpatient hemodialysis: a prospective randomized trial. Nephrol Dial Transplant. 2014;29(10):1947-1955.##31.	Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non‐supervised exercise therapy for intermittent claudication. Cochrane Dtabase Syst Rev. 2006; 19(2):CD005263.##32.	Organi  H, Firoozi F, Jabbari R. Effect of intradialytic exercise on hemodialysis adequency and improving patient condition in 4 month. Iran University Thesis.##33.	Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG. Time and exercise improve phosphate removal in hemodialysis patients. Am J Kidney Dis. 2004;43(1):85-89.##.   #### ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>بررسی ساختار عاملی تاییدی مقیاس افسردگی، اضطراب و ‌استرس (‌DASS‌) در دانشجویان</TitleF>
		<TitleE>Confirmatory Factor Structure of Depression, Anxiety and Stress Scale in Students

</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: افسردگی، اضطراب و استرس و سنجش آن&#8204;ها به&#8204;عنوان یک مسئله مرتبط با سلامت شناخته شده است. بنابراین پژوهش حاضر با هدف بررسی آزمون هم&#8204;ارزی و تغییرناپذیری جنسی مقیاس افسردگی، اضطراب و استرس (DASS) در دانشجویان دختر و پسر ایرانی انجام شد.
مواد و روش&#8204;ها: روش پژوهش حاضر، توصیفی از نوع بررسی تست&#8204;ها و همبستگی است. جامعه آماری شامل دانشجویان جدیدالورود سال 1392 کارشناسی دانشگاه شهید بهشتی می&#8204;باشند که 976 دانشجو (647 دختر و 329 نفر پسر) با استفاده از روش تمام&#8204;شماری، به وسیله مقیاس افسردگی، اضطراب و استرس (DASS) و نسخه کوتاه مقیاس بهزیستی روان&#8204;شناختی ریف مورد آزمون قرار گرفتند. نتایج با استفاده از نرم&#8204;افزار AMOS مورد تحلیل قرار گرفت.
یافته&#8204;ها: نتایج نشان داد که مدل 3 عاملی (افسردگی- اضطراب- استرس) برای کل دانشجویان توسط تحلیل عاملی تاییدی مورد تایید قرار گرفت و شاخص&#8204;های برازش نشان&#8204;دهنده&#8204;ی برازش خوب داده&#8204;ها با مدل 3 عاملی بود. همبستگی منفی این مقیاس با فرم کوتاه مقیاس بهزیستی روان&#8204;شناختی ریف نیز تأیید&#8204;کننده روایی این مقیاس می&#8204;باشد. هم&#8204;چنین ساختار عاملی بین دو گروه (دختر و پسر) نامتغیر است که این نشان می&#8204;دهد تفسیر سازه مکنون بین دو گروه یکسان است. نتایج تحلیل واریانس نیز نشان داد که در مولفه&#8204;های استرس و اضطراب، تفاوت معناداری بین دو جنس دختر و پسر وجود ندارد، اما در زیرمقیاس افسردگی، تفاوت اندکی بین دختران و پسران وجود دارد.
استنتاج: این مقیاس می&#8204;تواند به عنوان یک ابزار سنجش در مطالعات پژوهشی و موقعیت&#8204;های بالینی در هر دو جنس (مذکر و مونث) مورد استفاده قرار گیرد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Depression, anxiety, and stress and measuring their levels are regarded as important issues in health. This research aimed at investigating the sex equivalence and invariance of Depression, Anxiety and Stress Scale (DASS) in Iranian male and female students.
Materials and methods: A correlational study was done in 976 students (647 females and 329 males) in Shahid Beheshti University, 2014. The study population included all new students in undergraduate courses selected via complete enumeration. The participants responded to DASS and Ryff&#39;s Psychological Well-being Scales (RSPWB-SF). Data analysis was carried out in Amos 24.
Results: The three factor model (depression, anxiety, and stress) was confirmed through CFA for all students and goodness-of-fit indices showed that the model well fitted the data. The negative correlation between DASS and RSPWB-SF also confirmed the validity of the scale. Moreover, factor structure of the scale was invariant between males and females which showed that the interpretations of latent structures were the same between the two groups. The results of ANOVA also showed no significant differences between male and female students in anxiety and stress but a slight difference was found between them in depression.
Conclusion: The Depression, Anxiety and Stress Scale could be used as an assessment tool in research studies and clinical situations in both gender.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>94</FPAGE>
			<TPAGE>106</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/4
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/12/14
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/8
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/8/17
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>یوسف</Name>
				<MidName></MidName>
				<Family>اعظمی</Family>
				<NameE>Yousef</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Aazami</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری تخصصی روان شناسی، دانشکده روان شناسی و علوم تربیتی، دانشگاه علامه طباطبائی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مهدی</Name>
				<MidName></MidName>
				<Family>خانجانی</Family>
				<NameE>Mahdi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Khanjani</FamilyE>
				<Organizations>
				<Organization>استادیار گروه روان شناسی بالینی، دانشکده روان شناسی و علوم تربیتی، دانشگاه علامه طباطبائی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>khanjani.mahdi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد مهراد</Name>
				<MidName></MidName>
				<Family>صدر</Family>
				<NameE>Mohammad Mehrad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sader</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری تخصصی روان شناسی، دانشکده روان شناسی و علوم تربیتی، دانشگاه علامه طباطبائی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>multiple-group confirmatory factor analysis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>sex equivalence</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>sex invariance</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Depression</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Anxiety and Stress Scale</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>تحلیل عاملی تاییدی دوگروهی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>هم‌ارزی جنسی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>تغییرناپذیری جنسی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>مقیاس افسردگی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>اضطراب</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>استرس</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Bahadori-Khosroshahi J, Khanjani Z. Relationship of humor and negative life events with depression among students .ZJRMS.2012; 14(2): 96-100. (Persian)##2.	Sharif Nia H, Sharif SP, Esmaeili R, Goudarzian AH, Tahmasbi B, Yaghoobzadeh A, etal. Factors Influencing the Level of Death Depression in Patients with Cancer: A Path Analysis. J Mazandaran Uni Med Sci. 2017;26(145):318-331. (Persian)##3.	Mohamadi J, Mir Drikvand F, Azizi A. Efficacy of Mindfulness on Anxiety and Depression in Patients with Irritable Bowel Syndrome. Jour Mazandaran Uni Med Sci. 2015;25(130):52-61. (Persian)##4.	Carlson HM, Steuer J. Age, sex-role categorization, and psychological health in American homosexual and heterosexual men and women. J Soc Psychol .1985;125(2):203-211.##5.	Gomez R. Depression Anxiety Stress Scales: Factor structure and differential item functioning across women and men. Personal Individ Differ .2013  ;54(6):687-691.##6.	Rahnamay Namin M. Comparison of depression in students of Islamic Azad University living in Takestan, Abhar, and Bouin-Zahra dormitories (2009). J Qazvin Univ Med Sci .2012;16(2):83-86. (Persian)##7.	Segal ZV, Williams JMG, Teasdale JD. Midfulness-based cognitive therapy for depression: A new approach to preventing relapse. New York: Guilford Press; 2002.##8.	Kaplan H ,Sadock BJ. Synopsis of psychiatry: behavioral sciences/clinical psychiatry. 10thed .Florida:LWW; 2008.##9.	Montazeri A,MousaviSJ,Omidvar S,Hashemi A,Tavousi M. Depression in Iran: a systematic review of the literature.(2000-2010). PAYESH; 2013;12(6):567-594. (Persian)##10.	Hyman S, Chisholm D, Kessler R, Patel V, Whiteford H. Mental disorders In: Diseases control priorities related to mental, neurological, developmental and substance abuse disorders. Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P 2th ed. Washington (DC): World Bank; 2006.P:1-20.##11.	Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15(4):357-376.##12.	Mineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorders. Annu Rev Psychol 1998;49(1):377-412.##13.	Mousavi F, Taghavi Sh, Nematzadeh Z. Study of the Effect of Mental Stress on Mental Health of Medical Students of Iran Azad University, Tehran Medical Branch. Iranian Journal Surgery. 2012;20(1): 33-43. (Persian)##14.	Azad Marzabadi S, A'azami Y. Factors Causing Stress from the Perspective of Quran and Hadith. Jour Mil Med .2017;18(4): 299-307. (Persian)##15.	Pryce CR, Fuchs E. Chronic psychosocial stressors in adulthood: Studies in mice, rats and tree shrews. Neurobiol Stress. 2016 ;6: 94-103.##16.	Gammon J, Morgan-Samuel H. A study to ascertain the effect of structured student tutorial support on student stress, self-esteem and coping. Nurse Educ Practice .2005;5(3):161-171.##17.	Paykel ES. The evolution of life events research in psychiatry. J Affect Disord .2001 ;62(3):141-149.##18.	Baghiani Moghaddam MH, Ehrampoush MH, Rahimi B, Aminian AH, Aram M. Prevalence of depression among successful and unsuccessful students of Public Health and Nursing-Midwifery schools of Shahid Sadoughi University of Medical Sciences in 2008. J Med Educ Devel. 2011; 6(1): 17-24. (Persian)##19.	Hasanzadeh Taheri MM, Mogharab M, Akhbari SH, Raeisoon MR, Hasanzadeh Taheri E. Prevalence of depression among new registered students in Birjand University of Medical Sciences in the academic year 2009 -2010. J Birjand Uni Med Sci .2011;18(2):109-116. (Persian)##20.	Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales. Sydney: Psychology Foundation; 1995.##21.	Crawford JR, Henry JD. The Depression Anxiety Stress Scales (DASS): Normative data and latent structure in a large non‐clinical sample. Br J Clin Psychol. 2003;42(2):111-131.##22.	Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther .1997;35(1):79-89.##23.	Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. Psychol Assess .1998;10(2):176-181.##24.	Sahebi A, Salari RS, Asghari MJ. Validationof Depression Anxiety and Stress Scale (DASS-21) for an Iranian Population. J Dev Psychol .2005;1(4): 299-312. (Persian)##25.	Sefidi FA, Farzad V. Validated measure of Ryff psychological well-being among students of Qazvin University of Medical Sciences (2009). J Qazvin Univ Med Sci. 2012;16(1):66-71. (Persian)##26.	Ryff CD, Singer BH. Best news yet on the six-factor model of well-being. Soc Sci Res. 2006;35(4):1103-1119.##27.	Shokri O, Kadivar P, Farzad V, Daneshpor Z, Dastjerdi R, Paeezi M. The study of factor structure of Persian version (3, 9 and 14 item) of Ryyf's psychological Well-Being Scales among students. J Psychiatr Clin Psychol .2008; 2(14):152-161. (Persian)##28.	khanjani M, Shahidi Sh, Fathabadi J, Mazaheri MA, Shokri O. Factor structure and psychometric properties of the short (18 questions) Psychological well-being scale between male and female students. Thought Behav Clin Psychol .2014; 8(32): 27-36. (Persian)##29.	Ang RP, Huan VS, Braman OR. Factorial structure and invariance of the Academic Expectations Stress Inventory across Hispanic and Chinese adolescent samples. Child Psychiatr Hum Dev. 2007 ;38(1):73-87.##30.	Rigotti T, Schyns B, Mohr G. A short version of the occupational self-efficacy scale: Structural and construct validity across five countries. J  Career Assess. 2008;16(2):238-255.##31.	Meade AW, Lautenschlager GJ. A comparison of item response theory and confirmatory factor analytic methodologies for establishing measurement equivalence/invariance. Organ Res Method. 2004;7(4):361-388.##32.	Byrne BM, Watkins D. The issue of measurement invariance revisited. J Cross Cult Psychol .2003;34(2):155-175.##33.	Chan D. Detection of differential item functioning on the Kirton Adaption-Innovation Inventory using multiple-group mean and covariance structure analyses. Multivar Behav Res .2000;35(2):169-199.##34.	Joshanloo M, Rostami R, Nosratabadi M. Examining the factor structure of the Keyes’ comprehensive scale of well-being. Journal of Iranian Psychologists .2006;3(9):35-51. (Persian)##35.	Bayani AA, Koochekya AM, Bayani A. Reliability and validity of Ryyf's psychological Well-Being Scales. IJPCP .2008; 14(2): 146-151. (Persian)##36.	Shea TL, Tennant A, Pallant JF. Rasch model analysis of the Depression, Anxiety and Stress Scales (DASS). BMC Psychiatry .2009;9(1):21-31.##37.	BangasserD A, Wicks B. Sex‐specific mechanisms for responding to stress. J  Neurosci Res. 2017; 95(1-2): 75-82.##38.	Lee HS, Kim C. Structural Equation Modeling to Assess Discrimination, Stress, Social Support, and Depression among the Elderly Women in South Korea. Asian Nurs Res. 2016;10(3):182-188.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>بررسی رابطه عوامل دموگرافیک، مامایی و استرس با خوش بینی زنان باردار</TitleF>
		<TitleE>Relationship between Demographic and Obstetric Factors and Perceived Stress with Optimism in Pregnant Women

</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: بارداری تجربه&#8204;ای پر استرس تلقی می&#8204;شود. خوش&#8204;بینی به آینده باعث می&#8204;شود که فرد موقعیت استرس زا را با دید مثبتی ارزیابی کند. عوامل مختلفی با خوش&#8204;بینی زنان باردار در ارتباط است. در همین راستا، مطالعه حاضر با هدف بررسی رابطه عوامل دموگرافیک، مامایی و استرس با خوش&#8204;بینی زنان باردار انجام شد.
مواد و روش&#8204;ها: این مطالعه همبستگی بر روی 500 زن باردار مراجعه&#8204;کننده به 20 مرکز بهداشتی شهر مشهد در سال 1395 به روش نمونه&#8204;گیری چند مرحله&#8204;ای طبقه&#8204;ای خوشه&#8204;ای انجام شد. ابزار جمع&#8204;آوری داده&#8204;ها شامل پرسشنامه خوش&#8204;بینی (جهت&#8204;گیری زندگی)، پرسشنامه پژوهش&#8204;گر ساخته دموگرافیک و مامایی و استرس ادراک شده بود. 
یافته&#8204;ها: میانگین نمره خوش&#8204;بینی مادران باردار 0/4 &#177; 6/15 بود. متغیرهای کیفی مانند تحصیلات مادر و همسر، وضعیت مسکن، وضعیت درآمد، سابقه زایمان، تجربه قبلی زایمان و نگرانی در مورد جنسیت فرزند با خوش&#8204;بینی زنان در بارداری ارتباط معنی&#8204;داری داشت (001/0&#62;P) و متغیرهایی کمی مانند سن مادر (17/0&#160; r=، 001/0&#62;P)، تعداد فرزند زنده (13/0r=، 006/0=P)، تعداد زایمان (09/0 r=، 03/0=P) و سن بارداری (20/0&#160; r=، 001/0&#62;P) با خوش&#8204;بینی ارتباط مستقیم و معنی&#8204;دار و تعداد فرزند مرده (17/0 -&#160; r=، 001/0&#62;P)، تعداد سقط (15/0- r=، 001/0&#62;P) و استرس ادراک شده (77/0-r=، 001/0&#62;P) با خوش&#8204;بینی ارتباط معکوس و معنی&#8204;داری داشتند.
استنتاج: عوامل دموگرافیک مامایی و استرس با میزان خوش&#8204;بینی زنان در بارداری ارتباط دارد. هر چه میزان خوش&#8204;بینی مادر در بارداری افزایش یابد، مادر استرس کم&#8204;تری را درک می&#8204;کند. شناخت عوامل تاثیر گذار بر میزان خوش&#8204;بینی مادر در بارداری می&#8204;تواند زمینه را برای ارتقا سلامت روان در بارداری فراهم نماید.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Pregnancy is recognized as a stressful experience. Optimism in future gives a person a positive vision to analyze a stressful situation. Various factors are associated with optimism in pregnant women. The present study aimed to assess the demographic, obstetric, and stress factors with optimism in pregnant women.
Materials and methods: This descriptive-correlative study was conducted in 500 pregnant women attending 20 health centers in Mashhad, Iran 2016. They were selected via multi-stage sampling. Data collection tools included a demographic questionnaire, obstetrics and gynecology questionnaire, Life Orientation Test- Revised, and Perceived Stress Scale.
Results: The mean score for optimism in pregnant women was 15.6 &#177; 4.0. Qualitative variables such as education of mother and spouse, housing status, income, history of labor, previous experiences of delivery and concerns about the child&#39;s gender was significantly associated with optimism in pregnant women (P&#60; 0.001).There was a significant positive correlation&#160; between optimism and some quantitative variables including, maternal age (R=0.17, P&#60; 0.001), number of children (R=0.13, P &#60;0.006), parity (R=0.09, P&#60; 0.03), and gestational age (R=0.2, P&#60; 0.001). However, numbers of dead birth (R=-0.17 P&#60; 0.001) and abortions (R=-0.15 P&#60; 0.001) and perceived stress (R=-0.77 P&#60; 0.001) were found to have inverse correlation with optimism.
Conclusion: There is a relationship between demographic, obstetric characteristics and perceived stress and optimism. With higher levels of optimism in pregnancy, the mothers would experience lower rates of stress.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>107</FPAGE>
			<TPAGE>118</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/1
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/2/11
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/11
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/8/20
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>آزاده</Name>
				<MidName></MidName>
				<Family>سارانی</Family>
				<NameE>Azade</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sarani</FamilyE>
				<Organizations>
				<Organization>مربی، گروه مامایی، دانشکده پزشکی، واحد زاهدان، دانشگاه آزاد اسلامی، زاهدان ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سعیده</Name>
				<MidName></MidName>
				<Family>ریگی یوسف آبادی</Family>
				<NameE>Saeedeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rigi Yousefabad</FamilyE>
				<Organizations>
				<Organization>مربی، گروه مامایی، دانشکده پرستاری مامایی، دانشگاه علوم پزشکی ایرانشهر، ایرانشهر، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>saedehrigi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>حسین</Name>
				<MidName></MidName>
				<Family>زراعتی</Family>
				<NameE>Hossein</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zeraati</FamilyE>
				<Organizations>
				<Organization>مربی، گروه هوشبری، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی خراسان شمالی، بجنورد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>جواد</Name>
				<MidName></MidName>
				<Family>شاهین فر</Family>
				<NameE>Javad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shahinfar</FamilyE>
				<Organizations>
				<Organization>مربی، گروه هوشبری، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی خراسان شمالی، بجنورد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>optimism</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>pregnancy</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>stress</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>demographic factors</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>obstetric factors</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>بارداری</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>استرس</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>خوش بینی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>فاکتورهای دموگرافیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>فاکتورهای مامایی</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Srivastava S, Angelo KM. Optimism, effects on relationships. Encyclopedia of Human Relationships Thousand Oaks, CA: Sage. 2009.##2.	Kajbaf  MB, Arizy HR, Khodabakhshi  M. Standardization, Reliability, and Validity of Optimism Scale in Esfahan and a Survey of Relationship between Optimism, Selfmastery, and Depression. Journal of Psychological Studies. .2006;2(1):51-68. (Persian)##3.	Rezaie A, Mohammadzade A, Ghadampour EA, Noghabi RK. Optimism-pessimism and information processing styles as predictors of depression and life satisfaction. Journal of Foundamental of mental health. 2013;15(3):93-184. (Persian)##4.	Carver CS, Pozo C, Harris SD, Noriega V, Scheier MF, Robinson DS, et al. How coping mediates the effect of optimism on distress: a study of women with early stage breast cancer. J Pers Soc Psychol. 1993;65(2):375-382.##5.	Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol. 1994;67(6):1063-1071.##6.	Peterson C. The future of optimism. Am Psychol. 2000;55(1):44-55.##7.	Lavasani  GM, Egeie J, Mohammadi Masiri F. The Relationship between Meaning of Life and Optimism with Subjective Well-being. J Psychol. 2013;17(1):3-17. (Persian)##8.	Aghaei A, Raisi Dehkordi  R, Atashpur  H . Relationship between optimism and pessimism and mental health in adults in Isfahan. Knowl Res Psychol 2008 9(33): 117-30. (Persian)##9.	Segerstrom SC, Taylor SE, Kemeny ME, Fahey JL. Optimism is associated with mood, coping, and immune change in response to stress. J Pers Soc Psychol. 1998,6(4): 1646-1655.##10.	Shelby RA, Crespin TR, Wells-Di Gregorio SM, Lamdan RM, Siegel JE, Taylor KL. Optimism, social support, and adjustment in African American women with breast cancer. J Beh Med. 2008;31(5):433-444.##11.	Fournier M, de Ridder D, Bensing J. How optimism contributes to the adaptation of chronic illness. A prospective study into the enduring effects of optimism on adaptation moderated by the controllability of chronic illness. Per Individ Differ. 2002;33(7):1163-1183.##12.	salari P, Firoozi  M, Sahebi  A. Study of the Stressors Associated with Pregnancy. Journal of Sabzevar University of Medical Sciences. 2005;12(3):34-40. [Persian]##13.	Poursardar F, Poursardar  F, Panahandeh  A, Sangari A, Abdi zarrin  S. Effect  of Optimism on Mental Health and Life Satisfaction: A Psychological Model of Well-being. HAKIM. 2013;16(1):42-49.   (Persian)##14.	Lobel M, Yali AM, Zhu W, DeVincent CJ, Meyer BA. Beneficial associations between optimistic disposition and emotional distress in high-risk pregnancy. Psychol Health. 2002;17(1):77-95.##15.	Hamilton JG, Lobel M. Types, patterns, and predictors of coping with stress during pregnancy: Examination of the Revised Prenatal Coping Inventory in a diverse sample. J Psychosom Obstet Gyncol. 2008;29(2),97-104.##16.	Lobel M, DeVincent CJ, Kaminer A, Meyer BA. The impact of prenatal maternal stress and optimistic disposition on birth outcomes in medically high-risk women. Health Psychol. 2000;19(6):534-544.##17.	Rahimian Boogar  I. The Predictive Role of Happiness, Optimism and Demographical Status in Engagement in Health-related Behaviors. Knowl Health. 2013;8(1):17-23.##18.	Saisto T, Halmesmäki E. “Fear of childbirth: a neglected dilemma. Acta Obset Gynaecol Scandinavica. 2003;82(3):201-208.##19.	Bahadori Khosroshahi J, Hashemi Nosrat abad T. Relationship between social anxiety and optimism, self-efficacy and psychological well-being of students.  J Urmia Univ Med Sci.  2012;23(2):115-122. (Persian)##20.	Thome J, Espelage DL. Relations among exercise, coping, disordered eating, and psychological health among college students. Eat Behav. 2004;5(4):337-351.##21.	Hoseinzadeh  MR. Effects of optimism on psychological health. Online Professional J Noor. 2010 (373):26-29.   (Persian)##22.	Subramanian S, Nithyanandan M. Hardiness and optimism as moderators of cognitive emotion regulation strategies in coping negative life events by adolescents.[thesis,MA]. Department of Psychology, Bharathiar University India A .2007.##23.	Alibeyk f, Ahmadi A, Farahbakhsh K, Abedi A, Ali Beyk M. The Effect of Optimism Training on Quality of Life among Dormitory Female Students at Isfahan Medical University. Iranian Journal of Medical Education. 2012;12(9):710-718. (Persian)##24.	Jafar Tabatabaie TS, Ahadi H, KHamesan A. The effect of optimism training on the anxiety and depression of students of psychology at theAzad University of Birjand. Mod Care J. 2013;10(1),34-42. (Persian)##25.	Moyer CA, Yang H, Kwawukume Y, Gupta A, Zhu Y, Koranteng I, et al. Optimism/pessimism and health-related quality of life during pregnancy across three continents: a matched cohort study in China, Ghana, and the United States. BMC Preg Child. 2009;9(1):39.46.##26.	Hamzezade M, Bagherian F, Mansouri Sepehr R. The interactive effect of optimism with goal orientation on attention bias. Cont Psychol. 2013;7(2):410-415. (Persian)##27.	Seheier MF, Carver CS, Bridges MW. Distinguishing Optimism from neuroticism (and trait anxiety, self-mastery, and self esteem); a reevaluation of the life orientation test. J Pers Soc Psychol. 1994;6(10),63-78.##28.	Dolatiyan M, Mirab Zade A, Frozan AS, Sajadi H, Alavi Mahd H, Moafi  F, et al. Correlation between self-esteem and perceived stress in pregnancy and cophng strategies with it. Res J Shahid Beheshti Uni Med Sci. 2013;18(3):148-155. (Persian)##29.	Mazlom SR, Darban F, Modares GHorori M, Kashani Lotfabadi M, SHad M. The effect of Stress Inoculation Program (SIP) on nurses’ Perceived stress in psychiatric wards. Evidence Based Care J 2012; 2(1):35-44. (Persian)##30.	Taati  F, Shokri O, Shahidi  SH. The mediating role of optimism on the relationship between experience of and reaction to stressful academic experiences. Contem Psychol.2013,8(1),73-80. (Persian)##31.	Iwanaga M, Yokoyama H, Seiwa H. Coping availability and stress reduction for optimistic and pessimistic individuals. Pers Individ Differ. 2004;36(1):11-22.##32.	Yali AM, Lobel M. Stress-resistance resources and coping in pregnancy. Anxiety, Stress &#38; Coping. 2002;15(3):289-309.##33.	Mosavi Nasab SM, Taghavi SM, Mohammadi N. Optimism and Evaluation stress :According to the predictions of  two theoretical models psychological adaptation. J Kerman Uni Med Sci. 2006;13(2):111-120.  (Persian).##34.	Chang EC, Sanna LJ. Optimism, pessimism, and positive and negative affectivity in middle-aged adults: a test of a cognitive-affective model of psychological adjustment. Psychol Aging. 2001;19(3):524-531.##35.	Mattis JS, Fontenot DL, Hatcher-Kay CA, Grayman NA, Beale RL. Religiosity, optimism, and pessimism among African Americans. J Black Psychol. 2004;30(2):187-207.##36.	Schutte JW, Valerio JK, Carrillo V. Optimism and socioeconomic status: a cross-cultural study. SOC BEHAV PERSONAL. 1996;24(1):9-18.##37.	Achat H, Kawachi I, Spiro A, DeMolles DA, Sparrow D. optimism and depression as predictors of physical and mental health functioning: the normative aging study. Ann Behav Med. 2000,22(2),127-133.##38.	Azhari S, Sarani A, Mazlom SR, Aghamohammadian Sherbaf HA. The relationship between optimism with prenatal coping strategies. Iranian J Psych Nurs. 2015;3(1):71-83.##39.	Yousefzadeh S, Esmaeli Darmian M, Asadi Yoonesi MR, Shakeri MT. Investigating the Effect of Optimism Training during Pregnancy on Attitude and Mode of Delivery in Nulliparous Women Referred to Health Centers of Mashhad. Arak Med Uni J. 2016;19(2):89-98. (Persian)##40.	Moyer CA, Elsayed Y, Zhu Y, Wei Y, Engmann CM, Yang H. Is Generalized Maternal Optimism or Pessimism During Pregnancy Associated with Unplanned Cesarean Section Deliveries in China? J Preg. 2010.13(1),81-96##41.	Rasmussen HN, Scheier MF, Greenhouse JB. Optimism and physical health: a meta-analytic review. Ann Behav Med. 2009;37(3):239-256.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>بررسی کارایی فرایند اکسیداسیون پیشرفته بر پایه پرسولفات (UV/Na2S2O8) برای حذف مترونیدازول از محلول‌های آبی

</TitleF>
		<TitleE>Efficiency of Persulfate-based Advanced Oxidation Process (UV/Na2S2O8) in Removal of Metronidazole from Aqueous Solutions</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: آنتی&#8204;بیوتیک&#8204;ها به&#8204;طور گسترده&#8204;ای برای درمان بیماری&#8204;ها استفاده می&#8204;شوند. مترونیدازول یک آنتی&#8204;بیوتیک از خانواده نیتروایمیدازول می&#8204;باشد که به&#8204;طور گسترده&#8204;ای برای درمان بیماری&#8204;های عفونی ناشی از باکتری&#8204;ها و تک&#8204;یاخته&#8204;ها استفاده می&#8204;شود. این ترکیب تجزیه ناپذیر، دارای حلالیت بالا در آب، سمی، سرطان&#8204;زا و جهش&#8204;زا می&#8204;باشد. فرایند اکسیداسیون پیشرفته یک روش مؤثر در حذف مترونیدازول می&#8204;باشد. هدف از این پژوهش، بررسی کارآیی فرایند اکسیداسیون پیشرفته بر پایه پرسولفات (UV/Na2S2O8) برای حذف مترونیدازول از محلول&#8204;های آبی می&#8204;باشد.
مواد و روش&#8204;ها: در این مطالعه تجربی، اثر متغیرهای pH، غلظت پرسولفات و زمان تماس توسط یک لامپ UV-C با قدرت 16 وات مطالعه گردید و غلظت باقی مانده مترونیدازول توسط دستگاه اسپکتروفتومتر مدل UV-Vis مدل Cecil CE7400 سنجش شد.
یافته&#8204;ها: در این مطالعه، 9=pH، غلظت پرسولفات 7/0 میلی مول بر لیتر و زمان تماس 30 دقیقه، به&#8204;عنوان شرایط بهینه به دست آمد. نتایج نشان داد که فرایند حذف مترونیدازول توسط اکسیداسیون پیشرفته بر پایه پرسولفات (UV/Na2S2O8) از مدل سینتیک درجه اول پیروی می&#8204;نماید.
استنتاج: نتایج این بررسی نشان داد اکسیداسیون پیشرفته بر پایه پرسولفات (UV/Na2S2O8) روش مؤثری جهت حذف مترونیدازول از محلول&#8204;های آبی می&#8204;باشد و به&#8204;عنوان فرایندی مؤثر و کارآمد می&#8204;تواند جهت تصفیه محلول&#8204;های آبی مربوطه مورد استفاده قرار گیرد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Antibiotics are extensively used in treatment of diseases. Metronidazole is an antimicrobial agent and is a nitroimidazole derivative, which is widely used in treatment of infectious diseases caused by bacteria and protozoa. This compound is irrefrangible, toxic, carcinogenic, mutagenic, and has high solubility in water. Advanced oxidation process is an effective method for removal of metronidazole from aqueous solutions. The aim of this study was to evaluate the efficacy of advanced oxidation process based on persulfate (UV / Na2S2O8) to remove metronidazole from aqueous solutions.
Materials and methods: In this research, the effect of some variables such as pH, persulfate concentration and contact time was studied by a UV-C lamp (16 watts). Also, the remaining concentration of metronidazole was measured by UV-Vis spectrophotometer Cecil model CE7400.
Results: The optimum conditions in this study were obtained at pH=9، persulfate concentration of 0.7 mmol/l, and contact time of 30 min. The removal of metronidazole by advanced oxidation process based on persulfate (UV / Na2S2O8) followed the first-order kinetic model.
Conclusion: Persulfate-based advanced oxidation process (UV/Na2S2O8) is an effective method for removal of metronidazole from aqueous solution. It is recommended as an effective and efficient process that could be used for purification of aqueous solutions.
&#160;
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>119</FPAGE>
			<TPAGE>129</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/18
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/1/29
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/26
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/6/4
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>فاطمه</Name>
				<MidName></MidName>
				<Family>آزادبخت</Family>
				<NameE>Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Azadbakht</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>علی</Name>
				<MidName></MidName>
				<Family>اسرافیلی</Family>
				<NameE>Ali</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Esrafili</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مجتبی</Name>
				<MidName></MidName>
				<Family>یگانه بادی</Family>
				<NameE>Mojtaba</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Yeganeh Badi</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>جواد</Name>
				<MidName></MidName>
				<Family>ساجدی فر</Family>
				<NameE>Javad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sajedifar</FamilyE>
				<Organizations>
				<Organization>مربی، گروه مهندسی بهداشت حرفه‌ای، دانشکده بهداشت، دانشگاه علوم پزشکی نیشابور، نیشابور، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مهناز</Name>
				<MidName></MidName>
				<Family>امیری</Family>
				<NameE>Mahnaz</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Amiri</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>میترا</Name>
				<MidName></MidName>
				<Family>غلامی</Family>
				<NameE>Mitra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Gholami</FamilyE>
				<Organizations>
				<Organization>استاد، گروه مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>gholamim@iums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>metronidazole</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>persulfate</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>UV</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>aqueous solutions</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>مترونیدازول</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پرسولفات</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>UV</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>محلول‌های آبی</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Liu H, Liu W, Zhang J, Zhang C, Ren L, Li Y. Removal of cephalexin from aqueous solutions by original and Cu (II)/Fe (III) impregnated activated carbons developed from lotus stalks Kinetics and equilibrium studies. J Hazard Mater. 2011;185(2-3):1528-1535.##2.	Thiele-Bruhn S, Beck I-C. Effects of sulfonamide and tetracycline antibiotics on soil microbial activity and microbial biomass. Chemosphere. 2005;59(4):457-465.##3.	Sui M, Xing S, Sheng L, Huang S, Guo H. Heterogeneous catalytic ozonation of ciprofloxacin in water with carbon nanotube supported manganese oxides as catalyst. J Hazard Mater. 2012;227:227-236.##4.	Fang Z, Chen J, Qiu X, Qiu X, Cheng W, Zhu L. Effective removal of antibiotic metronidazole from water by nanoscale zero-valent iron particles. Desalination. 2011;268(1-3):60-67.##5.	Chen J, Qiu X, Fang Z, Yang M, Pokeung T, Gu F, et al. Removal mechanism of antibiotic metronidazole from aquatic solutions by using nanoscale zero-valent iron particles. Chemical Engineering Journal. 2012;181-182:113-119.##6.	Shemer H, Kunukcu YK, Linden KG. Degradation of the pharmaceutical metronidazole via UV, Fenton and photo-Fenton processes. Chemosphere. 2006;63(2):269-276.##7.	Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res Rev Mutat Res. 2002;511(2):133-144.##8.	Cheng W, Yang M, Xie Y, Liang B, Fang Z, Tsang EP. Enhancement of mineralization of metronidazole by the electro-Fenton process with a Ce/SnO 2–Sb coated titanium anode. Chem Eng J. 2013;220:214-220.##9.	Li K, Yediler A, Yang M, Schulte-Hostede S, Wong MH. Ozonation of oxytetracycline and toxicological assessment of its oxidation by-products. Chemosphere. 2008;72(3):473-478.##10.	Trovo AG, Nogueira RFP, Agüera A, Fernandez-Alba AR, Malato S. Degradation of the antibiotic amoxicillin by photo-Fenton process–chemical and toxicological assessment. Water Res. 2011;45(3):1394-1402.##11.	Albalghini M. Tracing of Residues of Some Pharmaceutical preparation in water. CU Theses. Egypt Giza. Cairo University;2015.##12.	Zazouli MA, Susanto H, Nasseri S, Ulbricht M. Influences of solution chemistry and polymeric natural organic matter on the removal of aquatic pharmaceutical residuals by nanofiltration. Water Res. 2009;43(13):3270-3280.##13.	Zazouli M, Ulbricht M, Nasseri S, Susanto H. Effect of hydrophilic and hydrophobic organic matter on amoxicillin and cephalexin residuals rejection from water by nanofiltration. Journal of Environmental Health Science &#38; Engineering. 2010;7(1):15-24 (persian)##14.	Samadi MT, Shokoohi R, Araghchian M, Tarlani Azar M. Amoxicillin Removal from Aquatic Solutions Using Multi-Walled Carbon Nanotubes. J Mazandaran Univ Med Sci . 2014;24(117):103-115. (persian)##15.	Dantas RF, Rossiter O, Teixeira AKR, Simões AS, da Silva VL. Direct UV photolysis of propranolol and metronidazole in aqueous solution. Chem Eng J. 2010;158(2):143-147.##16.	Gonçalves AG, Órfão JJ, Pereira MFR. Catalytic ozonation of sulphamethoxazole in the presence of carbon materials: catalytic performance and reaction pathways. J Hazard Mater. 2012;239:167-174.##17.	Wang H, Zhang G, Gao Y. Photocatalytic degradation of metronidazole in aqueous solution by niobate K 6 Nb 10.8 O 30. Wuhan Univ J Nat Sci. 2010;15(4):345-349.##18.	Chianeh FN, Parsa JB. Electrochemical degradation of metronidazole from aqueous solutions using stainless steel anode coated with SnO2 nanoparticles: experimental design. J Taiwan Inst Chem Eng. 2016;59:424-432.##19.	Homem V, Santos L. Degradation and removal methods of antibiotics from aqueous matrices–a review. J Environ Manage. 2011;92(10):2304-2347.##20.	Shahmoradi B, Maleki A, Byrappa K. Photocatalytic degradation of Amaranth and Brilliant Blue FCF dyes using in situ modified tungsten doped TiO 2 hybrid nanoparticles. Catal Sci Technol. 2011;1(7):1216-1223.##21.	Robinson T, McMullan G, Marchant R, Nigam P. Remediation of dyes in textile effluent: a critical review on current treatment technologies with a proposed alternative. Bioresour Technol.2001;77(3):247-255.##22.	Khan MH, Jung JY. Ozonation catalyzed by homogeneous and heterogeneous catalysts for degradation of DEHP in aqueous phase. Chemosphere. 2008;72(4):690-696.##23.	Ahmadi M, Rahmani H, Takdastan A, Jaafarzadeh N, Mostoufi A. A novel catalytic process for degradation of bisphenol A from aqueous solutions: a synergistic effect of nano-Fe 3 O 4@ Alg-Fe on O 3/H 2 O 2. Process Saf Environ Prot. 2016;104:413-421.##24.	Lindberg R, Jarnheimer PA, Olsen B, Johansson M, Tysklind M. Determination of antibiotic substances in hospital sewage water using solid phase extraction and liquid chromatography/mass spectrometry and group analogue internal standards. Chemosphere. 2004;57(10):1479-1488.##25.	Usman M, Faure P, Ruby C, Hanna K. Application of magnetite-activated persulfate oxidation for the degradation of PAHs in contaminated soils. Chemosphere. 2012;87(3):234-240.##26.	Wu J, Zhang H, Qiu J. Degradation of Acid Orange 7 in aqueous solution by a novel electro/Fe 2+/peroxydisulfate process. J Hazard Mater.2012;215:138-145.##27.	Seidmohammadi A, Asgari G, Torabi L. Removal of Metronidazole Using Ozone Activated Persulfate from Aqua Solutions in Presence of Ultrasound.  J Mazandaran Univ Med Sci. 2016;26(143):160-173. (persian)##28.	Esrafili A, Rezaei Kalantary R, Azari A, Ahmadi E, Gholami M. Removal of diethyl phthalate from aqueous solution using persulfate-based (UV/Na2S2O8/Fe2+) advanced oxidation process. J Mazandaran Univ Med Sci. 2016;25(132):122-135. (persian)##29.	Tsitonaki A, Petri B, Crimi M, Mosbæk H, Siegrist RL, Bjerg PL. In situ chemical oxidation of contaminated soil and groundwater using persulfate: a review. Crit Rev Environ Sci Technol. 2010;40(1):55-91.##30.	Samarghandi MR, Leili M, Harati R, Tarlani Azar M. Efficiency of electro/persulfate process by iron electrode in removing furfural from aqueous solution. J Mazandaran Univ Med Sci. 2014;24(119):95-108. (persian)##31.	Veisi F, Veisi A. Modeling bisphenol a removal from aqueous solution by activated carbon and eggshell. J Mazandaran Univ Med Sci. 2013;22(2):129-138.##32.	Qi C, Liu X, Lin C, Zhang X, Ma J, Tan H, et al. Degradation of sulfamethoxazole by microwave-activated persulfate: kinetics, mechanism and acute toxicity. Chem  Eng J. 2014;249:6-14.##33.	Pozar DM. Microwave engineering.4thed. Michigan, Wiley ; 2009.##34.	Veisi F, Zazouli MA, Ebrahimzadeh MA, Charati JY, Dezfoli AS. Photocatalytic degradation of furfural in aqueous solution by N-doped titanium dioxide nanoparticles. Environ Sci Pollut Res Int. 2016;23(21):21846-21860.##35.	Guo Y, Zhou J, Lou X, Liu R, Xiao D, Fang C, et al. Enhanced degradation of Tetrabromobisphenol A in water by a UV/base/persulfate system: Kinetics and intermediates. Chem Eng J .2014;254:538- 544.##36.	Bahrami Asl F, Kermani M, Farzadkia M, Esrafili A, Salahshour Arian S, Zeynalzadeh D,et al. Removal of Metronidazole from Aqueous Solution Using Ozonation Process. J Mazandaran Univ Med Sci .2015;24(121):131-140. (persian)##37.	Farzadkia M, Esrafili A, Baghapour MA, Shahamat YD, Okhovat N. Degradation of metronidazole in aqueous solution by nano-ZnO/UV photocatalytic process. Desalination Water Treat. 2014;52(25-27):4947-4952.##38.	Dai Q, Zhou J, Weng M, Luo X, Feng D, Chen J. Electrochemical oxidation metronidazole with Co modified PbO 2 electrode: Degradation and mechanism. Sep. Purif. Technol. 2016;166:109-116.##39.	Ta N, Hong J, Liu T, Sun C. Degradation of atrazine by microwave-assisted electrodeless discharge mercury lamp in aqueous solution. J Hazard Mater.2006;138(1):187-194.##40.	Shiying Y, Ping W, Xin Y, Guang W, Zhang W, Liang S. A novel advanced oxidation process to degrade organic pollutants in wastewater: Microwave-activated persulfate oxidation. J Environ Sci (China). 2009;21(9):1175-1180.##41.	Li Z, Hong H, Liao L, Ackley CJ, Schulz LA, MacDonald RA, et al. A mechanistic study of ciprofloxacin removal by kaolinite. Colloids Surf B Biointerfaces. 2011;88(1):339-344.##42.	Rahmani A, Shabanlo A, Majidi S, Tarlani-Azar M, Mehralipour J. Efficiency of Ciprofloxacin (CIP) Removal from Pharmaceutical Effluents Using the Ozone/Persulfate(O3/PS) Process.J Water &#38;Waste Water. 2016;27(1):40-48 .(persian)##43.	Abdoli A, Shokuhi R, Seid Mohammadi A, Asgari G. Survey of Catalytic O zonation Process with MgO-Modified Activated Carbon for the Removal of Metronidazole from Aqueous Solutions through a Fluidized Bed Reactor . J Sabzevar Uni Med Sci. 2016;23(1):84-94(persian)## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>   بررسی کارایی فرآیند سونوفنتون در حذف سولفاستامید از محیط های آبی در حضور نانو ذرات آهن صفر

</TitleF>
		<TitleE>Efficiency of Sonofenton Degradation in Removal of Sulfacetamide from Aqueous Solutions Using Nanoscale Zerovalent Iron Particles</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: در سال&#8204;های اخیر وجود آنتی&#8204;بیوتیک&#8204;ها در محیط&#8204;های آبی بسیار مورد توجه قرار گرفته است. ترکیبات مذکور به&#8204;دلیل عدم تجزیه کامل طی فرآیندهای متداول تصفیه در محیط باقی می&#8204;مانند. فرآیندهای اکسیداسیون پیشرفته به منظور حذف بسیاری از آلاینده&#8204;ها مورد استفاده قرار می&#8204;گیرند. هدف از مطالعه حاضر بررسی کارایی فرآیند سونوفنتون در حذف آنتی بیوتیک سولفاستامید در حضور نانو ذرات آهن صفر می&#8204;باشد.
مواد و روش&#8204;ها: تحقیق انجام شده یک مطالعه تجربی-آزمایشگاهی بود. نانو ذرات آهن صفر به روش احیای سولفات آهن توسط بور هیدرید سدیم تولید گردید. تأثیر پارامترهای مختلف از قبیل pH (9-3)، غلظت نانو ذرات آهن صفر (g/L 8-1 )، غلظت پراکسید هیدروژن (M 05/0-2 ) و زمان تماس (90-5 دقیقه ) بر کارایی فرآیند بررسی شد. میزان آنتی بیوتیک باقی&#8204;مانده با استفاده از دستگاه UV-HPLC مجهز به ستون C18 قرائت شد.
یافته&#8204;ها: طبق نتایج به دست آمده بیش&#8204;ترین میزان حذف سولفاستامید در 3=pH، زمان تماس 60 دقیقه، میزان g/L 5 &#160;نانو ذرات آهن صفر و غلظت 1 مولار پراکسید هیدروژن مشاهده شد. در شرایط بهینه مذکور، میزان حذف سولفاستامید 91 درصد و میزان حذف COD 27 درصد بوده است.
استنتاج: طبق آزمایشات صورت گرفته فرآیند سونوکاتالیست به همراه کاربرد نانو ذرات آهن صفر و پراکسید هیدروژن به&#8204;عنوان عامل اکسید کننده، روشی مؤثر در کاهش آنتی بیوتیک سولفاستامید و سایر ترکیبات مقاوم به تجزیه بیولوژیکی می&#8204;باشد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: In recent years, the presence of antibiotics in aquatic environment has received increasing attention. These compounds remain in the environment, because of incomplete elimination in conventional wastewater treatment processes. Advanced oxidation processes are used to remove many pollutants. The aim of this study was to evaluate the efficiency of sono-fenton degradation in removal of sulfacetamide in presence of zerovalent iron nanoparticles.
Materials and methods: An experimental-laboratory scale study was carried out in which NZVI was synthesized through reducing iron sulfate by sodium borohydride. The effects of some variables such as pH (3-9), NZVI concentration (1-8g/L), H2O2 concentration (0.05-2 M) and contact time (5-90 min) were investigated on the process efficiency. Concentration of residual antibiotic was analyzed by HPLC-UV equipped with a C18 column.
Results: The maximum removal efficiency was observed at pH=3, 60 min contact time, 5 g/L NZVI concentration and H2O2 concentration of 1 M. In these optimal conditions, the removal efficiency was 91% and COD removal degree was 27%.
Conclusion: The experiments showed that the sonocatalytic process using NZVI nanoparticles along with adding H2O2 as an oxidant is an efficient method to remove sulfacetamide and other biological resistant compounds.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>130</FPAGE>
			<TPAGE>146</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/7
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/12/17
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/26
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/6/4
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>ترکان</Name>
				<MidName></MidName>
				<Family>عبدیلی</Family>
				<NameE>Torkan</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Abdili</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد، مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی اردبیل، اردبیل، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مهدی</Name>
				<MidName></MidName>
				<Family>فضل زاده</Family>
				<NameE>Mehdi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Fazlzadeh</FamilyE>
				<Organizations>
				<Organization>مربی،گروه مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی اردبیل، اردبیل، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مرتضی</Name>
				<MidName></MidName>
				<Family>عالیقدری</Family>
				<NameE>Morteza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Alighadri</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی اردبیل، اردبیل، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>کورش</Name>
				<MidName></MidName>
				<Family>رحمانی</Family>
				<NameE>Kourosh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rahmani</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه مهندسی بهداشت محیط، دانشکده بهداشت، دانشگاه علوم پزشکی اردبیل، اردبیل، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>krahmanii@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>sonocatalytic</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>sulfacetamide</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>zerovalent iron nanoparticle</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>advanced oxidation process</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سونوکاتالیست</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سولفاستامید</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>نانو ذرات آهن صفر</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>فرآیند اکسیداسیون پیشرفته</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>##1.	Dehghani S, Jafari AJ, Farzadkia M, Gholami M. Sulfonamide antibiotic reduction in aquatic environment by application of fenton oxidation process. Iranian J Environ Health Sci Eng. 2013;10(1):29.##2.	Martín de Vidales MJ, Robles‐Molina J, Domínguez‐Romero JC, Cañizares P, Sáez C, Molina‐Díaz A, et al. Removal of sulfamethoxazole from waters and wastewaters by conductive‐diamond electrochemical oxidation. J Chem Technol Biot. 2012;87(10):1441-1449.##3.	Oturan N, Wu J, Zhang H, Sharma VK, Oturan MA. Electrocatalytic destruction of the antibiotic tetracycline in aqueous medium by electrochemical advanced oxidation processes: effect of electrode materials. Appl Catal B: Environmental. 2013;140-141:92-97.##4.	Wu J, Zhang H, Oturan N, Wang Y, Chen L, Oturan MA. Application of response surface methodology to the removal of the antibiotic tetracycline by electrochemical process using carbon-felt cathode and DSA (Ti/RuO 2–IrO 2) anode. Chemosphere. 2012;87(6):614-620.##5.	Dehghani S, Jonidi Jafari A, Farzadkia M, Gholami M. Investigation of the efficiency of Fenton’s advanced oxidation process in sulfadiazine antibiotic removal from aqueous solutions. J Arak Univ Med Sci. 2012;15(7):19-29.(persian).##6.	Leili M, Fazlzadeh M, Bhatnagar A. Green synthesis of nano-zero-valent iron from Nettle and Thyme leaf extracts and their application for the removal of cephalexin antibiotic from aqueous solutions. Environ Technol. 2017; 12: 1-15.##7.	Hoseini M, Safari GH, Kamani H, Jaafari J, Mahvi A. Survey on Removal of Tetracycline Antibiotic from Aqueous Solutions by Nano-Sonochemical Process and Evaluation of the Influencing Parameters. Iran J Health Environ. 2015;8(2):141-152.(persian).##8.	Homem V, Santos L. Degradation and removal methods of antibiotics from aqueous matrices–a review. J Environ Manage. 2011;92(10):2304-2347.##9.	Rahmani K, Faramarzi MA, Mahvi AH, Gholami M, Esrafili A, Forootanfar H, et al. Elimination and detoxification of sulfathiazole and sulfamethoxazole assisted by laccase immobilized on porous silica beads. Int Biodeter Biodegr. 2015;97:107-114.##10.	Liu Y, Wang J. Degradation of sulfamethazine by gamma irradiation in the presence of hydrogen peroxide. J Hazard Mater. 2013;250-251:99-105.##11.	Dirany A, Sirés I, Oturan N, Oturan MA. Electrochemical abatement of the antibiotic sulfamethoxazole from water. Chemosphere. 2010;81(5):594-602.##12.	Nagamalleswari G, Phaneemdra D, Prabakar E, Suresh V, Ramarao N. New colorimetric method development and validation of sulfacetamide in bulk and formulation by different analytical reagents. International Journal of Advances in Pharmaceutical Analysis. 2013;3(2):30-36.##13.	Rahmani H, Gholami M, Mahvi AH, Alimohammadi M, Azarian G, Esrafili A, et al. Tinidazole Removal from Aqueous Solution by Sonolysis in the Presence of Hydrogen Peroxide. Bull Environ Contam Toxicol. 2014;92(3):341-346.##14.	Fazlzadeh M, Rahmani A, Nasehinia HR, Rahmani H, Rahmani K. Degradation of sulfathiazole antibiotics in aqueous solutions by using zero valent iron nanoparticles and hydrogen peroxide. Koomesh. 2016; 18(3):350-356.(persian).##15.	Turkdogan FI, Yetilmezsoy K. Appraisal of potential environmental risks associated with human antibiotic consumption in Turkey. J Hazard Mater. 2009;166(1):297-308.##16.	Adams C, Wang Y, Loftin K, Meyer M. Removal of antibiotics from surface and distilled water in conventional water treatment processes. Journal of Environmental Engineering. 2002;128(3):253-260.##17.	Azari A, Esrafili A, Ahmadi E, Gholami M. Performance evaluation of magnetized multiwall carbon nanotubes by iron oxide nanoparticles in removing fluoride from aqueous solution. J Mazandaran Univ Med Sci. 2015;25(124):128-142.(persian).##18.	Ahmed MB, Zhou JL, Ngo HH, Guo W. Adsorptive removal of antibiotics from water and wastewater: progress and challenges. Sci Total Environ. 2015;532:112-126.##19.	Almasi A, Dargahi A, Amrane A, Fazlzadeh M, Mahmoudi M, Hashemian A. Effect of the retention time and the phenol concentration the stabilization pond efficiency in the treatment of oil refinery wastewater. Fresenius Environmental Bulletin. 2014;23(10a):2541-2548.##20.	Sirés I, Brillas E. Remediation of water pollution caused by pharmaceutical residues based on electrochemical separation and degradation technologies: a review. Environ Int. 2012;40:212-229.##21.	Brillas E, Sirés I. Electrochemical removal of pharmaceuticals from water streams: reactivity elucidation by mass spectrometry. TrAC-Trends Anal Chem. 2015;70:112-121.##22.	Dadban Shahamat Y, Zazouli MA, Asgharnia H, Dehghanifard E. Evaluation of rapid purification of high concentrations of 2, 4-Dinitrophenol in wastewater using catalytic ozonation with carboneus nanocomposite. J Mazandaran Univ Med Sci. 2016;25(133):138-149.(persian).##23.	Azizi E, Fazlzadeh M, Ghayebzadeh M, Hemati L, Beikmohammadi M, Ghaffari HR, et al. application of advanced oxidation process (H2O2/UV) for removal of organic  materials from pharmaceutical industry efflueent. Environment Protection Engineering. 2017;43(1):183-191.(persian).##24.	Dargahi A, Pirsaheb M, Hazrati S, Fazlzadehdavil M, Khamutian R, Amirian T. Evaluating efficiency of H2O2 on removal of organic matter from drinking water. Desalination and Water Treatment. 2015;54(6):1589-1593.##25.	Methatham T, Lu MC, Ratanatamskul C. Removal of 2, 4-dichlorophenol as herbicide’s by-product by Fenton’s reagent combined with an electrochemical system. Desalination and Water Treatment. 2011;32(1-3):42-48.##26.	Wang C, Shih Y. Degradation and detoxification of diazinon by sono-Fenton and sono-Fenton-like processes. Sep Purif Technol. 2015;140:6-12.##27.	Chelliapan S, Sallis P. Removal of organic compound from pharmaceutical wastewater using advanced oxidation processes. J Sci Ind Res (JSIR).2013; 72(4).##28.	Parastar S, Nasseri S, Borji SH, Fazlzadeh M, Mahvi AH, Javadi AH, et al. Application of Ag-doped TiO2 nanoparticle prepared by photodeposition method for nitrate photocatalytic removal from aqueous solutions. Desalination and Water Treatment. 2013;51(37-39):7137-7144.##29.	Jamali H, Inaloo KD, Ghaffari H, Kheradpishe Z, Nikpay A. Optimization of factors affecting the application of Fenton process in sofa and detergent wastewater treatment. J Hormozgan Univ Med Sci. 2013;17(4):317-324.(persian).##30.	Farzadkia M, Rahmani K, Gholami M, Esrafili A, Rahmani A, Rahmani H. Investigation of photocatalytic degradation of clindamycin antibiotic by using nano-ZnO catalysts. Korean J Chem Eng. 2014;31(11):2014-2019.##31.	Yehia F, Eshaq G, Rabie A, Mady A, ElMetwally A. Phenol degradation by advanced Fenton process in combination with ultrasonic irradiation. Egyptian Journal of Petroleum. 2015;24(1):13-18.##32.	Samaei MR, Maleknia H, Azhdarpoor A. Effects of pH on the Kinetics of Methyl Tertiary Butyl Ether Degradation by Oxidation Process (H 2 O 2/Nano Zero-Valent Iron/Ultrasonic). Jundishapur J Health Sci. 2015;7(3):e30285.(persian).##33.	Fazlzadeh M, Rahmani K, Zarei A, Abdoallahzadeh H, Nasiri F, Khosravi R. A novel green synthesis of zero valent iron nanoparticles (NZVI) using three plant extracts and their efficient application for removal of Cr (VI) from aqueous solutions. Adv Powder Technol. 2017;28(1):122-130.##34.	Fazlzadeh M, Abdoallahzadeh H, Khosravi R, Alizadeh B. Removal of Acid Black 1 from Aqueous Solutions Using Fe3O4 Magnetic Nanoparticles. J Mazandaran Univ Med Sci. 2016;26(143):174-186.(persian).##35.	Shokoohi R, Mahmoudi MM, Ghilan RA. Efficiency of Magnetic Nanoparticles Modified with Sodium Alginate for Removal of Bisphenol A from Aqueous Solutions Using heterogeneous Fenton Process. J Mazandaran Univ Med Sci. 2017;27(148):88-99.##36.	Bhavani R, Sivasamy A. Sonocatalytic degradation of malachite green oxalate by a semiconductor metal oxide nanocatalyst. Ecotoxicol Environ Saf. 2016;134(Pt2):403-411.##37.	Wei Y, Wang X, Guo W, Wang J. Mechanistic study of the degradation of azo dye reactive brilliant red K-2BP by ultrasound radiation and zero-valent iron. Environ Eng Sci. 2012;29(6):399-405.##38.	Fazlzadeh M, Rahmani K, Zarei A, Abdoallahzadeh H, Nasiri F, Khosravi R. A novel green synthesis of zero valent iron nanoparticles (NZVI) using three plant extracts and their efficient application for removal of Cr(VI) from aqueous solutions. Advanced Powder Technology.2017; 28(1):122-130.##39.	Mueller NC, Nowack B. Nanoparticles for remediation: solving big problems with little particles. Elements. 2010;6(6):395-400.##40.	Dianatitilaki R, Safarpour M. Nitrate Removal from Water by Nano zero Valent Iron in the Presence and Absence of ultraviolet light. J Mazandaran Univ Med Sci. 2014;24(113):151-161.(persian).##41.	Fu F, Dionysiou DD, Liu H. The use of zero-valent iron for groundwater remediation and wastewater treatment: a review. J Hazard Mater. 2014;267:194-205.##42.	Zhou X, Lv B, Zhou Z, Li W, Jing G. Evaluation of highly active nanoscale zero-valent iron coupled with ultrasound for chromium (VI) removal. Chem Eng J. 2015;281:155-163.##43.	Seidmohammadi A, Asgari G, Torabi L. Removal of Metronidazole Using Ozone Activated Persulfate from Aqua Solutions in Presence of Ultrasound. J Mazandaran Univ Med Sci. 2016;26(143):160-173.(persian).##44.	Zha S, Cheng Y, Gao Y, Chen Z, Megharaj M, Naidu R. Nanoscale zero-valent iron as a catalyst for heterogeneous Fenton oxidation of amoxicillin. Chem Eng J. 2014;255:141-148.##45.	Zazouli MA, Yousefi Z, Eslami A, Ardebilian MB. Municipal solid waste landfill leachate treatment by fenton, photo-fenton and fenton-like processes: Effect of some variables. Iran J Environ Health Sci Eng. 2012;9(1):3.##46.	Liu Y, Choi H, Dionysiou D, Lowry GV. Trichloroethene hydrodechlorination in water by highly disordered monometallic nanoiron. Chem Mater. 2005;17(21):5315-5322.##47.	Zazouli MA, Balarak D, Mahdavi Y. Application of Azolla Filiculoides biomass for 2-Chlorophenol and 4-Chrorophenol Removal from aqueous solutions.Iran J Health Sci.2013;1(2):43-55.##48.	Liu A, Liu J, Zhang WX. Transformation and composition evolution of nanoscale zero valent iron (nZVI) synthesized by borohydride reduction in static water. Chemosphere. 2015;119:1068-1074.##49.	Eslami S, Ebrahimzadeh MA, Biparva P, Abedi Rad M. Zero Valent Iron-Based Nanoparticles: Synthesis, Characterization and their Application in Biology and Medicine. J Mazandaran Univ Med Sci. 2016;26(142):285-310.##50.	American Public Health Association, American Water Works Association, Water Environment Federation APHA-AWWA-WPCF. Standard methods for the examination of water and wastewater. American Public Health Association(APHA); 1981.##51.	Zhou H, Shen Y, Lv P, Wang J, Li P. Degradation pathway and kinetics of 1-alkyl-3-methylimidazolium bromides oxidation in an ultrasonic nanoscale zero-valent iron/hydrogen peroxide system. J Hazard Mater. 2015;284:241-252.##52.	Khamaruddin PF, Bustam MA, Omar AA, editors. Using Fenton’s reagents for the degradation of diisopropanolamine: effect of temperature and pH. International Conference on Environment and Industrial Innovation IPCBEE; 2011.IACSIT Press, Singapore.##53.	Zhang W, Gao H, He J, Yang P, Wang D, Ma T, et al. Removal of norfloxacin using coupled synthesized nanoscale zero-valent iron (nZVI) with H 2 O 2 system: Optimization of operating conditions and degradation pathway. Sep Purif Technol. 2017;172:158-167.##54.	Wang L, Yang J, Li Y, Lv J, Zou J. Removal of chlorpheniramine in a nanoscale zero-valent iron induced heterogeneous Fenton system: Influencing factors and degradation intermediates. Chem Eng J. 2016;284:1058-1067.##55.	Zazouli M, Ebrahimzadeh MA, Yazdani Charati J, Shiralizadeh Dezfoli A, Rostamali E, Veisi F. Effect of sunlight and ultraviolet radiation in the titanium dioxide (TiO2) nanoparticles for removal of furfural from water. J Mazandaran Univ Med Sci. 2013;23(107):126-138.(persian).##56.	Daraei H, Kamali H. Synthesis of iron nanoparticles and evaluation of their operation in phenol and 2-chlorophenol removal from aqueous solution. Journal of Health in the Field. 2017;1(3):31-40.(persian)##57.	Malakootian M, Asadi M. Efficiency of fenton oxidation process in removal of phenol in aqueous solutions. 2011.22(3)(79):46-52.(persian).##58.	Celalettin O, Muhammed K, Serkan S. The sonochemical decolorisation of textile azo dye CI Reactive Orange. J of Color Technol. 2011;127(4):268-273.##59.	Azari A, Babaie A-A, Rezaei-Kalantary R, Esrafili A, Moazzen M, Kakavandi B. Nitrate removal from aqueous solution by carbon nanotubes magnetized with nano zero-valent iron. J Mazandaran Univ Med Sci. 2014;23(2):15-27.##60.	Cui X, Zeng P, Qiu G, Liu Y, Song Y, Xie X, et al. Pilot-scale treatment of pharmaceutical berberine wastewater by Fenton oxidation. Environmental Earth Sciences. 2015;73(9):4967-4977.#### ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>حذف رنگ راکتیو آبی 19 از محیط های آبی با استفاده از فرآیند سونوشیمی در حضور نانوذرات ‌دی‌اکسید تیتانیوم</TitleF>
		<TitleE>Removal of Reactive Blue 19 Dye from Aqueous Solutions Using Sonochemistry Process in Presence of TiO2 Nanoparticles


</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: رنگ&#8204;ها موادآلی سمی با ساختار پیچیده&#8204;ای هستند، که در مراحل تولید منسوجات نظیر رنگرزی، تکمیل و چاپ استفاده می&#8204;شوند و مشکلات زیست محیطی بسیاری ایجاد می&#8204;کنند. رنگ راکتیو آبی 19 در حال حاضر در صنعت نساجی ایران کاربرد گسترده&#8204;ای دارد. این مطالعه با هدف بررسی امکان سنجی استفاده از فرآیند سونوشیمی و TiO2 به&#8204;عنوان کاتالیست در حذف رنگ راکتیو آبی 19 از محلول&#8204;های آبی انجام شد.
مواد و روش&#8204;ها: این&#8204; مطالعه در مقیاس آزمایشگاهی می&#8204;باشد. در این مطالعه اثر متغیرهایی هم&#8204;چون مقدار نانوذرات TiO2 ، pH، غلظت اولیه رنگ و مدت زمان آزمایش بر رنگ&#8204;بری رنگ مذکور بررسی شد. غلظت ماده رنگ&#8204;زای RB19 باقی&#8204;مانده نیز با استفاده از دستگاه اسپکتروفتومتر جذب نوری Carry 100 در طول موج 592 نانومتر تعیین شد. از روش آماری سطح پاسخ بر مبنای طراحی مرکب مرکزی (CCD) جهت ارزیابی اثر متغیرهای مستقل بر راندمان حذف و پیشگویی بهترین پاسخ استفاده شد. این مدل با آنالیز آماری ANOVA تاثیر چشمگیر متغیرها را تایید می&#8204;نماید.
یافته&#8204;ها: تصاویر سه بعدی نشان می&#8204;دهد که بیشترین راندمان رنگ&#8204;بری در شرایط خنثی از نظر pH به دست آمده و با افزایش غلظت رنگ، راندمان رنگ&#8204;بری کاهش می&#8204;یابد. در طی مدت 62 دقیقه رنگ&#8204;بری به حداکثر مقدار رسیده و افزایش بیشتر مدت زمان تاثیرچندانی بر رنگ&#8204;بری ندارد. تحت شرایط بهینه (غلظت رنگ g/L 08/0، زمان تماس 5/62 دقیقه، 6=pH و مقدار TiO2 g/L 63/1) درصد رنگبری فرآیند مذکور 7/94 درصد بود.
استنتاج: روش پیشنهادی به&#8204;دلیل عدم استفاده مواد شیمیایی اکسنده (نظیر H2O2 یا HOCl) که معمولا باقی&#8204;مانده&#8204; آن&#8204;ها از عوامل مخرب محیط زیست به شمار می&#8204;آیند، می&#8204;تواند بعنوان یک روش سبز برای رنگ بری آلاینده&#8204;های رنگی مورد توجه قرار گیرد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Colors are toxic organic materials with complex structures used in textile production stages such as dyeing, finishing and printing that cause environmental problems. One of the most widely used colorant in textile is reactive blue 19 dye. This study aimed to examine the feasibility of TiO2 as catalysts and sonochemistry process for discoloration of reactive blue 19 from aqueous solutions.
Materials and methods: The study was conducted in laboratory scale. The effect of different parameters affecting the decolorization of reactive blue 19, including the amount of TiO2 nanoparticles, pH, initial dye concentration and the time was investigated. The remaining concentration of RB19 was analyzed by UV-Vis carry 100 spectrophotometer at a wavelength of 592 nm. The response surface methodology was used based on central composite design (CCD) to evaluate the effect of independent variables on the removal efficiency and to predict the best answer. This model with ANOVA analysis confirmed the significant effect of variables.
Results: The experiments and 3D plots showed that higher decolorization was obtained in neutral pH and decolorization efficiency was decreased with increment of initial dye concentration. The highest decolorization was achieved at 62 min and additional time was not effective on decolorization. In current study, 94.7 % discoloration was achieved in optimum conditions, namely 0.08 g/L RB19, pH=6.0, and 1.63 g/L TiO2 at 62.5 min.
Conclusion: The proposed method could be considered as green method for discoloration of colorful pollutant because it does not use oxidant chemicals such as hydrogen peroxide or hypochlorite, which their residues are harmful to the environment.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>147</FPAGE>
			<TPAGE>161</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/5
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/10/16
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/14
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/3/24
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>سرور</Name>
				<MidName></MidName>
				<Family>صفا</Family>
				<NameE>Sorur</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Safa</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکترای مهندسی بهداشت محیط، دانشکده پردیس بین الملل، دانشگاه علوم پزشکی و خدمات بهداشتی درمانی شهید صدوقی یزد، یزد، ایرانکمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی و خدمات بهداشتی درمانی شهید صدوقی یزد، یزد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>نوید</Name>
				<MidName></MidName>
				<Family>نصیری‌زاده</Family>
				<NameE>Navid</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Nasirizadeh</FamilyE>
				<Organizations>
				<Organization>دانشیار، دانشکده فنی. گروه مهندسی نساجی و پلیمر، دانشگاه آزاد اسلامی واحد یزد، یزد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nasirizadeh@iauyazd.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد</Name>
				<MidName></MidName>
				<Family>دهقانی</Family>
				<NameE>Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Dehghani</FamilyE>
				<Organizations>
				<Organization>باشگاه پژوهشگران جوان و نخبگان، دانشگاه آزاد اسلامی واحد یزد، یزد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Mohamad.deh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد تقی</Name>
				<MidName></MidName>
				<Family>قانعیان</Family>
				<NameE>Mohammad Taghi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ghaneian</FamilyE>
				<Organizations>
				<Organization>دانشیار، دانشکده بهداشت. گروه مهندسی بهداشت محیط، دانشگاه علوم پزشکی و خدمات بهداشتی درمانی شهید صدوقی یزد، یزد، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>reactive blue 19</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>sonochemistry</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>TiO2</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>central composite design</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>رنگ راکتیو آبی 19</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سونوشیمی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>TiO2</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>طراحی مرکب مرکزی (CCD)</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>##1.	Daneshvar N, Aber S, Vatanpour V, Rasoulifard MH. Electro-Fenton treatment of dye solution containing Orange II: Influence of operational parameters. J Electroanal Chem. 2008;615(2):165-174.##2.	Al-Kdasi A, Idris A, Saed K, Guan CT. Treatment of textile wastewater by advanced oxidation processes—a review. Global nest: the Int J. 2004;6(3):222-230.##3.	Moussavi G, Mahmoudi M. Removal of azo and anthraquinone reactive dyes from industrial wastewaters using MgO nanoparticles. J Hazard Mater. 2009;168(2):806-812.##4.	Jiraratananon R, Sungpet A, Luangsowan P. Performance evaluation of nanofiltration membranes for treatment of effluents containing reactive dye and salt. Desalination. 2000;130(2):177-183.##5.	Dianati Tilaki R, Kavyani S, Hassani Nejad-Darzi SK, Yazdani Cahrati J. Kinetics Study on Adsorption of Three Azo Dyes (Reactive Red 198, Cationic Red GTL 18 and Cationic Red GRL 46) by Zeolite Clinoptilolite. J Mazandaran Univ Med Sci. 2014;24(118):158-169.##6.	Bellakhal N, Dachraoui M, Oturan N, Oturan M. Degradation of tartrazine in water by electro-Fenton process. Journal de la Société Chimique de Tunisie .2006;8(2):223.##7.	de Lima ROA, Bazo AP, Salvadori DMF, Rech CM, de Palma Oliveira D, de Aragão Umbuzeiro G. Mutagenic and carcinogenic potential of a textile azo dye processing plant effluent that impacts a drinking water source. Mutat Res. 2007;626(1):53-60.##8.	Xu XR, Li HB, Wang WH, Gu JD. Degradation of dyes in aqueous solutions by the Fenton process. Chemosphere. 2004;57(7):595-600.##9.	Demirbas E, Nas M. Batch kinetic and equilibrium studies of adsorption of Reactive Blue 21 by fly ash and sepiolite. Desalination. 2009;243(1-3):8-21.##10.	Ghaneian M, Ehrampoush M, Ghanizadeh G, Dehvary M, Abootoraby M, Jasemizad T. Application of solar irradiation/K2S2O8 photochemical oxidation process for the Removal of reactive blue 19 dye fromaqueous solutions. ijhe. 2010;3(2):165-176.##11.	Julson AJ, Ollis DF. Kinetics of dye decolorization in an air–solid system. Appl Catal B. 2006;65(3-4):315-325.##12.	Azbar N, Yonar T, Kestioglu K. Comparison of various advanced oxidation processes and chemical treatment methods for COD and color removal from a polyester and acetate fiber dyeing effluent. Chemosphere. 2004;55(1):35-43.##13.	Arslan I, Balcioǧlu IA, Bahnemann DW. Advanced chemical oxidation of reactive dyes in simulated dyehouse effluents by ferrioxalate-Fenton/UV-A and TiO 2/UV-A processes. Dyes Pigm. 2000;47(3):207-218.##14.	He C, Yu Y, Hu X, Larbot A. Influence of silver doping on the photocatalytic activity of titania films. Appl Surf Sci. 2002;200(1-4):239-247.##15.	Riaz U, Ashraf S. Semi-conducting poly (1-naphthylamine) nanotubes: A pH independent adsorbent of sulphonate dyes. Chem Eng Process. 2011;174(2):546-555.##16.	Zhang F, Yediler A, Liang X, Kettrup A. Effects of dye additives on the ozonation process and oxidation by-products: a comparative study using hydrolyzed CI Reactive Red 120. Dyes Pigm. 2004;60(1):1-7.##17.	Errais E, Duplay J, Darragi F, M'Rabet I, Aubert A, Huber F, et al. Efficient anionic dye adsorption on natural untreated clay: Kinetic study and thermodynamic parameters. Desalination. 2011;275(1-3):74-81.##18.	Mahmoodi NM, Arami M, Limaee NY. Photocatalytic degradation of triazinic ring-containing azo dye (Reactive Red 198) by using immobilized TiO 2 photoreactor: Bench scale study. J Hazard  Mater. 2006;133(1):113-118.##19.	Bahena CL, Martínez SS, Guzmán DM, Hernández MdRT. Sonophotocatalytic degradation of alazine and gesaprim commercial herbicides in TiO 2 slurry. Chemosphere. 2008;71(5):982-989.##20.	Shen D, Fan J, Zhou W, Gao B, Yue Q, Kang Q. Adsorption kinetics and isotherm of anionic dyes onto organo-bentonite from single and multisolute systems. J Hazard Mater .2009;172(1):99-107.##21.	Mezenner NY, Bensmaili A. Kinetics and thermodynamic study of phosphate adsorption on iron hydroxide-eggshell waste. Chem Engin J. 2009;147(2-3):87-96.##22.	Abdelsalam ME, Birkin PR. A study investigating the sonoelectrochemical degradation of an organic compound employing Fenton's reagent. Phys Chem Chem Phys. 2002;4(21):5340-5345.##23.	Chen X, Mao SS. Titanium dioxide nanomaterials: synthesis, properties, modifications, and applications. Chem Rev. 2007;107(7):2891-2959.##24.	Fujishima A, Rao TN, Tryk DA. Titanium dioxide photocatalysis. J. Photochem. Photobiol.. 2000;1(1):1-21.##25.	Hoffmann MR, Martin ST, Choi W, Bahnemann DW. Environmental applications of semiconductor photocatalysis. Chem Rev. 1995;95(1):69-96.##26.	Shiraishi Y, Saito N, Hirai T. Adsorption-driven photocatalytic activity of mesoporous titanium dioxide. J Am Chem Soc. 2005;127(37):12820-12822.##27.	Zhan S, Chen D, Jiao X, Song Y. Mesoporous TiO 2/SiO 2 composite nanofibers with selective photocatalytic properties. Chem Commun. 2007(20):2043-2045.##28.	Liu S, Yu J, Jaroniec M. Tunable photocatalytic selectivity of hollow TiO2 microspheres composed of anatase polyhedra with exposed {001} facets. J Am Chem Soc. 2010;132(34):11914-11916.##29.	Lazar MA, Daoud WA. Selective adsorption and photocatalysis of low-temperature base-modified anatase nanocrystals. Rsc Adv. 2012;2(2):447-452.##30.	Lorimer J, Mason T, Plattes M, Phull S, Walton D. Degradation of dye effluent. Pure Appl Chem. 2001;73(12):1957-1968.##31.	Vajnhandl S, Le Marechal AM. Case study of the sonochemical decolouration of textile azo dye Reactive Black 5. J Hazard Mat. 2007;141(1):329-335.##32.	Şayan E, Edecan ME. An optimization study using response surface methods on the decolorization of Reactive Blue 19 from aqueous solution by ultrasound. Ultrason Sonochem. 2008;15(4):530-538.##33.	Radi MA, Nasirizadeh N, Rohani-Moghadam M, Dehghani M. The comparison of sonochemistry, electrochemistry and sonoelectrochemistry techniques on decolorization of CI Reactive Blue 49. Ultrason Sonochem. 2015;27:609-615.##34.	Siddique M, Farooq R, Khan ZM, Khan Z, Shaukat S. Enhanced decomposition of reactive blue 19 dye in ultrasound assisted electrochemical reactor. Ultrason Sonochem. 2011;18(1):190-196.##35.	Rezaee A, Ghaneian M, Taghavinia N, Aminian M, Hashemian S. TiO2 nanofibre assisted photocatalytic degradation of reactive blue 19 dye from aqueous solution. Environ Technol. 2009;30(3):233-239.##36.	He Z, Lin L, Song S, Xia M, Xu L, Ying H, et al. Mineralization of CI Reactive Blue 19 by ozonation combined with sonolysis: Performance optimization and سdegradation mechanism. Sep Purif Technol. 2008;62(2):376-381.##37.	Dutta S, Parsons SA, Bhattacharjee C, Jarvis P, Datta S, Bandyopadhyay S. Kinetic study of adsorption and photo-decolorization of Reactive Red 198 on TiO 2 surface. Chem Eng J .2009;155(3):674-679.##38.	Bourikas K, Stylidi M, Kondarides DI, Verykios XE. Adsorption of acid orange 7 on the surface of titanium dioxide. Langmuir. 2005;21(20):9222-9230.##39.	Toor AP, Verma A, Jotshi C, Bajpai P, Singh V. Photocatalytic degradation of Direct Yellow 12 dye using UV/TiO 2 in a shallow pond slurry reactor. Dyes and pigments. 2006;68(1):53-60.##40.	Mahmoodi NM, Arami M, Limaee NY, Tabrizi NS. Decolorization and aromatic ring degradation kinetics of Direct Red 80 by UV oxidation in the presence of hydrogen peroxide utilizing TiO 2 as a photocatalyst. Chem  Engin J. 2005;112(1):191-196.##41.	Kansal SK, Ali AH, Kapoor S. Photocatalytic decolorization of biebrich scarlet dye in aqueous phase using different nanophotocatalysts. Desalination. 2010;259(1):147-155.##42.	Ghanbarian M, Mahvi AH, Nabizadeh R, Saeedniya S. A pilot study of RO16 discoloration and mineralization in textile effluents using the nanophotocatalytic process. J of Water and Wastewater. 2009;20(1):45-51.##43.	Maleki A, Mahvi AH, Ebrahimi R, Zandsalimi Y. Study of photochemical and sonochemical processes efficiency for degradation of dyes in aqueous solution. Korean J Chem Eng. 2010;27(6):1805-1810.##44.	He Z, Song S, Zhou H, Ying H, Chen J. CI Reactive Black 5 decolorization by combined sonolysis and ozonation. Ultrason Sonochem. 2007;14(3):298-304.##45.	Dareini F, Amini MA, Zarei SH, Saghi MH. Removal of Acid Black 1 dye from aqueous solution using nano-iron particles. 2014;20(5):782-790.##46.	Barros WR, Steter JR, Lanza MR, Motheo AJ. Degradation of amaranth dye in alkaline medium by ultrasonic cavitation coupled with electrochemical oxidation using a boron-doped diamond anode. Electrochimica Acta. 2014;143:180-187.##47.	Gogate PR, Pandit AB. A review of imperative technologies for wastewater treatment II: hybrid methods. Advances Environ Res  2004;8(3):553-597.##48.	Soleymani AR, Saien J, Chin S, Le HA, Park E, Jurng J. Modeling and optimization of a sono-assisted photocatalytic water treatment process via central composite design methodology. Process Saf Environ Prot. 2015;94:307-314.##49.	Rivera M, Pazos M, Sanromán M. Improvement of dye electrochemical treatment by combination with ultrasound technique. J Chem Tech   Biotech . 2009;84(8):1118-1124.##50.	Sathishkumar P, Mangalaraja RV, Rozas O, Mansilla HD, Gracia-Pinilla M, Anandan S. Low frequency ultrasound (42kHz) assisted degradation of Acid Blue 113 in the presence of visible light driven rare earth nanoclusters loaded TiO2 nanophotocatalysts. Ultrason Sonochem. 2014;21(5):1675-1681.##51.	Malakootian M, Asadi A, Mahvi AH. Decolorization of Reactive Blue 19 dye in dying industry wastewater by electro-Fenton process. Journal of Environment Science and Technology. 2011;16(93):159-167.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>ارزیابی میزان سرب و کادمیم در آب و خاک کشاورزی و تجمع آن در مغز، گوشت و پوست کیوی در شهرستان آستارا، سال 1394</TitleF>
		<TitleE>Lead and Cadmium Contaminations in Soil and Irrigation Water and Their Accumulation in Pith, Flesh and Skin of Kiwifruit in Astara, North of Iran 2015</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: فلزات سنگین از عوامل مهم آلاینده محیط &#8204;زیست به شمار می&#8206;روند که احتمال آلودگی خاک، گیاهان و محصولات کشاورزی به آن&#8204;ها از طریق آبیاری زمین با آب یا پساب آلوده وجود دارد. هدف از این مطالعه توصیفی مقطعی، ارزیابی میزان سرب و کادمیم در آب و خاک کشاورزی و تجمع آن در مغز، گوشت و پوست کیوی می&#8204;باشد.
مواد و روش&#8204;ها: تعداد 100 نمونه کیوی، 15 نمونه خاک و 25 نمونه آب طی دوره آبیاری از هر کدام از مناطق مرکز، شمال، جنوب، شرق و غرب باغ به&#8204;طور تصادفی از باغ&#8204;های وسیع کشت کیوی در شمال ایران جمع&#8204;آوری و غلظت کل سرب و کادمیم در آن&#8204;ها با دستگاه جذب اتمی اندازه&#8204;گیری شد. تجزیه و تحلیل&#8204;های آماری با آزمون آنالیز واریانس تحت نرم افزارSPSS&#160; نسخه 1/10 انجام شد.
یافته&#8204;ها: نتایج تحقیق نشان می دهد غلظت سرب در نمونه&#8204;های خاک و گوشت کیوی به ترتیب 74/33 و 93/2 و غلظت کادمیم به ترتیب 04/2 و 0026/0 میلی&#8204;گرم بر کیلوگرم می&#8204;باشد. هم&#8204;چنین غلظت سرب و کادمیم در نمونه&#8204;های آب آبیاری به ترتیب 0044/0 و 0016 /0 میلی&#8204;گرم بر لیتر بوده است. بین میانگین غلظت فلزات سنگین در خاک و مقدار آن در بافت کیوی ارتباط معناداری وجود دارد و در بخش&#8204;هایی که آلودگی خاک به سرب و کادمیم بیش&#8204;تر بوده، آلودگی محصول نیز به طور معنی&#8204;داری بیش&#8204;تراست (05/0p&#60;). مقایسه غلظت این عناصر در نمونه&#8204;های آب با حدود مجاز آن نشان می&#8206;دهد که میزان سرب و کادمیم در نمونه&#8204;های آب کشاورزی، کم&#8204;تر از حد مجاز بوده است.
استنتاج: با توجه به آلودگی خاک کشاورزی به فلزات سنگین و ارتباط خاک با آب و تاثیر سوء فلزات سنگین بر سلامت انسان، پایش این محصول ارزشمند کشاورزی و انجام کنترل&#8204;های زیست محیطی ضروری است.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Heavy metals cause major environmental pollution. They accumulate in soil, plants and crops through irrigation with polluted effluents or wastewaters. The aim of this cross-sectional study was to evaluate the concentration of lead and cadmium in soil and irrigation water and their accumulation in pith, flesh, and the skin of kiwifruit.
Materials and methods: A sample of one hundred kiwifruit, 15 soil and 25 irrigation water samples were randomly collected from the center, north, south, east, and west of a big kiwifruit garden located in north of Iran. Total concentrations of lead and cadmium were determined in all samples with furnace atomic absorption spectroscopy. Statistical analysis was performed applying ANOVA test in SPSS V10.1.
Results: The concentrations of lead in soil and flesh of kiwifruit were 33.74 and 2.93 and the concentrations of cadmium were 2.04 and 0.0026 mg/kg, respectively. The concentrations of lead and cadmium in irrigating water were 0.0044 and 0.0016 mg/L, respectively. There was a significant relation between the mean concentrations of heavy metals in the soil and that of the kiwifruit flesh. In areas with higher rate of lead and cadmium contamination the kiwifruits were found to be significantly more contaminated (P&#60;0.05). The mean concentration of these heavy metals in irrigation water were lower than national and international threshold levels.
Conclusion: Heavy metal contamination in soil and the cross relation between irrigation water and soil, calls for appropriate monitoring of such a valuable fruit and routine environmental controls are highly necessary.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>162</FPAGE>
			<TPAGE>172</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/30
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/11/11
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/12
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/4/21
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>بهروز</Name>
				<MidName></MidName>
				<Family>اکبری آدرگانی</Family>
				<NameE>Behrouz</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Akbari-adergani</FamilyE>
				<Organizations>
				<Organization>دانشیار، مرکز تحقیقات آزمایشگاهی غذا و دارو، سازمان غذا و دارو، وزارت بهداشت، درمان و آموزش پزشکی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>analystchemist@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>صدیقه</Name>
				<MidName></MidName>
				<Family>رهنما</Family>
				<NameE>Sedigheh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rahnama</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد علوم و صنایع غذایی، دانشکده کشاورزی، دانشگاه آزاد اسلامی، دامغان، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فائزه</Name>
				<MidName></MidName>
				<Family>شیرخان</Family>
				<NameE>Faezeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shirkhan</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد علوم و صنایع غذایی، دانشگاه آزاد اسلامی، واحد علوم دارویی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>kiwifruit</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>lead</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>cadmium</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>accumulation</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>soil</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>water</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>کیوی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سرب</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>کادمیم</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>تجمع</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>خاک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>آب</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Ghasemzadeh M, Alipour RG, Fatthi Moghadam F. Effect of harvesting time on antioxidant capacity and keeping quality of actinidia deliciosa c.v. Hayward fruit. Journal of Crops Improvement. 2011; 13(1):55-64. (persian)##2.	Zakipure-Molkabadi E, Hamidi Esfehani Z, Abbasi S. Formulation of Leather from Kivi Fruit Lisses. Iran J Sci Technol. 2011; 6(4): 263-270. (persian)##3.	Duruib JO, Ogwuegbu MO, Egwurug JN. Heavy metal pollution and human biotoxic effects. International Journal Physical Sciences. 2007; 2(5):112-118.##4.	Mohajer R, Salehi MH, Mohammadi j. Lead and cadmium concentration in Agricultural Crops (Lettuce, cabbage, beet root and onion) of Isfahan province. Iranian Journal of Health and Environment. 2014; 7(1)(23): 1-10. (persian)##5.	Cheragi M, Sohrabi M, Shayesteh K. Determination of copper and cadmium concentr ation in greenhouse tomatoes produced in Hamadan province during 2012. Journal of Food Hygiene.  2014; 3(12): 31-40. (persian)##6.	Givianrad MH, Sadeghi T, Larigani K, Hosseini SE. Determination of cadmium and lead in lettuce, mint and leak cultivated in different sites of southern Tehran. Journal of Food Technology and Nutrition.  2011; 8(2): 38-43. (persian)##7.	Akbari-adergani B, Gharanfoli F, Hassanzade M, Khashyarmanesh Z, Rezaee R, Karimi G. 2012, Determination of heavy metals in different honey brands from Iranian markets.  Food Addit Contam Part B Surveil. 2012; 5(2): 105-111.##8.	Sadeghzadeh FS, Akbari-Adergani B. Bioaccumulation and Exposure Assessment of Lead and Cadmium Due to Consumption of Penaeus semisulcatus A Post-market Surveillance in Tehran 2012. J Health Syst Res. 2014; 10(3):628-639. [Persian]##9.	Yargholi B. Cadmium absorption by tomatoes and different growth stage in polluted soil. Journal of Agricultural Engineering Research. 2012; 12(4):1-18. (persian)##10.	Chary NS, Kamala CT, Raj SS. Assessing risk of heavy metals from consuming food grownon sewage irrigated soils and food chain transfer. Ecotoxicol Environ Saf.  2008; 69(3): 513-524. ##11.	Norton GJ, Deacon CM, Mestrot A, Feldmann, J, Jenkis P, Meharge AA. Cadmium and lead in vegetable and fruit producte selectd from specific regional area of the UK. Sci Total Environ. 2015; 533: 520-527.##12.	Fang B, X Zhu. High content of five heavy metals in four fruits: Evidence from a case study of pujiang country, zhejiane province, china. Food Control. 2014; 39: 62-67.##13.	Zohrehvand F, Takdastan A, Jaafarzadeh N, Ramezani Z, Ahmadi angali K, Gharibi H. Assessment of lead contamination in vegetables, irrigation water and soil in farmland irrigater by surface water in ahvaz. J Mazandaran Univ Med Sci. 2014; 24(118): 226-231. (persian)##14.	Akbari-adergani B, Ezeddin M, Moghaddam HH, Shoeibi S. Effect of production production process on concentration of lead arsenic in sun flower, oil. J Mazandaran Univ Med Sci. 2015; 25(127): 38-48. (persian)##15.	Zafarzadeh A, Rahimzadeh H. Concentration of cadmium, lead, zinc and copper in the cucumber and tomatoe in northern Iran. J Gorgan Univ Med Sci. 2015; 17(1): 77-83. (persian)##16.	Institute of Standard and industrial Research of Iran (ISIRI). Iranian National Standard, Food and Feed. Maximum limit of heavy metals 2010; No. 12968.##17.	Singeh BR, Marwall RP. Plant availability of heavy metal in a sludge treated soil. J Envirion Quall.  1992; 21(3): 344-349.##18.	Shariati S, Aghanabati SA, Mosavi harami SR, Modabberi S, Adabi MH. Assessment of population rate cauded by the mining industries and processing of lead and zinc on the water and soil of Anguran-Dandy Region. Geoscience. 2011; 21(81): 45-54. (persian)##19.	Akbari-Adergani B. Physical and chemical experiments for Water Quality Control, 1st ed. Chap 4. Esfahan: Esfahan University of Medical Sciences Publication; 2013. P. 59-78. (persian)##20.	Institute of Standard and industrial Research of Iran (ISIRI). Specification for drinking water. ISIRI, 1997; No. 1053.##21.	Codex Alimntarius commission (WHO/ FAO). Food additives and contaminants joint, (WHO/FAO). food standard program. 2001.##22.	Khaledian MR, Motamed MK , Rezaei M, Bayat M, Maleknia B. Effect of heavy metals concentration of irrigation water from different source on the contamination of paddy field soil. Journal of Water and Soil Conservation. 2014; 21(4):275-285.(persian)##23.	Bahadir T, Bakan G, Altas L, Buyukgungor H. The investigation of lead removal by biosorption: An application at storage battery industry wastewater. Enzyme Microb Tech. 2007; 41(1-2): 98–102.##24.	Bayramoğlu G, Arıca MY. Removal of heavy mercury (II), Cadmium (II) and Zink (II) metal ions by live and heat inactivated lentinus edodes pellets. Chem Eng J. 2008; 143(1-3):133–140.##25.	Babel S, Kurniawan TA. Low-cost ad- sorbents for heavy metals uptake from contaminated water: a review. J Hazard Mater.  B97 2003; 28(1-3): 219–243.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>بررسی میزان آگاهی دانشجویان سال آخر دندانپزشکی و دندانپزشکان شهر ساری نسبت به فوریت های پزشکی در مطب دندانپزشکی در سال 95</TitleF>
		<TitleE>Assessment of Senior Students' and Dentists' Knowledge about Medical Emergencies in Dental Offices, Sari, Iran 2016

</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: اکثر فوریت&#8204;های پزشکی که در مطب دندانپزشکی رخ می&#8204;دهد،&#8204; می&#8204;توانند حیات فرد را به مخاطره اندازند. بنابراین یک دندانپزشک باید آگاهی کامل جهت تشخیص و درمان صحیح فوریت&#8204;ها را داشته باشد. هدف از انجام این مطالعه، بررسی آگاهی دندانپزشکان و دانشجویان سال آخر در زمینه شناخت و درمان فوریت&#8204;های دندانپزشکی بود.
مواد و روش&#8204;ها: این مطالعه مقطعی بر روی ١١۴ نفر از دندانپزشکان و دانشجویان دندانپزشکی سال آخر شهر ساری در سال ۹۵ انجام شد و پرسشنامه&#8204;ای معتبر شامل ۲۰ سوال در اختیار آن&#8204;ها قرار گرفت. این پرسشنامه شامل اطلاعات دموگرافیک و 17 سوال آگاهی (امتیاز 17-14: عالی، 14-11: خوب، 11-8: متوسط و زیر 8: ضعیف) بود. آنالیز آماری توصیفی و تحلیلی با استفاده از نرم افزار آماری SPSS 20 و با سطح معنی&#8204;داری 05/0 صورت پذیرفت.
یافته&#8204;ها: در این مطالعه، میزان آگاهی ۷/١۶ درصد شرکت کنندگان در حد ضعیف، ٣/۶۹ درصد در حد متوسط، ۲/١٣ درصد در حد خوب و ١ درصد عالی بود. تفاوت آماری معنی&#8204;داری بین سطح آگاهی دانشجویان و دندانپزشکان (۴٣۰/۰ p =) و هم&#8204;چنین بین خانم&#8204;ها و آقایان یافت نشد (6٣۰/۰ = (P.
استنتاج: میزان آگاهی دندانپزشکان و دانشجویان سال آخر دندانپزشکی ساری در زمینه تشخیص و درمان فوریت&#8204;های پزشکی در مطب در حد مطلوبی نمی&#8204;باشد که نیازمند مداخله از طریق برگزاری کارگاه آموزشی و برنامه&#8204;های آموزش مداوم می&#8204;باشد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Most of medical emergencies occurring in dental offices could be life &#8211; threatening. So, a dentist must have appropriate knowledge for recognizing and management of these emergencies. The aim of this study was to investigate the knowledge of dentists and senior dental students on the management of medical emergencies in dental offices.
Materials and methods: This analytic cross-sectional research was carried out in Sari among 114 dentists and senior dental students in 2016. A validated questionnaire consisting of 20 questions was administered. The questionnaire included demographic information and also 17 questions about knowledge (scores 14-17: excellent, 11-14: good, 8-11: moderate, and less than 8: poor). Data was analyzed using descriptive and analytical tests in SPSS V20 and a significance level of 0.05 was considered.
Results: The levels of knowledge of participants were found to be poor in 16.7%, moderate in 69.3%, good in 13.2%, and excellent in 1%. There was no significant differences in levels of knowledge between dentists and dental students (P = 0.430) and also between men and women (P= 0.630).
Conclusion: Insufficient levels of knowledge in dentists and senior dental students in Sari on diagnosis and management of dental emergencies call for interventions such as workshops and training programs.

&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>173</FPAGE>
			<TPAGE>178</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/302017/08/9
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/5/18
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/122017/09/24
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/7/2
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>مریم</Name>
				<MidName></MidName>
				<Family>زمان زاده</Family>
				<NameE>Maryam</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zamanzadeh</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه آسیب شناسی دهان، فک و صورت، دانشکده دندانپزشکی، دانشگاه علوم پزشکی مازندران،ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>اعظم</Name>
				<MidName></MidName>
				<Family>حدادی</Family>
				<NameE>Azam</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Haddadi</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه اندودنتیکس، دانشکده دندانپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Haddadi_azam@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمود</Name>
				<MidName></MidName>
				<Family>موسی زاده</Family>
				<NameE>Mahmood</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Moosazadeh</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات علوم بهداشتی، پژوهشکده اعتیاد، دانشگاه علوم پزشکی مازندران، ساری ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mmoosazadeh1351@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>آرزو</Name>
				<MidName></MidName>
				<Family>کریم زاده</Family>
				<NameE>Arezoo</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Karimzadeh</FamilyE>
				<Organizations>
				<Organization>دندانپزشک، ساری ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Baran.m2025@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>آناهیتا</Name>
				<MidName></MidName>
				<Family>قربانی</Family>
				<NameE>Anahita</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ghorbani</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه بیماری های دهان و فک و صورت، دانشکده دندانپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Emergencies</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Dentists</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Knowledge</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>فوریت‌های پزشکی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>دندانپزشکان</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>آگاهی</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Malamed SF. Medical emergencies in the dental office. St. Louis, Elsevier Health Sciences; 7th ed. 2014.##2.	Müller MP, Hänsel M, Stehr SN, Weber S, Koch T. A state-wide survey of medical emergency management in dental practices: incidence of emergencies and training experience. Emerg Med J. 2008; 25(5):296-300.##3.	DeLong CM, Bragg R, Simmons JA. Evidence for spatial representation of object shape by echolocating bats (Eptesicus fuscus). J Acoust Soc Am. 2008; 123 (6):4582-4598.##4.	Bavitz JB. Emergency management of hypoglycemia and hyperglycemia. Dent Clin North Am. 1995; 39 (3):587-594.##5.	Malamed SF. Managing medical emergencies. J Am Dent Assoc. 1993; 124 (8):40-53.##6.	Patel K, Driscoll P. Dental knowledge of accident and emergency senior house officers. Emerg Med J. 2002; 19 (6):539-541.##7.	Nunn P. Medical emergencies in the oral health care setting. J Dent hyg. 2000; 74 (2):136-151; quiz 52-55.##8.	Stein PS. Medical emergencies in dentistry: Prevention and Preparation. Woman Dent J. 2004; 25-29.##9.	Babaee N, Mir B, Poorsattar A, Serajpoor H. Assessment of Babol′ s dentist knowledge regarding medical emergencies in dental office in 2010. Journal of Dental Medicine (jdm). 2013; 26 (4):314-320. (persian)##10.	Amir Chaghmaghi M, Sarabadani J, Delavarian Z, MirzaAli A. Evaluation of Knowledge among Dental Specialists about Common Medical Emergencies in Dental Offices in Mashhad-Iran in 2009-2010. J Mashad Dent Sch. 2011; 34(4):263-270. (persian)##11.	Birang R, Kaviani N, Behnia M, Mirghaderi M. Isfahan dentists’ readiness for medical emergencies: their knowledge and access to necessary equipments. Iran J Med Educ. 2005; 5(2):47-54. (persian)##12.	Hashemipour M, Ataie Z, Orandi S. The Knowledge and practice of dentists about medical emergency in private dental offices. J Dent Shiraz Univ Med Sci. 2009; 10(3):222-233. (persian)##13.	Farhad Mollashahi L, Honarmand M. Assessment of knowledge and attitude of general dental practitioners about medical emergencies in Zahedan-Iran. J Mashad Dent Sch. 2009; 32(4):319-324.(persian)##14.	Morowati MA, Aghaaghili AM, Mosaffa. Investigating general dentists knowledge in regard with medical emergencies in Yazd in 2013.Yazd Journal of Dental Research.2014; 3(1):176-184.(persian)## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>مقایسه نگرش زنان و مردان نسبت به زمان فرزند آوری</TitleF>
		<TitleE>Comparing the Attitudes of Men and Women towards the Birth of First Child
</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: فاصله ازدواج تا اولین تولد بخاطر نقش مهمی که از یک طرف در تعداد موالید یک زوج و از طرف دیگر در سلامت مادر و کودک دارد در مطالعات جمعیتی و بهداشت باروری از اهمیت خاصی برخوردار است.
مواد و روش&#8204;ها: مطالعه حاضر یک مطالعه پیمایشی مقطعی می&#8204;باشد. در این مطالعه از پرسشنامه برای گردآوری اطلاعات استفاده شده است. جامعه آماری در این مطالعه افراد در شرف ازدواج استان کهگیلویه و بویراحمد است.روش نمونه&#8204;گیری در این مطالعه، نمونه در دسترس می&#8204;باشد. تعداد نمونه آماری در مطالعه حاضر 400 نفر ( 200 زن و 200 مرد ) می&#8204;باشد. برای تجزیه و تحلیل اطلاعات از نرم افزار spss استفاده شده است.
یافته&#8204;ها: نتایج نشان داد که میانگین فاصله ازدواج تا تولد اولین فرزند برای مردان 2.22 سال ولی برای زنان 1.95 سال است. براساس نتایج، متغیر محل سکونت &#160;مردان و متغیرهای سن ازدواج &#160;زنان و همچنین موقعیت اقتصادی- اجتماعی &#160;و وضعیت اشتغال &#160;آنها اثر مستقل و معناداری بر نگرش آنها نسبت به فاصله ازدواج تا تولد اولین فرزند داشته اند.
استنتاج: در جامعه مورد مطالعه، افراد به لحاظ ایده&#8204;ای موافق فرزندآوری در 5 سال نخست زندگی شان هستند بنابراین توجه سیاستگذاران، باید بر بهبود شرایط کاری زنان شاغل، بهبود مراقبت&#8204;های بهداشتی در زمان حاملگی و فراهم کردن شرایط ازدواج برای جوانان در سنین 20 تا30 سالگی متمرکز شود.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: The time between marriage and first birth has a major role in the number of a couple&#8217;s births, and maternal and children health. Therefore, population and fertility health studies are highly interested in this area.
Materials and methods: We conducted a cross-sectional survey and a questionnaire was used to collect the data. The research population included 400 people (200 males and 200 females) who were getting married in near future in Kohgiluyeh and Boyer Ahmad, Iran. The participants were selected via convenient sampling. Data analysis was done in SPSS.
Results: The results showed that the average time-interval between marriage and a first birth for men and women is 2.22 and 1.95 years, respectively. Some variables were found to have significant direct effects on the attitudes of participants towards birth of first child including place of residence (city or village) in men and the age, employment status, and family&#8217;s socio-economic status in women.
Conclusion: In the population studied, people agreed to the idea of having a child in the first 5 years of their marriage. So policy makers should provide appropriate conditions such as improving the working conditions of women and improving health care during pregnancy. Moreover, they should provide the suitable conditions for marriage of young people aged 20 to 30 years.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>179</FPAGE>
			<TPAGE>183</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/302017/08/92017/02/5
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/11/17
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/122017/09/242017/06/14
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/3/24
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>فاطمه</Name>
				<MidName></MidName>
				<Family>ترابی</Family>
				<NameE>Fateme</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Torabi</FamilyE>
				<Organizations>
				<Organization>استادیار، جمعیت شناسی، دانشکده علوم اجتماعی، دانشگاه تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فرزاد</Name>
				<MidName></MidName>
				<Family>قربانی</Family>
				<NameE>Farzad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ghorbani</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد جمعیت شناسی، دانشکده علوم اجتماعی، دانشگاه تهران،تهران،ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>f.ghorbani69@ut.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مسعود</Name>
				<MidName></MidName>
				<Family>کوچانی</Family>
				<NameE>Masoud</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Kuchani</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد جمعیت شناسی، دانشکده علوم اجتماعی، دانشگاه تهران،تهران،ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>time-interval</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>marriage</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>first birth</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>fertility health</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>marriage age</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Kohgiluyeh and Boyer-ahmad</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>فاصله ازدواج تا اولین تولد</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>بهداشت باروری</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سن ازدواج</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>استان کهگیلویه و بویراحمد</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Rahimi Foroushani A, Kazemi M, Ghanbarnejad A, Eshragian MR, Majlesi F. First Birth Factors Affecting distance using Cox regression model. Hyat. 2016; 22(3): 255-264.(persian).##2.	Zare Mehrjardi R, Mohammadi Nia Tayyebe, Hosseini G. &#34;Factors Related to delay the birth of first child (the study of married women 15-49 years living in Maybod. Journal of Health in Feild. 2016; 15(3): 30-42.(persian).##3.	Shah Abadi Z, Saraee H, Khalaj Abadi Farahani F. The investigation of attitude toward studying continuation after marriage and its effect on parening decision (the studying of women who are about to marriage in Nayshabour town). Social Science Quarterly. 2016; 25(71): 126-162.(persian).##4.	Abbasi-Shavazi MJ, McDonald P, Hosseini Chavoshi, M. Changes in family, fertility behavior and attitudes in iran. Demographyand Sociology Program. Working Papers in Demography. 2003; 88.##5.	Abbasi Shavazi MJ, Razeghi Nasrabad BH. Patterns and Influencing factors on the interval between marriage and first birth in Iran. Journal of Population Association of Iran. 2010; 5(9): 77-105. [Persian]##6.	Awang H. Determinants of waiting time to third pregnancy using censored linear regression.J Biosoc Sci. 2003; 35(1): 59-70.##7.	Bongaarts J.(population Council, Policy Research Division). The fertility impact of changes in the timing of childbearing in the developing word. The Population Concil, 1999;PP 33.##8.	De Jong GF, Sell RR. Changes in childlessness in the united state: A demographic path Analysis. Popul Stud(Camb). 1977; 31(1): 129-141.##9.	Edwards ME. Education and Occupations: Reexamining the Conventional Wisdom about Later First Births among American Mothers. Sociol Forum. 2002; 17(3): 423-443.##10.	Moregan SP. Late Nineteenth and Early twentieth – Century Childlessness. American Journal of Sociology. 1991; 97(3): 779-807.##11.	Kumar GA, Danabalan M. Determinants of Delayed First Birth. Indian Journal of Community Medicine. 2006; 31(4): 272-273.##12.	Parsa A. Birth spacing and Influencing factors on it among women in the city Boyer. (Master Thesis). Shiraz University. 2007.(persian).##13.	Trussell J, Menkern J. Early child bearing and subsequent fertility. Fam Plan Perspect. 1978; 10 (4): 209-218.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>گزارش میزان باقی مانده آفت کش ها در نمونه های ملون به روش گاز کروماتوگرافی طیف سنجی جرمی</TitleF>
		<TitleE>Pesticide Residue Levels in Melon Samples Using Gas Chromatography-Mass Spectrometry</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: با توجه به کاربرد گسترده سموم دفع آفات نباتی در کشاورزی و افزایش نگرانی&#8204;های مربوط به مخاطرات آفت&#8204;کش&#8204;ها، در این تحقیق میزان باقی&#8204;مانده انواع سموم آفت&#8204;کش به روش کروماتوگرافی گازی - طیف سنجی جرمی در تعدادی ملون ارزیابی شد.
مواد و روش&#8204;ها: در پژوهش تجربی حاضر، 75 نمونه ملون جمع&#8204;آوری شده از میادین تره&#8204;بار تهران جهت آنالیز هم&#8204;زمان جهت پایش هم&#8204;زمان انواعی از آفت&#8204;کش&#8204;های پرمصرف در ملون&#8204;ها توسط دستگاه GC/MS در دو مد اسکن و (Selected Ion Monitoring) SIM مورد آنالیز قرار گرفتند.
یافته&#8204;ها: از 75 نمونه بررسی شده، 8 درصد دارای انواع باقی&#8204;مانده سموم شامل آفت&#8204;کش پیریمیکارب در سطح &#181;g/g 007/0، آفت&#8204;کش دی متوآت در سطح &#181;g/g03/0، آفت&#8204;کش متالاکسیل در سطح &#181;g/g 015/0، آفت&#8204;کش آلفا اندوسولفان در سطح &#181;g/g 012/0 و پرمترین در سطح &#181;g/g008/0 بودند که همگی آلودگی کم&#8204;تر از حدود مجاز مقرر شده توسط Codex و آمریکا داشتند (05/0&#62; p).
استنتاج: از آن&#8204;جایی&#8204;که در ایران حدود مجاز آفت&#8204;کش&#8204;ها در ملون تعیین نشده است، لذا نتایج این تحقیق می&#8204;تواند در تعیین حدود مجاز آفت&#8204;کش&#8204;ها مورد استفاده مراجع ذی صلاح و متولی امر قانون&#8204;گذاری آفت&#8204;کش&#8204;ها قرار گیرد.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Widespread use of plant pesticides in agriculture resulted in increasing concerns about pesticide hazards. In this research, the residual levels of pesticides in melons were evaluated by gas chromatography-mass spectrometry (GC-MS).
Materials and methods: In this study, 75 samples of melons in Tehran market were used for simultaneous analysis of a variety of common pesticides in melons by GC/MS in two modes of scanning and SIM (Selected Ion Monitoring).
Results: Among the samples, 8% were found with different types of residual pesticides, including pirimicarb (0.007 &#956;g/g), dimethoate (0.03 &#956;g/g), metalaxyl (0.015 &#956;g/g), Alpha-endosulfan (0.012 &#956;g/g), and permethrin (0.008 &#956;g/g). All contaminations were less than the limits set by the Codex and the United States of America (P&#60; 0.05).
Conclusion: The standard limitations of pesticides in melons are not yet recommended in Iran, so, current findings could be used by authorities in determining these residual limits.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>184</FPAGE>
			<TPAGE>188</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/302017/08/92017/02/52017/04/24
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/2/4
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/122017/09/242017/06/142017/11/11
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/8/20
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>شهرام</Name>
				<MidName></MidName>
				<Family>شعیبی</Family>
				<NameE>Shahram</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shoeibi</FamilyE>
				<Organizations>
				<Organization>دانشیار اداره کل آزمایشگاهای کنترل غذا و دارو، سازمان غذا و دارو وزارت بهداشت، درمان و آموزش پزشکی تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مریم</Name>
				<MidName></MidName>
				<Family>امیر احمدی</Family>
				<NameE>Maryam</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Amirahmadi</FamilyE>
				<Organizations>
				<Organization>استادیار اداره کل آزمایشگاهای کنترل غذا و دارو، سازمان غذا و دارو وزارت بهداشت، درمان و آموزش پزشکی تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>بهروز</Name>
				<MidName></MidName>
				<Family>جنت</Family>
				<NameE>Behrooz</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Jannat</FamilyE>
				<Organizations>
				<Organization>دانشیار مرکز تحقیقات حلال، وزارت بهداشت، درمان و آموزش پزشکی تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>منان</Name>
				<MidName></MidName>
				<Family>حاجی محمودی</Family>
				<NameE>Mannan</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hajimahmoodi</FamilyE>
				<Organizations>
				<Organization>استاد گروه کنترل دارو وغذا، دانشکده داروسازی، دانشگاه علوم پزشکی تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ایمان</Name>
				<MidName></MidName>
				<Family>معظمی گودرزی</Family>
				<NameE>Iman</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Moazzami Goodarzi</FamilyE>
				<Organizations>
				<Organization>دکترای داروسازی، دانشکده داروسازی، دانشگاه علوم پزشکی تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>معصومه</Name>
				<MidName></MidName>
				<Family>بهزاد</Family>
				<NameE>Masoomeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Behzad</FamilyE>
				<Organizations>
				<Organization>کارشناس گروه کنترل دارو وغذا، دانشکده داروسازی، دانشگاه علوم پزشکی تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>نفیسه</Name>
				<MidName></MidName>
				<Family>صادقی</Family>
				<NameE>Naficeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sadeghi</FamilyE>
				<Organizations>
				<Organization>دانشیار مرکز تحقیقات حلال، وزارت بهداشت، درمان و آموزش پزشکی تهران، ایران،دانشیار گروه کنترل دارو وغذا، دانشکده داروسازی، دانشگاه علوم پزشکی تهران، ایران  عضو مرکز تحقیقات سلامت آب، سازمان غذا و دارو ، وزارت بهداشت، درمان و آموزش پزشکی تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nsadeghi@sina.tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>pesticides</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>GC-MS</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>melon</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>باقی‌مانده آفت‌کش</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>گاز کروماتوگرافی طیف سنجی جرمی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>ملون</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Lehotay SJ. Analysis of pesticide residues in mixed fruit and vegetable extracts by direct sample introduction/gas chromatography/tandem mass spectrometry. J AOAC Int 2000; 83(3): 680–697.##2.	Beyer A, Biziuk M. Methods for determining pesticides and polychlorinated biphenyls in food samples--problems and challenges. Crit Rev Food Sci Nutr 2008; 48(10): 888–904.##3.	Anastassiades M, Lehotay SJ, Stajnbaher D, Schenck FJ. Fast and easy multiresidue method employing acetonitrile extraction/partitioning and &#34;dispersive solid-phase extraction&#34; for the determination of pesticide residues in produce. J AOAC Int 2003; 86(22): 412–431.##4.	Tadeo ,Jose L.Analysis of pesticides in food and environmental samples. Taylor &#38; Francis Group.(2008) ,LLC.P,144.##5.	Anastassiades M. Validation of a simple and rapid multiresidue method (QuEChERS) and its implementation in routine pesticide analysis. Poster presented at MGPR Symposium. 2003.##6.	José LT. Analysis of pesticides in food and environmental samples. Taylor &#38; Francis Group. EBook. 2008; PP.144.##7.	Ebadi AG, Shokrzadeh M, Zare S. A Survey and Measurement of Residues of Lindane (Organochlorine Pesticides) in Cultivated Cucumber of Mazandaran Province (Iran). P J N 2005; 4 (5): 291-293.##8.	Camino-Sa´nchez FJ, Zafra-Go´mez A, Ruiz-Garcı´a J, Bermu´dez-Peinado R, Ballesteros O, Navalon A, et al. Accredited method for the determination of 121 pesticide residues in fruits and vegetables by gas chromatography–tandem mass spectrometry. J Food Comp. Anal 2011; 24(3): 427-440.##9.	Martínez Vidal JL, Arrebola FJ, Mateu-Sánchez M. Application of gas chromatography–tandem mass spectrometry to the analysis of pesticides in fruits and vegetables. J Chromatogr A 2002; 959(1-2): 203–213.#### ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>برآورد هم ابتلایی آنفولانزا با دیگر بیماری ها - مقاله  متاآنالیز در کشورهای ناحیه مدیترانه شرقی</TitleF>
		<TitleE>Estimating Co-morbidity of H1N1 Pandemic and Other Diseases: A Meta-analysis of Countries in Eastern Mediterranean Region</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: ویروس آنفولانزا به&#8204;عنوان یک عامل اختلال حاد سیستم تنفسی بوده که مسری می&#8204;باشد و از طریق سرفه و یا عطسه از فردی به فرد دیگر منتقل می&#8204;گردد. در سال 2009 بیماری پاندمی آنفولانزا در برخی نواحی مشاهده شد. هدف از این مطالعه برآورد هم ابتلایی بیماری آنفولانزا با دیگر بیماری&#8204;ها در پاندمی سال 2009- در کشورهای ناحیه مدیترانه شرقی می&#8204;باشد.
مواد و روش&#8204;ها: تمام مطالعات در پایگاه&#8204;های بین المللی مورد جست و جو قرار گرفتند. جهت افزایش حساسیت، جست و جوی منابع توسط دو پژوهشگر و به&#8204;صورت مجزا صورت گرفت. در نهایت مقالات واجد شرایط که از لحاظ کیفیت و معیارهای ورود و خروج ارزیابی شدند، وارد مطالعه متاآنالیز شدند. هتروژنیسیتی بین نتایج مطالعات اولیه توسط آزمون Q وI2 تعیین شد. هم&#8204;چنین برآورد هم ابتلایی نمونه&#8204;های تایید شده در کشورهای مختلف براساس فاصله اطمینان 95 درصد در نمودار انباشت نشان داده شد.
یافته&#8204;ها: این مطالعه متاآنالیز شامل 33311 مقاله مرتبط با پرسش حاضر می&#8204;باشد. نتایج متاآنالیز نشان می&#8204;دهد که بیشترین میزان هم ابتلایی(81.85 ، 59.75)70.80 و نارسایی کبدی(12.6 ، 0.34)6.20 در عمان و بیشترین میزان ابتلا به چاقی (41.34 ، 13.66) 27.50 و دیابت(49.78 ، 20.22) 35.00 در قطر و هم&#8204;چنین بیشترین میزان نارسایی قلبی(43.98 ، 6.02) 25.00 ، بیماری کلیوی(48.13 ، 16.67) 32.40، بدخیمی (79.06، 48.94) 64.06 و بیماری ریوی(29.80، 18.40) 24.10 به ترتیب در عمان ، تانزانیا، جوردن وایران مشاهده شده است.
استنتاج: این مطالعه متا آنالیز نشان می&#8204;دهد که شیوع هم ابتلایی در نواحی مختلف از شرق مدیترانه با هم تفاوت دارد که می&#8204;تواند به فاکتورهایی از قبیل: اختلالات ریوی، دیابت، اختلالات سیستم تنفسی، بیماری&#8204;های قلبی، بیماری&#8204;های کلیوی و چاقی مربوط باشد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Influenza A (H1N1), an acute respiratory disorders, is a highly contagious virus and can spread from person to person through sneezing or coughing. In 2009, pandemic influenza A (H1N1) emerged in some regions. This meta-analysis aimed at estimating the co-morbidity of 2009 H1N1 pandemic and other diseases in countries in the WHO Eastern Mediterranean Region.
Materials and methods: All studies were searched in international databases. In order to increase the search sensitivity, the references were evaluated by two researchers independently. Then, eligible articles were selected by performing quality assessment of each article and implementation of inclusion/exclusion criteria. The heterogeneity observed among the results of primary studies were defined by Q and I2 tests. The co-morbidity rate of confirmed cases based on different countries and confidence intervals (95% CI) are expressed in forest plot graph.
Results: This meta-analysis included 33311 articles. The highest incidence of Comorbidity is correct and liver failure are reported in Oman with 70.80 (59.75, 81.85) and 6.20 (0.34, 12.6), respectively. Also, the highest rate of obesity 27.50 (13.66, 41.34) and diabetes 35.00 (20.22, 49.78) were found in Qatar. Heart failure 25.00 (6.02, 43.98), kidney failure 32.40 (16.67, 48.13), malignancy 64.06 (48.94, 79.06), and COPD 24.10 (18.40, 29.80) were observed more in Oman, Tanzania, Jordan, and Iran, respectively.
Conclusion: This Meta- analysis showed that the incidence of co-morbidity is various among different countries in the WHO Eastern Mediterranean Region, which might be associated with some factors such as lung disease, diabetes, kidney failure, obesity, cardiac and respiratory failure.&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>189</FPAGE>
			<TPAGE>211</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/302017/08/92017/02/52017/04/242017/03/17
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/12/27
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/122017/09/242017/06/142017/11/112017/09/12
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/6/21
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>طهورا</Name>
				<MidName></MidName>
				<Family>موسوی</Family>
				<NameE>Tahoora</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mousavi</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکترای بیولوژی سلولی مولکولی، کمیته تحقیقات دانشجویی، مرکز تحقیقات بیولوژی سلولی مولکولی، دانشکده پزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>stm.jmums@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>علی اصغر</Name>
				<MidName></MidName>
				<Family>نادی</Family>
				<NameE>Aliasghar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Nadi</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری، مرکز تحقیقات علوم بهداشتی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>stm.jmums@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمو د</Name>
				<MidName></MidName>
				<Family>موسی زاده</Family>
				<NameE>Mahmood</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Moosazadeh</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات علوم بهداشتی، پژوهشکده اعتیاد، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>jcc.mazums@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمدرضا</Name>
				<MidName></MidName>
				<Family>حق شناس</Family>
				<NameE>Mohammadreza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Haghshenas</FamilyE>
				<Organizations>
				<Organization>استاد، گروه میکروب شناسی، مرکز تحقیقات بیولوژی سلولی مولکولی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haghshenas2001@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>co-morbidity</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>meta- analysis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>influenza</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>incidence</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>هم ابتلایی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>متاآنالیز</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>آنفولانزا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>شیوع</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Nandost Kenari S, Haghshenas M, Mirzaei M, Rezaee MS, Tabrizi A. Prevalence of Influenza A Viruses in Patients with Flu Symptoms Attending Mazandaran Provinces Health Centers, 2009-2013. J Mazandaran Univ Med Sci. 2014;24(119):1-10.(persian)##2.	Haghshenas M, Jafarian E, Babamahmoodi F, Tabrizi A, Nandoost S, Alizadeh-Navaei R. Prevalence of influenza A/H3N2 virus in northern Iran from 2011 to 2013. Caspian J Intern Med. 2015;6(2):116-119.(persian)##3.	Ahmad AS, Puttaswamy C, Mudasser S, Abdelaziz O. Clinical presentation and outcome in hospitalized patients of 2009 pandemic influenza A (H1N1) viral infection in Oman. Oman Med J. 2011;26(5):329-336.##4.	Haghshenas MR, Asgari A, Babamahmoodi F, Rezai MS, Tabrizee A, Nandoost S. Prevalence of Influenza A/H1N1 Virus in North of Iran (Mazandaran), 2009-2011. J Mazandaran Univ Med Sci. 2013;22(92):50-57.(persian)##5.	BinSaeed AA. Characteristics of pandemic influenza A (H1N1) infection in patients presenting to a university hospital in Riyadh, Saudi Arabia. Ann Saudi Med. 2010;30(1):59-62.##6.	Centers for Disease Control and Prevention (CDC). Swine-origin influenza A (H1N1) virus infections in a school-New York City, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(17):470-472.##7.	Centers for Disease Control and Prevention (CDC).Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. MMWR Morb Mortal Weekly Rep. 2009;58(15):400-402.##8.	Agha A, Alrawi A, Munayco CV, AlAyed MS, Al-Hakami M, Korairi H, et al. Characteristics of Patients Hospitalized with 2009 H1N1 Influenza in a Tertiary Care Hospital in Southern Saudi Arabia. Mediterr J Hematol Infect Dis. 2012;4(1).e2012002.##9.	Viasus D, Paño‐Pardo J, Pachon J, Campins A, López‐Medrano F, Villoslada A, et al. Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect. 2011;17(5):738-446.##10.	Shlomai A, Nutman A, Kotlovsky T, Schechner V, Carmeli Y, Guzner-Gur H. Predictors of pandemic (H1N1) 2009 virus positivity and adverse outcomes among hospitalized patients with a compatible syndrome. Isr Med Assoc J. 2010;12(10):622-627.##11.	Myers KP, Olsen CW, Gray GC. Cases of swine influenza in humans: a review of the literature. Clin Infect Dis. 2007;44(8):1084-1088.##12.	Abdelaty NM. Risk factors and prognostic criteria in 230 patients with influenza A (H1N1) infection. Egyptian Journal of Chest Diseases and Tuberculosis. 2013;62(1):1-8.##13.	Hosseini RF, Ghaffari J, Ranjbar A, Haghshenas MR, Rafatpanah H. Infections in Children with Asthma.J Pediatr Rev (mazandaran University of Medival Science). 2013;1(1):34-45.(persian)##14.	Virus NS-OIAHN, Team I. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;2009(360):2605-2615.##15.	Donaldson LJ, Rutter PD, Ellis BM, Greaves FE, Mytton OT, Pebody RG, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ. 2009;339:b5213.##16.	AlMazroa MA, Memish Z, AlWadey AM. Pandemic influenza A (H1N1) in Saudi Arabia: description of the first one hundred cases. Ann Saudi Med. 2010;30(1):11-14.##17.	Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-1499.##18.	Chaari A, Dammak H, Chtara K, Bahloul M, Bouaziz M. ACUTE KIDNEY INJURY IN CRITICALLY ILL A (H1N1)‐INFECTED PATIENTS: A STUDY OF THE PROGNOSES. J Ren care. 2011;37(3):128-133.##19.	Momen-Heravi M, Afzali H, Soleimani Z, Sharif A, Razzaghi R, Moravvegi SA, et al. Clinical Presentation and Final Outcome in Definite Cases of Influenza A (H1N1) in Kashan, Iran. Zahedan J Res Med Sci. 2015;17(1):37-39.(persian)##20.	Pajankar S, Al Qassabi SS, Al Harthi SM. Clinical features and outcome of 65 laboratory confirmed cases of H1N1 in Muscat, Sultanate of Oman. Oman Med J. 2012;27(3):201-206.##21.	Damak H, Chtara K, Bahloul M, Kallel H, Chaari A, Ksibi H, et al. Clinical features, complications and mortality in critically ill patients with 2009 influenza A (H1N1) in Sfax, Tunisia. Influenza other Respir Viruses. 2011;5(4):230-240.##22.	Al-Lawati J, Al-Tamtami N, Al-Qasmi A, Al-Jardani A, Al-Abri S, Al Busaidy S. Hospitalised patients with Influenza A (H1N1) in the Royal Hospital, Oman: Experience of a tertiary care hospital, July–December 2009. Sultan Qaboos Univ Med J. 2010;10(3):326-334.##23.	Ayatollahi J, Golestan M, Sharifi MR, Esform E, Shahcheraghi SH. Investigation of the Relationship Between Demographic Characteristics and Frequency of Mortality in Certain Cases of Influenza A (H1N1) From Yazd Province (Iran).Jundishapur Journal of Microbiology  . 2013;6(10): 1-5.(persian)##24.	Gooya MM, Soroush M, Hemati P, Moghadami M, Sabayan B, Razavi SHE, et al. Influenza A (H1N1) pandemic in Iran: report of first confirmed cases from June to November 2009. Arch Iran Med. 2010;13(2):91-98.##25.	Al-Tawfiq JA, Abed M, Saadeh BM, Ghandour J, Shaltaf M, Babiker MM. Pandemic influenza A (2009 H1N1) in hospitalized patients in a Saudi Arabian hospital: epidemiology and clinical comparison with H1N1-negative patients. J Infect Public Health. 2011;4(5):228-234.##26.	Nisar N, Aamir UB, Badar N, Mehmood MR, Alam MM, Kazi BM, et al. Prediction of clinical factors associated with pandemic influenza A (H1N1) 2009 in Pakistan. PloS One. 2014;9(2):e89178.##27.	Alavi SM, Nashibi R, Moradpoor F. Prevalence and Mortality of Influenza A (H1N1) Virus Among Patients With Acute Respiratory Infection in Southwest Iran. Jundishapur J Microbiol. 2014;7(4):e9263.##28.	Ahmed MAE, Awadalla NJ, Saleh AB. Clinical epidemiology comparison of H1N1 RT‐PCR‐positive and RT‐PCR‐negative pneumonia during the 2009–2010 pandemic in Mansoura University Hospitals, Egypt. Influenza Other Respir Viruses. 2011;5(4):241-246.##29.	Al Soub H, Ibrahim AS, Al Maslamani M, Al-khal AL, Shaath S, Hamza NA. Epidemiology, Risk Factors, Clinical Features, and Outcome of Adult Patients With Severe Pandemic A/H1N1/2009 Influenza in Qatar: A Retrospective Study. Infect Dis Clin Practice. 2014;22(6):339-343.##30.	Honarvar B, Asadi N, Ghaffarpasand F, Moghadami M, Kasraeian M. Pregnancy outcomes among patients infected with pandemic H1N1 influenza virus in Shiraz, Iran. Int J Gynecol Obstet. 2010;111(1):86-87.##31.	Moradi A, Sigaroodi A, Poosh-Ashkan L, Nadji SA, Tabarsi P, Mansouri SD, et al. Clinical and Demographic Characteristics of Confirmed Cases in H1N1 (2009) Influenza. Tanaffos. 2011;10(2):15-19.(persian)##32.	Saleh P, Noshad H, Naghili B. Clinical manifestations of patients with novel H1N1 infection hospitalized in Infectious Disease ward, Sina hospital, Tabriz, Iran. Archives of Clinical Infectious Diseases. 2010;5(4):200-205.##33.	Bakhshayeshkaram M, Saidi B, Tabarsi P, Zahirifard S, Ghofrani M. Imaging findings in patients with H1N1 influenza A infection. Iran J Radiol. 2011;8(4):230-234.(persian)##34.	Rihani R, Hayajneh W, Sultan I, Ghatasheh L, Abdel-Rahman F, Hussein N, et al. Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. 2011;46(11):1430-1436.##35.	Al-Mahrezi A, Samir N, Al-Zakwani I, Al-Muharmi Z, Balkhair A, Al-Shafaee M. Clinical characteristics of influenza A H1N1 versus other influenza-like illnesses amongst outpatients attending a university health center in Oman. Int J Infect Dis. 2012;16(7):e504-e507.##36.	Al-Busaidi M, Al Maamari K, Al’Adawi B, Alawi FB, Al-Wahaibi A, Belkhair A. Pandemic influenza a H1N1 in Oman: epidemiology, clinical features, and outcome of patients admitted to Sultan Qaboos University Hospital in 2009. Oman Med J. 2016;31(4):290-297.##37.	Owayed AF, Husain EH, Al-Khabaz A, Al-Qattan HY, Al-Shammari N. Epidemiology and clinical presentation of pandemic influenza A (H1N1) among hospitalized children in Kuwait. Med Princ Pract. 2011;21(3):254-258.##38.	Naseem A, Satti S, Khan MA, Saeed W. A clinical account of hospitalized 2009 pandemic influenza A (H1N1) cases. J Coll Physicians Surg Pak. 2011;21(2):97-102.##39.	Barakat A, Ihazmad H, El Falaki F, Tempia S, Cherkaoui I, El Aouad R. 2009 Pandemic influenza A virus subtype H1N1 in Morocco, 2009–2010: epidemiology, transmissibility, and factors associated with fatal cases. J Infect Dis. 2012;206(suppl 1):S94-S100.##40.	Mestoui O, Lemriss S, El Mzibri M, Filali-Maltouf A, El Kabaj S. MONITORING AND CHARACTERIZATION OF EMERGENT INFLUENZA A H1N1 2009 VIRUSES IN RABAT, MOROCCO DURING 2009-2010. European Scientific Journal( ESJ). 2014;10(33).##41.	Alsadat R, Dakak A, Mazlooms M, Ghadhban G, Fattoom S, Betelmal I, et al. Characteristics and outcome of critically ill patients with 2009 H1N1 influenza infection in Syria. Avicenna J Med. 2012;2(2):34-37.##42.	Louriz M, Mahraoui C, Azzouzi A, Fihri MTEF, Zeggwagh AA, Abidi K, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in an university hospital of Morocco. Int Arch Med. 2010;3(1):26.##43.	Taha I. Characteristics of pregnant Women admitted with 2009 H1N1 Influenza in a referral maternity hospital at Al-Madinah, Saudi Arabia. The Egyptian Journal of Hospital Medicine. 2013;52:650-658.##44.	Amine IL, Bajjou T, El Rhaffouli H, Laraqui A, Hilali F, Menouar K, et al. Pandemic influenza A (H1N1) 2009 in Morocco: experience of the Mohammed V Military Teaching Hospital, Rabat, 12 June to 24 December 2009. Euro Surveill. 2011;16(23):19887.##45.	Moghadami M, Kazeroni A, Honarvar B, Ebrahimi M, Bakhtiari H, Akbarpour M, et al. Influenza A (H1N1) virus pandemic in Fars province: a report from southern Iran, July-December 2009. Iranian Red Crescent Medical Journal. 2010;12 (3):231-238.(persian)##46.	Faramarzi H, Khalily Zade M, Bazrgar M, Panahi N, Fathi B. Statistical Study of Clinical Predictors of Influenza A (H1N1) in Iran. Archives of Clinical Infectious Diseases. 2012;7(3):88-91.##47.	Najafi N1, Davoudi AR1, Baba Mahmoodi F1, Tayebi A1, Alian S1, Ghassemian R1,et al. Epidemiological, clinical and laboratory features of patients hospitalized with 2009 pandemic influenza in north of Iran. Caspian J Intern Med. 2012;3(1):377-381.##48.	Khan G, Al-Mutawa J, Hashim MJ. Pandemic (H1N1) 2009, Abu Dhabi, United Arab Emirates, May 2009-March 2010. Emerg Infect Dis. 2011;17(2):292-295.##49.	Balkhy HH, El-Saed A, Sallah M. Epidemiology of H1N1 (2009) influenza among healthcare workers in a tertiary care center in Saudi Arabia: a 6-month surveillance study. Infect Control Hosp Epidemiol. 2010;31(10):1004-1010.##50.	Husain EH, AlKhabaz A, Al-Qattan HY, Al-Shammari N, Owayed AF. Hospitalization patterns and outcomes of infants with Influenza A (H1N1) in Kuwait. J Infect Dev Ctries. 2012;6(8):632-636.##51.	Alsufiani HA, Aljabri HA, Morsy MM, Abdelaziz NA, Allugmani MD, Alkabli BM, et al. Clinical and laboratory characteristics of childhood pandemic 2009 H1N1 Influenza. Experience from the western region of Saudi Arabia. Saudi Med J. 2014;35(6):624-625.##52.	Mansour DE, El-Shazly AA, Elawamry AI, Ismail AT. Comparison of ocular findings in patients with H1N1 influenza infection versus patients receiving influenza vaccine during a pandemic. Ophthalmic Res. 2012;48(3):134-138.##53.	Tabarsi P, Moradi A, Marjani M, Baghaei P, Hashemian SM, Nadji SA, et al. Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection. Ann Thorac Med. 2011;6(2):91-95.##54.	Al-Khuwaitir TS, Al-Abdulkarim AS, Abba AA, Yousef AM, El-Din MA, Rahman KT, et al. H1N1 influenza A. Preliminary evaluation in hospitalized patients in a secondary care facility in Saudi Arabia. Saudi Med J. 2009;30(12):1532-1536.##55.	Hashemian SM, Tabarsi P, Nadji SA, Jamaati H, Mohajerani SA, Shamaee M, et al. Secondary infection and clinical aspects after pandemic swine–origin influenza a (H1N1) admission in an Iranian critical care unite. Int J Crit Illn Inj Sci. 2014;4(4):309-313.##56.	Jafarbegloo E, Tehrani TD, Abedini Z, Sheykholeslami NZ. Pregnancy Outcomes Among Hospitalized Patients Infected With 2009 H1N1 Influenza Virus in Qom, Iran, in Oct-Nov. 2009. Nursing and Midwifery Studies. 2013;1(3):163-166.(persian)##57.	Mady A, Ramadan OS, Yousef A, Mandourah Y, Amr A, Kherallah M. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. J Infect Public Health. 2012;5(1):52-56.##58.	Javadi AA, Ataei B, Khorvash F, Babak A, Rostami M, Mostafavizadeh K, et al. Clinical features of novel 2009 influenza A (H1N1) infection in Isfahan, Iran. J Res Med Sci. 2011;16(12):1550-1554.##59.	Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361(20):1935-1944.##60.	Merler S, Poletti P, Ajelli M, Caprile B, Manfredi P. Coinfection can trigger multiple pandemic waves. J Theor Biol. 2008;254(2):499-507.##61.	Cheraghi Z, Doosti Irani A, Rezaiean S, Ahmadzadeh J, Poorolajal J, Erfani H, et al. Influenza A (H1N1) in Hamedan Province, Western Iran in 2009: A Case-Control Study. J Res Health Sci. 2010;10(1):15-21.##62.	Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA. 2009;302(17):1896-1902.##63.	Akinnusi ME, Pineda LA, El Solh AA. Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med. 2008;36(1):151-158.##64.	El-Solh A, Sikka P, Bozkanat E, Jaafar W, Davies J. Morbid obesity in the medical ICU.Chest. 2001;120(6):1989-1997.##65.	Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.##66.	Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009.Euro Surveill. 2008;14(33):127-136.##67.	Yu H, Feng Z, Uyeki TM, Liao Q, Zhou L, Feng L, et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis. 2011;52(4):457-465.##68.	Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA. 2009;302(17):1872-1879.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>اهمیت و کاربرد انواع مدل‌های موشی در تحقیقات سرطان: راهنمایی‌هایی در انتخاب بهترین مدل</TitleF>
		<TitleE>Significance and Applications of Murine Models in Cancer Research: Guidelines for Selecting the Best Model</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>موش&#8204; یک &#8204;مدل ارجح ارگانیسمی در تحقیقات سرطان و تومور در زمینه بیولوژی سرطان (آغاز، پیشرفت و متاستاز) یا توسعه و بررسی روش&#8204;های بالقوه درمانی است. مدل&#8204;های مختلفی از جمله موش&#8204;های مهندسی ژنتیک شده (GEM)، زنوگرافت&#8204;ها و مدل&#8204;های شیمیایی در این حوزه مورد استفاده قرار می&#8204;گیرند. مطالعه حاضر با مرور و بررسی آخرین یافته&#8204;ها و مقالات این مدل&#8204;های موشی وکاربردهایشان را در جنبه&#8204;های مختلف تحقیقات حوزه سرطان معرفی کرده و مزایا و معایب هریک را مورد بحث قرار داده است. این مقاله با در نظر گرفتن محدودیت&#8204;های مدل&#8204;های مختلف موشی و تفاوت&#8204;های بنیادی بین موش و انسان (هم&#8204;چون اختلافات بین&#8204;گونه&#8204;ای و تفاوت&#8204;های فارماکولوژیکی) به ذکر فرصت&#8204;های فراهم شده توسط هر یک پرداخته و بسته به هدف تحقیق، نکاتی کلیدی جهت انتخاب بهترین مدل موشی در تحقیقات سرطان را ذکر کرده است.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Mice are the preferred model organisms in tumor and cancer research, concerning tumor biology (initiation, progression, and metastasis) or developing and screening the potential therapeutics. Different murine models including genetically engineered mice (GEM), xenografts, and chemical models may be used for this purpose. By reviewing the most recent scientific reports and publications, in the current paper, these models and their applications in different aspects of cancer research are introduced and their advantages and pitfalls are discussed. This article summarizes the opportunities provided by each model and their limitations and the fundamental differences between mouse and human such as species-specific and pharmacological differences. This article shed light on some key points for selection of the best murine model depending on the purpose of the research.
&#160;
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>212</FPAGE>
			<TPAGE>231</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/302017/08/92017/02/52017/04/242017/03/172017/05/15
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1396/2/25
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/122017/09/242017/06/142017/11/112017/09/122017/07/5
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/4/14
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>مرجان</Name>
				<MidName></MidName>
				<Family>عابدی</Family>
				<NameE>Marjan</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Abedi</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری زیست‌شناسی سلولی و مولکولی، گروه زیست‌شناسی، دانشکده علوم، دانشگاه اصفهان، اصفهان، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>m.abedi@sci.ui.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سهیلا</Name>
				<MidName></MidName>
				<Family>رهگذر</Family>
				<NameE>Soheila</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rahgozar</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه زیست‌شناسی، دانشکده علوم، دانشگاه اصفهان، اصفهان، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>rahgozar@sci.ui.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>mice model</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>cancer</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>preclinical studies</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>in vivo assays</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>موش</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سرطان</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>مطالعات پیش-بالینی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سنجش‎های in vivo</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Samuels AL, Peeva VK, Papa RA, Firth MJ, Francis RW, Beesley AH, et al. Research article Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia. BMC Genomics. 2010; 11: 256.##2.	Choi SY, Lin D, Gout PW, Collins CC, Xu Y, Wang Y. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev. 2014; 79-80: 222-237.##3.	Jacoby E, Chien CD, Fry TJ. Murine models of acute leukemia: important tools in current pediatric leukemia research. Front Oncol. 2014;4 :95.##4.	Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Bri J Cancer. 2010;102 (11):1555-7157.##5.	Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 2014; 344(1):1-12.##6.	Watson JD. Molecular biology of the gene. Molecular biology of the gene. 7th ed. New York: WA Benjamin, 2014.##7.	Lunardi A, Nardella C, Clohessy JG, Pandolfi PP. Of model pets and cancer models: an introduction to mouse models of cancer. Cold Spring Harb Protoc. 2014; 2014(1):17-31.##8.	Walrath JC, Hawes JJ, Dyke T Van, Reilly KM. Genetically Engineered Mouse Models in Cancer Research. Adv Cancer Res. 2010;106 :113-164.##9.	Anisimov VN, Ukraintseva SV, Yashin AI. Cancer in rodents: does it tell us about cancer in humans? Nat Rev Cancer. 2005;5 (10):807-819.##10.	Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, Van Bladeren PJ, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 2000;30 (12):1131-1152.##11.	Wong NC, Bhadri VA, Maksimovic J, Parkinson-Bates M, Ng J, Craig JM, et al. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics. 2014;15 :416.##12.	van Miltenburg MH, Jonkers J. Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr Opin Genet Dev. 2012;22 (1):21-27.##13.	Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB. The Molecular Basis of Cancer: Expert Consult-Online.3rd ed. Elsevier Health Sciences; 2008.##14.	Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011; 6: 95-119.##15.	Day C, Merlino G, Dyke T. Preclinical Mouse Cancer Models:A Maze of Opportunities and Challenges. Cell. 2015; 163(1):39-53.##16.	Brakebusch C, Pihlajaniemi T. Mouse as a model organism: from animals to cells. Springer Netherland, 2011.##17.	Luch A. Nature and nurture – Lessons from chemical carcinogenesis. Nat Rev Cancer. 2005;5(2):113–125.##18.	Loeb L, Harris C. Advances in chemical carcinogenesis: A historical review and prospective. Cancer Res. 2008; 68(17):6863–6872.##19.	Steele VE, Lubet RA, Moon RC. Preclinical animal models for the development of cancer chemoprevention drugs: Cancer Chemoprevention. Springer, 2005. p. 39-46.##20.	Enker WE, Jocobitz JL. Experimental carcinoma of the colon induced by 1, 2-dimethylhydrazine-diHCl: value as a model of human disease. J Surg Res. 1976; 21(4):291-299.##21.	Justice M, Siracusa L, Stewart A. Technical approaches for mouse models of human disease. Dis Model Mech. 2011(4):305-310.##22.	Torres-Ruiz R, Rodriguez-Perales S. CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling. Int J Mol Sci. 2015; 16(9):22151-2268.##23.	Zender L, Xue W, Zuber J, Semighini C, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008;135(5):852 – 864.##24.	Bric A, Miething C, Bialucha C, Scuoppo C, Zender L, Krasnitz A, et al. Functional identification of tumor suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. 2009;16(4):324 – 335.##25.	Hemann M, Fridman J, Zilfou J, Hernando E, Paddison P, Cordon-Cardo C, et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet. 2003;33(3):396 – 400.##26.	Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang T-W, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20(10) :1138 – 1146.##27.	Kersten K, Visser K, Miltenburg M, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2017;9(2):137-153.##28.	Annunziato S, Kas S, Nethe M, Yucel H, Del Bravo J, Pritchard C, et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev. 2016; 30(12):1470 – 1480.##29.	Maresch R, Mueller S, Veltkamp C, Ollinger R, Friedrich M, Heid I, et al. Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. Nat Commun. 2016;7: 10770.##30.	Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer. 2010;10 (7):470-480.##31.	Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer. 2007; 7 (9):645-658.##32.	Le Magnen C, Dutta A, Abate-Shen C. Optimizing mouse models for precision cancer prevention. Nat Rev Cancer. 2016; 16(3): 1-10.##33.	Ma Y, Jia Y, Chen L, Ezeogu L, Yu B, Xu N, et al. Weaknesses and Pitfalls of Using Mice and Rats in Cancer Chemoprevention Studies. J Cancer. 2015;6 (10):1058-1065.##34.	Richmond A, SU Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1(2-3):77-82.##35.	Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 2006; 66 (7):3355-3359.##36.	Kohnken R, Porcu P, Mishra A. Overview of the Use of Murine Models in Leukemia and Lymphoma Research. Fron Oncol 2017;7: 22.##37.	Rahgozar S, Moafi A, Abedi M, Entezar E, Moshtaghian J, Ghaedi K, et al. mRNA expression profile of multidrug resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2. Cancer Biol Ther. 2014;15(1):35–41.##38.	Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995; 9 (12):1985–1989.##39.	Fischer M, Schwieger M, Horn S, Niebuhr B, Ford A, Roscher S. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene. 2005; 24(51):7579–7591.##40.	Giovanella B, Yim S, Stehlin J, Williams L. Development of invasive tumors in the “nude” mouse after injection of cultured human melanoma cells. J Natil Cancer Inst. 1972(48):1531–1533.##41.	Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338–350.##42.	Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015; 15(15):311-316.##43.	Yu L, Baxter P, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, et al. A clinically relevant orthotopicxenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010;12(6):580–594.##44.	Bult CJ, Krupke DM, Begley DA, Richardson JE, Neuhauser SB, Sundberg JP, et al. Mouse Tumor Biology (MTB): a database of mouse models for human cancer. Nucleic Acids Res. 2015; 43(Database issue):D818-D824.##45.	Meyer LH, Debatin KM. Diversity of human leukemia xenograft mouse models: implications for disease biology. Cancer Res. 2011; 71 (23):7141-7144.##46.	Hollingshead MG, Stockwin LH, Alcoser SY, Newton DL, Orsburn BC, Bonomi CA, et al. Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies. BMC Genomics. 2014; 15:393.##47.	Kamel-Reid S, Letarte M, Doedens M, Greaves A, Murdoch B, Grunberger T, et al. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood. 1991;78 (11):2973–2981.##48.	Woiterski J, Ebinger M, Witte KE, Goecke B, Heininger V, Philippek M, et al. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcgammanull mice reﬂects individual leukemogenecity and highly correlates with clinical outcome. Int J Cancer. 2013(133):1547–1556.##49.	Harvey S, Muller W. Transgenic Mouse Models—A Seminal Breakthrough in Oncogene Research.  Mouse Models of Cancer: a Laboratory manual: Cold Spring Harbor Laboratory Press; 2014. p. 17-26.##50.	Marx V. Models: stretching the skills of cell lines and mice. Nat Methods. 2014;11(6):617-620.##51.	de Jong M, Essers J, van Weerden WM. Imaging preclinical tumour models: improving translational power. Nat Rev Cancer. 2014; 14 (7):481-493.##52.	Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res. 2006; 312(5):594–607.##53.	Kulke M, Bergsland E, Ryan D, Enzinger P, Lynch T, Zhu AX, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006;24(22):3555–3561.##54.	Moschos S, Odoux C, Land S, Agarwala S, Friedland D, Volker K, et al. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: A novel combination of antiangiogenic and immunomodulatory agents . Melanoma Res. 2007; 17(17):193-200.##55.	Rangarajan A, Weinberg RA. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer. 2003;3(12):952-959.##56.	Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006; 5(9):1-14.##57.	Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L. Telomere dysfunction promotesnon-reciprocal translocations and epithelial cancers in mice. Nature. 2000; 406:6796):641-645.##58.	Bos PD, Nguyen DX, Massague J. Modeling metastasis in the mouse. Curr Opin Pharmacol. 2010;10 (5):571-577.##59.	Rampetsreiter P, Casanova E, Eferl R. Genetically modified mouse models of cancer invasion and metastasis. Drug Discov Today Dis Models. 2011; 8(2):67-74.##60.	Saxena M, Christofori G. Rebuilding cancer metastasis in the mouse. Mol Oncol. 2013; 7(2):283-296.##61.	Sabolic I, Breljak D, Ljubojevic M, Brzica H. Are mice, rats, and rabbits good models for physiological, pharmacological and toxicological studies in humans? Periodicum Biologorum. 2011; 113(1):7-16.##62.	Xu D, Peltz G. Can Humanized Mice PredictDrug “Behavior” in Humans? Annu Rev Pharmacol Toxicol. 2016; 56: 323-338.##63.	Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000; 32(1):56–67.##64.	Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4a on the disposition of debrisoquine in the mouse. Mol Pharmacol. 2001; 60 (6):1260–1267.##65.	Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L.  Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metabo Dispos. 2003; 31(5):548–58.##66.	Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol. 2006; 46:41-64.##67.	Xia HJ, Chen CS. Progress of non-human primate animal models of cancers.Dongwuxue Yanijiu. 2011; 32 (1):70-80.##68.	Abedi M, Rahgozar S. The best animal models in cancer research: Genetically engineered mice or Xenografts (In Persian). The First National Congress of Animal Models Applications in Expreimental Medicine Research. 2016:144.##69.	Denayer T, Stohr T, Van Roy M. Animal models in translational medicine: Validation and prediction. New Horizons in Translational Medicine. 2014; 2(1):5-11.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>آیا مصرف بیس فسفونات ها کنترااندیکاسیون درمان های دندانپزشکی است؟</TitleF>
		<TitleE>Is using Bisphosphonate a Contraindication for Dental Treatments?

</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>بیس فسفونات&#8204;ها دسته&#8204;ایی از داروها هستند که برای درمان بیماری&#8204;های خاص استخوانی مانند مالتیپل میلوما و سرطان&#8204;های متاستاتیک استخوانی استفاده می&#8204;شوند. اگرچه مکانیسم عمل دقیق بیس فسفونات&#8204;ها شناخته نشده، ولی نقش این داروها در سرکوب رگ&#8204;زایی و ریمادلینگ استخوانی ثابت شده است. استئونکروزفکین (BRONJ) عارضه&#8204;ی جانبی در بیمارانی است که بیس فسفونات دریافت می&#8204;کنند، این عارضه به ندرت رخ می&#8204;دهد ولی در صورت وقوع، مشکلات جدی برای بیماران به وجود می&#8204;آورد و حتی می&#8204;تواند منجر به شکستگی&#8204;های پاتولوژیک در مندیبل شود.
شیوعBRONJ در بیمارانی که بیس فسفونات داخل وریدی مانند زالندرونات و پامیدرونات مصرف می&#8204;کنند، به&#8204;صورت چشم&#8204;گیری از بیمارانی که بیس فسفونات خوراکی مصرف می&#8204;کنند، بیش&#8204;تر است. احتمال وقوع BRONJ در مندیبل 2 برابر ماگزیلاست و 60-70 درصد بیماران، به دنبال جراحی&#8204;های دندانی به BRONJ مبتلا می&#8204;شوند.
علائم و نشانه&#8204;ها ممکن است قبل از وقوع استئونکروز مشاهده شوند که شامل درد، لقی دندان&#8204;ها و زخم&#8204;های مخاطی است. ویژگی&#8204;های تصویربرداری در BRONJ اختصاصی نیست. رادیوگرافی&#8204;های پری&#8204;اپیکال و پانورامیک شاخص&#8204;های غربال&#8204;گری اولیه هستند، درحالی&#8204;که CT و MRI اطلاعات کامل&#8204;تری در اختیار ما می&#8204;گذارند. درمان&#8204;های غیر جراحی شامل داروهای ضد درد، آنتی بیوتیک&#8204;ها و دهان&#8204;شویه&#8204;های ضد میکروبی و درمان&#8204;های جراحی شامل دبریدمان و ریسکشن است که در مراحل پیشرفته&#8204;تر توصیه شده است.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Bisphosphanates include a group of medicines used in treatment of specific bone diseases, such as multiple myeloma and osteo- high metastatic cancers. Though the exact mechanism of such medicines has not yet been known, the role these medicines play in the suppression of innervations and bone remodeling has been proved. Bisphosphonate related osteonecrosis of jaws (BRONJ) is a complication caused by using Bisphosphanates. It is a rare infliction, but, when it occurs, it brings about grave consequences for the patients including pathological fractures in the mandible. The BORNJ prevalence in patients who take intravenous Bisphosphates (BPs), such as Zolendronate, and Pamidronate is significantly higher than that in patients taking such medicines orally. The probability of BRONJ onset in mandible is twice higher than in maxilla; and some 60-70% of the patients are reported to be inflicted with BRONJ following dental surgeries. The signs and symptoms may occur prior to the presence of osteonecrosis, which include pain, loose teeth, and membranous lesions. The imaging features in BRONJ are non-specific. Peri-apical and panoramic imaging are the primary screening indices, while CT scanning and MRI provide us with more accurate information. Nonsurgical treatment protocols include anti-pain medicines, antibiotics, and anti-microbial mouthwashes, while surgical treatments include debriding and resection which are being suggested in more advanced cases.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>232</FPAGE>
			<TPAGE>244</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/302017/08/92017/02/52017/04/242017/03/172017/05/152016/08/2
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/5/12
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/122017/09/242017/06/142017/11/112017/09/122017/07/52017/02/28
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1395/12/10
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>محدثه</Name>
				<MidName></MidName>
				<Family>حیدری</Family>
				<NameE>Mohadese</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Heidari</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه پریودنتیکس، دانشکده دندانپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Heidari-mohadeseh@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سپیده</Name>
				<MidName></MidName>
				<Family>متولی</Family>
				<NameE>Sepideh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>motevali</FamilyE>
				<Organizations>
				<Organization>دندانپزشک عمومی، کمیته تحقیقات دانشجویی، دانشکده دندانپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sepideh.motevaliii@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>آویده</Name>
				<MidName></MidName>
				<Family>معبودی</Family>
				<NameE>Avideh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Maboodi</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه پریودنتیکس، مرکز تحقیقات دیابت، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>avideh48188@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فرهاد</Name>
				<MidName></MidName>
				<Family>ثبوتی</Family>
				<NameE>Farhad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sobouti</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه ارتودنتیکس، دانشکده دندانپزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>farhad_sobouti@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Bisphosphonate</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>osteonecrosis of the jaws</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>dental treatments</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>بیس فسفونات</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>استئونکروز فکین</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>درمان‌های دندانپزشکی</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Spanou A, Lyritis GP, Chronopoulos E, Tournis S. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review. Oral Dis. 2015;21(8):927-936.##2.	Holzinger D, Seemann R, Klug C, Ewers R, Millesi G, Baumann A, et al. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncol. 2013;49(1):66-70.##3.	Kuhl S, Walter C, Acham S, Pfeffer R, Lambrecht JT. Bisphosphonate-related osteonecrosis of the jaws--a review. Oral Oncol. 2012;48(10): 938-947.##4.	Marx RE, Stern DS. Biopsy principles and techniques. In: Marx RE, Stern DS, editors. Oral and maxillofacial pathology: a rationale for diagnosis and treatment. Chicago: Quintessence; 2002. p. 36–8.##5.	Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced necrosis of the jaw: a growing epidemic. J Oral Maxillofacial Surg 2003;61(9):1115–6.##6.	Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433–41.##7.	Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg . 2003; 61(9): 1115-1117.##8.	Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003;61(10):1238-1239.##9.	Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005;182(8):413-415.##10.	Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527-534.##11.	Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg .2005;63(5):682-689.##12.	Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 2003;4(5):284-292.##13.	Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol. 2002;29(6 Suppl 21):3-11.##14.	Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma. 2006;7(3):192-198##15.	Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol. 2002;29(6 Suppl 21):3-11.##16.	Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2007;104(2):186-193.##17.	Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62(22):6538-6544.##18.	Body JJ. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast. 2003;12 Suppl 2:S37-44.##19.	Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002;61(5):1255-1262.##20.	Hovi L, Saarinen UM, Donner U, Lindqvist C. Opportunistic osteomyelitis in the jaws of children on immunosuppressive chemotherapy. J Pediatr Hematol Oncol. 1996;18(1):90-94.##21.	Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104(1):83-93.##22.	Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32(11):1123-1128.##23.	Ficarra G, Beninati F. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects. Head Neck Pathol. 2007;1(2):132-140.##24.	Siddiqi A, Payne AG, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma? 2009;108(3):e1-8.##25.	Pozzi S, Marcheselli R, Sacchi S, et al. Analysis of frequency and risk factors fordevelopingbisphosph-onatassociated necrosis of the jaw. Blood 2005;106.##26.	Beninati F, Pruneti R, Ficarra G. Bisphosphonate-related osteonecrosis of the jaws (Bronj). Med Oral Patol Oral Cir Bucal. 2013;18(5):e752-758.##27.	Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Research. 2009;20 Suppl 4:87-95.##28.	Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2-12.##29.	Sarasquete ME, Gonzalez M, San Miguel JF, Garcia-Sanz R. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis. 2009;15(6):382-387.##30.	Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356-5362.##31.	Hoff, A.O., Toth, B.B., Altundag, K., Johnson, M.M., Warneke, C.L., Hu, M. et al, Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–836.##32.	Maboudi A, Milani S. Preeclampsia and Periodontal Diseases: A Review Study.  J Mazandaran Univ Med Sci. 2016;26(137):224-234.(persian)##33.	Kashi Z, Ehsani Z, Maboodi A, Bahar A, Rezai N. Relationship between periodontitis and inflammatory factors with gestational diabetes. J Mazandaran Univ Med Sci. 2015;25(131):24-31.(persian)##34.	Amiri AA, Maboudi A, Bahar A, Farokhfar A, Danesh var F, Khoshgoeian HR, et al. Relationship between type 2 diabetic retinopathy and periodontal disease in Iranian adults. N Am J Med Sci .2014;6(3):139-144.##35.	Rogers MJ, Watts DJ, Russel RGG. Overview of bisphospho-nates.Cancer. 1997;80(Suppl):1652–1660##36.	Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67(5 Suppl):75-84.##37.	Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol.. 2007;28(6):1139-1145.##38.	Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105(3):358-364.##39.	Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14(8):2387-2395.##40.	Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(2):249-258.##41.	Ho L, Quan V, Henderson R. Zoledronate-related osteonecrosis of the mandible. Clin Nucl Med.2008;33(1):68##42.	Dannemann C, Gratz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone. 2007;40(4):828-834.##43.	Lew DP, Waldvogel FA. Osteomyelitis. Lancet .2004;364(9431):369-379.##44.	von Schewelov T, Carlsson A, Dahlberg L. Cross-linked N-telopeptide of type I collagen (NTx) in urine as a predictor of periprosthetic osteolysis. J Orthop Res. 2006;24(7):1342-1348.##45.	Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397-2410.##46.	Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(6):1167-1173.##47.	Nisi M, La Ferla F, Karapetsa D, Gennai S, Miccoli M, Baggiani A, et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg. 2015;44(5):586-591.##48.	Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg.2009;67(5 Suppl):96-106.##49.	Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 2006;24(9):1475-1477.##50.	Shimura K, Shimazaki C, Taniguchi K, Akamatsu S, Okamoto M, Uchida R, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol. 2006 ; 84(4): 343-345.##51.	Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol. 2006;77(4):738-743.##52.	Kumar SK, Meru M, Sedghizadeh PP. Osteonecrosis of the jaws secondary to bisphosphonate therapy: a case series. J Contemp Dent Pract. 2008;9(1):63-69.##53.	Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg. 2007;65(7):1321-1327.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>مروری بر علل، انواع و درمان خشکی دهان و بیماری‌های مرتبط با آن در طب سنتی ایرانس</TitleF>
		<TitleE>A Review on the Etiology, Types and Treatment of Dry Mouth and Related Diseases Based on Iranian Traditional Medicine 


</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: خشکی دهان اختلال شایعی است که غالبا در اثر کاهش میزان ترشح بزاق و گاهی نیز در اثر تغییر کیفیت بزاق رخ می&#8207;دهد امروزه در متون طبی خشکی&#8207;دهان به خودی خود یک بیماری محسوب نمی&#8207;شود، بلکه معمولا به&#8207;عنوان عارضه حاصل از بیماری&#8207;های دیگر، داروها، پرتودرمانی و شیمی&#8207;درمانی می&#8207;باشد. با وجود درمان&#8207;هایی که در طب رایج برای خشکی دهان وجود دارد ولی تاکنون درمان کاملاً موثری که قابل توصیه عمومی به بیماران باشد معرفی نشده است. در این راستا می&#8207;توان از توان بالقوه مکاتب طب مکمل، برای شناخت بیش&#8207;تر این بیماری استفاده کرد و برخی راه&#8207;های درمانی یا کنترلی را پیشنهاد نمود.
مواد و روش&#8204;ها: در این مطالعه کتاب&#8207;های معتبر طب سنّتی ایران و نرم افزار &#34;کتابخانه جامع طب سنتی و اسلامی نور&#34; و پایگاه&#8207;های اطلاعاتیpubmed و Web of science و Scopus بررسی شد.
یافته&#8204;ها: این مطالعه نشان می&#8207;دهد که طیف وسیعی از بیماری&#8207;ها از جمله بیماری&#8207;های دماغی، تنفسی، قلبی، گوارشی، انواع تب&#8207;ها و مسمومیت&#8207;ها وجود دارند که خشکی دهان یکی از علائم آن&#8207;ها است. با این دیدگاه، خشکی دهان صرفاً یک علامت موضعی ناشی از اختلال عملکرد غدد بزاقی نیست و می&#8207;تواند نشانه وجود اختلال در سایر اعضا و ارگان&#8207;های بدن باشد.
استنتاج: با توجه به دیدگاه متفاوت طب سنتی ایران به مقوله سلامت و بیماری، جستجو در منابع آن برای پیدا کردن راهکارهای متفاوت با طب رایج در برخورد با خشکی دهان و درمان آن می&#8207;تواند راهگشا باشد؛ و اصول درمانی طب سنتی ایران در کنار روش&#8207;های درمانی طب نوین، می&#8207;توانند به عنوان درمان مکمل استفاده شوند.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Dry mouth is a common disorder that often occurs due to reduction of the amount of saliva or change in the saliva quality. Dry mouth is not a disease itself, but it is usually a complication of other diseases, medications, radiation therapy, and chemotherapy. Conventional medical treatments for dry mouth are not highly effective. But, complementary medicine could potentially suggest some treatments or prevention methods for dry mouth.
Materials and methods: In this study, Iranian traditional medicine (ITM) books and the &#34;comprehensive library of Islamic and traditional medicine&#34; software were used. Also, electronic databases including, PubMed, Web of Science, and Scopus were searched for relevant articles.
Results: A wide range of diseases were found to be responsible for dry mouth, including mental, respiratory, cardiovascular, and gastrointestinal diseases, food poisoning, and fever. Therefore, dry mouth is not only the results of salivary dysfunction but also it can be associated with dysfunction in other organs.
Conclusion: Due to different views of ITM on health and diseases, search in the ITM sources can be useful in finding new methods for treatment of dry mouth. The principles of ITM can be used alongside conventional medicine as a complementary therapy.
&#160;
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>245</FPAGE>
			<TPAGE>257</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2016/10/92017/06/232016/12/172015/12/102017/04/52017/02/12017/01/82017/07/172017/03/42017/05/12017/04/182017/03/72017/01/52017/01/302017/08/92017/02/52017/04/242017/03/172017/05/152016/08/22016/12/18
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1395/9/28
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2017/11/82017/09/232017/06/252017/10/222017/09/122017/11/12017/07/112017/09/272017/11/82017/11/112017/08/262017/08/262017/06/142017/07/122017/09/242017/06/142017/11/112017/09/122017/07/52017/02/282017/09/11
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1396/6/20
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>غزاله</Name>
				<MidName></MidName>
				<Family>حیدری راد</Family>
				<NameE>: Ghazaleh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Heydarirad</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه طب سنتی، دانشکده طب سنتی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>رسول</Name>
				<MidName></MidName>
				<Family>چوپانی</Family>
				<NameE>Rasool</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Choopani</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه طب سنتی، دانشکده طب سنتی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سیده صدیقه</Name>
				<MidName></MidName>
				<Family>یوسفی</Family>
				<NameE>Seyde Sedighe</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Yousefi</FamilyE>
				<Organizations>
				<Organization>. استادیار، گروه طب سنتی، مرکز تحقیقات طب سنتی و مکمل، دانشگاه علوم پزشکی مازندران، دانشگاه علوم پزشکی مازندران،ساری، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>s.yousefi@mazums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>xerostomia</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>salivary gland hypofunction</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Iranian traditional medicine</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>خشکی دهان</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>کم‌کاری غدد بزاقی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>طب سنتی ایران</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>##1.	Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Revs. 2011;(12):cd008934.##2.	Furness S, Bryan G, McMillan R, Birchenough S, Worthington HV. Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev. 2013;30(8):CD009603.##3.	Gerdin EW, Einarson S, Jonsson M, Aronsson K, Johansson I. Impact of dry mouth conditions on oral health‐related quality of life in older people. Gerodontology. 2005;22(4):219-226.##4.	Minicucci EM, Pires RB, Vieira RA, Miot HA, Sposto MR. Assessing the impact of menopause on salivary flow and xerostomia. Aust Dent J. 2013;58(2):230-234.##5.	Vissink A, Mitchell JB, Baum BJ, Limesand KH, Jensen SB, Fox PC, et al. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys. 2010; 78(4):983-991.##6.	Bakhtiari S, Azimi Hosseini S, Ghaem Maghami A. Review of routine therapeutic management of common oral lesions. J Dent Sch Shahid Beheshti Univ Med Sci. 2008; 25 (4) :348-356.(persian)##7.	Sahba S, Ghadimi S, Talaeepour A R, Haddad P, Zolfeghari I. The Efficacy of Iranian Made Saliva Substitute vs. VA-OraLube in Improvement of Oral-Health-Related Quality of Life in Radiotherapy-Induced Xerostomia. J Dent Sch Shahid Beheshti Univ Med Sci. 2009; 27 (3) :136-145.(persian)##8.	Shahraz S, GHaziani T. Iran Farma. Teymourzade Institu. Tayeb Publisher;2007. (persian)##9.	Taylor SE. Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia. Expert opin Pharmacother. 2003;4(9):1489-1497.##10.	Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth–2nd edition. Gerodontology. 1997;14(1):33-47.##11.	Khodadoost M, Comparison of the effect of Shebet Oil and Diclofenac Gel on clinical symptoms in patients with Knee osteoarthritis: A randomized, double-blind, controlled Clinical trial. Tehran: Tehran university of Medical science, Iranian Traditional Medicine College.2011.(persian)##12.	Naseri M. Healthy Vilage. Tehran: Traditional and Complementary Pub; 2009.(persian)##13.	Davies AN. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliat Med. 2000;14(3):197-203.##14.	Naseri M.  Iranian Traditional Medicine and its development using the guidelines of the World Organisation. Daneshvar Medicine.2004; 11(52): 53-68.(persian)##15.	Gorji A, Khaleghi Ghadiri M. History of epilepsy in Medieval Iranian medicine. Neurosci Biobehav Rev. 2001;25(5):455-461.##16.	Naseri M, Rezaizade H, Choopani R, Anushirvani M. Review of  Iranian traditional medicine. Iranian Traditional Medicine Institu; 2009.(persian)##17.	Kermani NA. Sharh al- Asbab va al- Alamat (Arabic). Part I. Iran: Jalaleddin Matbooat institute,  2008:603.##18.	Arzani MA. Tebb-E-Akbari.  Tehran, Iran: Institute of Medical History, Islamic and  Complementary Medicine ; Iran University of Medical Sciences, vol. 1, 2005.##19.	Mohammade Chagmini M. Canonche Fi Tebb. Translated By : Esamil Nazem .  Tehran, Iran: Institute of Medical History, Islamic and  Complementary Medicine, Iran University of Medical Sciences; 2007.##20.	Arzani MA. Mizan- Al- Tebb. Tehran, Iran: Institute of Medical History, Islamic and  Complementary Medicine, Iran University of Medical Sciences; Vol.1.  2005.##21.	Aghili Khorasani M. Kholastol Hekmah. Tehran, Iran: Intisharatva Amoozesh Enghelab Islami Press;1992.##22.	Avicenna. Canon of Medicine (Lithograph in Arabic). Rome, Italy: Typographia Medicea; 1593.##23.	Chashti MAK. Medicine. Exir-e-Azam. Tehran university of Medical Science: Institute for Islamic and Complementary Medicine; 2007.##24.	Jorjani E. Al- Aghraz Al- Tayyebeh Va Al- Mabahes Al- Aalanieh.  (Persian). Pt I. Iran: Tehran University Puplication; 2009: P. 631.##25.	Gilani MK . Hefzol Sehhe- Naseri. AlMaee Institue; Tehran, Iran, 2008.##26.	Chaghmini MM. Mostahzar al-tabib and Mostabshar al-labib:translation of Canonche, new painting. Paris, Lahoor, 1th ed.##27.	Baha-al- Doleh Razi. Kholasat al Tajareb.Tehran:  University of medical science,Tehran, 1th ed, 2008.##28.	Razi MZ. Al-Havi (Liber Continent). Beyrouth; Dar Ehya oT Tarat Alarabi Pub .2001.##29.	Shams-o- Din A. Kazaen al- Molook.Tehran:  Almaee Pub , 2008.##30.	Sharaf-Kandi A. The Canon of Medicine of Avicenna [translated]. Tehran: Soorush Pub; 1988.##31.	Vincent T, DeVita Jr MD,   Lawrence TS.  Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology (Cancer: Principles &#38; Practice (DeVita). 9th ed.  USA: Phihadelphia; 2011.##32.	Ganjineh  Baharestan. Tehran: Musium laiberary and Documents Center of the Islamic Consultative Assembly, 2007.(persian)##33.	Jorjani SE. Aghraz- al- Tebbiea and Al Mabahes- al-AalaIie. Iranian Cultural Foundation, 1th ed. Tehran:1962.##34.	Heravi Y. Tebbe Yusefi.Tehran:  Iran University of Medical Science, 1th ed ,2003.(persian)##35.	Sharif M. Zad-al- Mosaferin.Qom: Jalaleddin Pub, 1th ed,2008.(persian)##36.	Arzani M. Fosool- Al-Aaraz. Tehran:  Iran University of Medical Science, 1th ed . 2008.(persian)##37.	Kermani M. Daghaegh-Al-Alaj. Kerman: Saadat Press, 1th ed, 1983.##38.	Ali khan V. Elm al Abdan. Lekehno : Monshi Nulkeshvar, 1 th ed, 1978.##39.	Agktari E, Sohrabvand F, Bius S. Infertility and fertility banned in Iran. Institute of Medical History Studies, Islamic and Complementary Medicine. Tehran: Ismailis Press, 1th ed .  2000.##40.	Ebn Elias Shirazi M. Kefaye Mansoori, resaleh choobe chini. Tehran: Iran university of medical science, 1th ed, 2003.##41.	Jorjani E. Theoretical Foundations of traditional medicine.Tehran:  Iran university of Medical Science,1 th ed ,2004.(persian)##42.	Shirazi M. Ghiyasiyeh. Qom:  Ehyae Tebb Pub. 1th ed .(persian)##43.	Chaghmini M. Ghanunche fI Tebb.Tehran:  Aieej Pub , 1th ed.  2010.(persian)##44.	Rezaeizadeh H, Alizadeh M, Naseri M, Ardakani MS. The traditional Iranian medicine point of view on health and disease. Iranian Journal of Public Health. 2009;38(Suppl. 1):169-172.(persian)##45.	Aghili MH. Makhzan-al-Advieh. Tehran: Tehran University of Medical Sciences. 2009;328.(persian)##46.	Jorjani SE. Khafi Alaee.Etellaat Institue, Part 1, Tehran:  Iran,1990. (persian)##47.	Tonekaboni SMM. Tohfat-Al- Momenin,Edited by Shams Ardakani et al. Tehran:  Shahid behashti Traditional and Herbal Research Centre, 2007. (persian)##48.	Han G, Park JW, Ko SJ, Son J, Seon J, Kim J, et al. Yukmijihwang-tang for the treatment of xerostomia in the elderly: study protocol for a randomized, double-blind, placebo-controlled, two-center trial. Trials. ## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>

</ARTICLES>

</JOURNAL>
</XML>
